{"questions": [{"id": "58ec6eb5eda5a5767200000c", "body": "Is Enlimomab effective for stroke treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11673584"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "BACKGROUND: There has been recent interest in the possible role of reperfusion-induced inflammation with neuronal injury after stroke.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 135, "offsetInEndSection": 283, "text": "Enlimomab, a murine intercellular adhesion molecule-1 (ICAM-1) antibody, reduces leukocyte adhesion and infarct size in experimental stroke studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 284, "offsetInEndSection": 385, "text": "The purpose of the current clinical trial was to evaluate the use of enlimomab after ischemic stroke.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 385, "offsetInEndSection": 545, "text": "METHODS: A total of 625 patients with ischemic stroke were randomized to receive either enlimomab (n = 317) or placebo (n = 308) within 6 hours of stroke onset.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 729, "offsetInEndSection": 906, "text": "The primary efficacy endpoint was the response to therapy at 90 days on the Modified Rankin Scale; other endpoints included Barthel Index (BI) and NIH Stroke Scale and survival.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1242, "text": "The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 1434, "offsetInEndSection": 1630, "text": "CONCLUSIONS: The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 1243, "offsetInEndSection": 1358, "text": "There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}, {"offsetInBeginSection": 1034, "offsetInEndSection": 1148, "text": "Fewer patients had symptom-free recovery on enlimomab than placebo (p = 0.004), and more died (22.2 versus 16.2%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584"}]}, {"id": "5a885add61bb38fb24000017", "body": "What is the H4S47C cleavage mapping method used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24737863", "http://www.ncbi.nlm.nih.gov/pubmed/25491770", "http://www.ncbi.nlm.nih.gov/pubmed/26275423"], "snippets": [{"offsetInBeginSection": 113, "offsetInEndSection": 349, "text": "To identify nucleosomes with alternative structures genome-wide, we used H4S47C-anchored cleavage mapping, which revealed that 5% of budding yeast (Saccharomyces cerevisiae) nucleosome positions have asymmetric histone-DNA interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25491770"}, {"offsetInBeginSection": 439, "offsetInEndSection": 707, "text": "Micrococcal nuclease (MNase) sequence-based profiles of asymmetric nucleosome positions revealed a corresponding asymmetry in MNase protection near the dyad axis, suggesting that the loss of DNA contacts around H4S47 is accompanied by protection of the DNA from MNase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25491770"}, {"offsetInBeginSection": 164, "offsetInEndSection": 327, "text": "To map fission yeast centromeres, we applied H4S47C-anchored cleavage mapping and native and cross-linked chromatin immunoprecipitation with paired-end sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275423"}, {"offsetInBeginSection": 570, "offsetInEndSection": 768, "text": "Inner kinetochore proteins CENP-A, CENP-C, CENP-T, CENP-I, and Scm3 are highly enriched throughout the central domain except at tRNA genes, with no evidence for preferred kinetochore assembly sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275423"}, {"offsetInBeginSection": 991, "offsetInEndSection": 1193, "text": "Our results suggest that CENP-T particles occupy linkers between CENP-A nucleosomes and that classical regional centromeres differ from other centromeres by the absence of CENP-A nucleosome positioning.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275423"}, {"offsetInBeginSection": 708, "offsetInEndSection": 939, "text": "Chromatin immunoprecipitation mapping of selected nucleosome remodelers indicated that asymmetric nucleosomes are bound by the RSC chromatin remodeling complex, which is required for maintaining nucleosomes at asymmetric positions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25491770"}, {"offsetInBeginSection": 861, "offsetInEndSection": 990, "text": "CENP-A nucleosomes protect less DNA from nuclease digestion than H3 nucleosomes, while CENP-T protects a range of fragment sizes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275423"}, {"offsetInBeginSection": 328, "offsetInEndSection": 569, "text": "H3 nucleosomes are nearly absent from the central domain, which is occupied by centromere-specific H3 (cenH3 or CENP-A) nucleosomes with two H4s per particle that are mostly unpositioned and are more widely spaced than nucleosomes elsewhere.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275423"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Nucleosomes in active chromatin are dynamic, but whether they have distinct structural conformations is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25491770"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1125, "text": "DOI: http://dx.doi.org/10.7554/eLife.01861.001.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24737863"}]}, {"id": "5ac725250340b9f058000006", "body": "Which miRNA is associated with the circular RNA ciRS-7?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24014594", "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "http://www.ncbi.nlm.nih.gov/pubmed/25873049", "http://www.ncbi.nlm.nih.gov/pubmed/27929395"], "snippets": [{"offsetInBeginSection": 107, "offsetInEndSection": 299, "text": "The identification of competing endogenous RNA and circular RNA (circRNA) as important regulators of miRNA activity underscores the increasing complexity of ncRNA-mediated regulatory networks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014594"}, {"offsetInBeginSection": 300, "offsetInEndSection": 484, "text": "Particularly, the recently identified circular RNA, ciRS-7, which acts as a designated miR-7 inhibitor/sponge, has conceptually changed the mechanistic understanding of miRNA networks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014594"}, {"offsetInBeginSection": 358, "offsetInEndSection": 450, "text": "We previously identified a highly expressed circular RNA (circRNA) in human and mouse brain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346"}, {"offsetInBeginSection": 451, "offsetInEndSection": 578, "text": "Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346"}, {"offsetInBeginSection": 922, "offsetInEndSection": 1104, "text": "In the mouse brain, we observe overlapping co-expression of ciRS-7 and miR-7, particularly in neocortical and hippocampal neurons, suggesting a high degree of endogenous interaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "The emerging landscape of circular RNA ciRS-7 in cancer (Review).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873049"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Deficiency in the Ubiquitin Conjugating Enzyme UBE2A in Alzheimer's Disease (AD) is Linked to Deficits in a Natural Circular miRNA-7 Sponge (circRNA; ciRS-7).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929395"}, {"offsetInBeginSection": 579, "offsetInEndSection": 747, "text": "ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346"}, {"offsetInBeginSection": 582, "offsetInEndSection": 719, "text": "This review will summarize the origin and functions of ciRS-7 and discuss the relationship among ciRS-7, its target molecules and cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873049"}, {"offsetInBeginSection": 331, "offsetInEndSection": 394, "text": "Also, ciRS-7 acts as a natural competing endogenous RNA, a.k.a.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873049"}]}, {"id": "5aae6a86fcf456587200000e", "body": "What are the 3 types of ultraviolet (UV) solar radiation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25040832", "http://www.ncbi.nlm.nih.gov/pubmed/20519675", "http://www.ncbi.nlm.nih.gov/pubmed/17204418", "http://www.ncbi.nlm.nih.gov/pubmed/12821280", "http://www.ncbi.nlm.nih.gov/pubmed/9577442", "http://www.ncbi.nlm.nih.gov/pubmed/22268421", "http://www.ncbi.nlm.nih.gov/pubmed/21192130", "http://www.ncbi.nlm.nih.gov/pubmed/11920550", "http://www.ncbi.nlm.nih.gov/pubmed/22163847", "http://www.ncbi.nlm.nih.gov/pubmed/16897517"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Epidermal UV-A absorbance and whole-leaf flavonoid composition in pea respond more to solar blue light than to solar UV radiation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25040832"}, {"offsetInBeginSection": 95, "offsetInEndSection": 205, "text": "One large group of phenolics, flavonoids, is considered particularly responsive to ultraviolet (UV) radiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25040832"}, {"offsetInBeginSection": 206, "offsetInEndSection": 333, "text": "However, here we demonstrate that solar blue light stimulates flavonoid biosynthesis in the absence of UV-A and UV-B radiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25040832"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Effects of solar UV-A and UV-B radiation on gene expression and phenolic accumulation in Betula pendula leaves.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519675"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Ultraviolet (UV) radiation is an important environmental factor for plant communities; however, plant responses to solar UV are not fully understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519675"}, {"offsetInBeginSection": 150, "offsetInEndSection": 364, "text": "Here, we report differential effects of solar UV-A and UV-B radiation on the expression of flavonoid pathway genes and phenolic accumulation in leaves of Betula pendula Roth (silver birch) seedlings grown outdoors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519675"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1100, "text": "Furthermore, there were strong positive correlations between PAL expression and accumulation of four flavonols under the UV treatments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519675"}, {"offsetInBeginSection": 1101, "offsetInEndSection": 1255, "text": "Our findings in silver birch contribute to a more detailed understanding of plant responses to solar UV radiation at both molecular and metabolite levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519675"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Sunlight, skin cancer and vitamin D: What are the conclusions of recent findings that protection against solar ultraviolet (UV) radiation causes 25-hydroxyvitamin D deficiency in solid organ-transplant recipients, xeroderma pigmentosum, and other risk groups?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17204418"}, {"offsetInBeginSection": 126, "offsetInEndSection": 415, "text": "We have shown that patients that have to protect themselves against solar UV radiation for medical reasons, including patients with xeroderma pigmentosum (XP), basal cell nevus syndrome (BCNS), lupus erythematodes (LE) or transplant recipients, are at risk to develop vitamin D deficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17204418"}]}, {"id": "5ac08fe7d0c506ce46000003", "body": "Of what origin is the MCF-7 cell line?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21116879", "http://www.ncbi.nlm.nih.gov/pubmed/176383", "http://www.ncbi.nlm.nih.gov/pubmed/15183541", "http://www.ncbi.nlm.nih.gov/pubmed/16158200", "http://www.ncbi.nlm.nih.gov/pubmed/25725141", "http://www.ncbi.nlm.nih.gov/pubmed/7604203", "http://www.ncbi.nlm.nih.gov/pubmed/25733816"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "MCF-7/ADR cells have been widely used as a multidrug-resistant breast cancer cell model in cancer research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 108, "offsetInEndSection": 221, "text": "The origin of MCF-7/ADR has been a matter of debate since MCF-7/ADR cells were re-designated NCI/ADR-RES in 1998.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 222, "offsetInEndSection": 327, "text": "Many recent studies still describe MCF-7/ADR cells as originating from the breast cancer cell line MCF-7.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 328, "offsetInEndSection": 390, "text": "Thus, the real origin of MCF-7/ADR cells remains more unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 391, "offsetInEndSection": 555, "text": "In this study, a new adriamycin (ADR)-resistant cell line MCF-7/ADR' was reproduced using the same procedure employed during the initial establishment of MCF-7/ADR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 556, "offsetInEndSection": 838, "text": "Since the MCF-7/ADR' cell line was definitely derived from parental MCF-7 cells, we were able to directly compare these cell lines together with MCF-7/ADR using immunocytochemical, morphological, and consecutive DNA fingerprinting analyses to determine the true origin of MCF-7/ADR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 839, "offsetInEndSection": 1057, "text": "Both ADR-resistant cell lines displayed some similar phenotypic characteristics, such as high levels of P-glycoprotein (P-gp) expression, increased vacuolation, abundant filamentous material, and irregular pseudopodia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 1058, "offsetInEndSection": 1188, "text": "With increasing concentrations of ADR, the DNA fingerprints of MCF-7/ADR' cells were always identical to the parental MCF-7 cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}, {"offsetInBeginSection": 1189, "offsetInEndSection": 1276, "text": "However, the DNA fingerprints of MCF-7/ADR cells did not relate to MCF-7 or MCF-7/ADR'.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879"}]}, {"id": "589a247078275d0c4a000035", "body": "Dinutuximab is used for treatment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26917818", "http://www.ncbi.nlm.nih.gov/pubmed/28389455", "http://www.ncbi.nlm.nih.gov/pubmed/25940913", "http://www.ncbi.nlm.nih.gov/pubmed/26934530", "http://www.ncbi.nlm.nih.gov/pubmed/26891967", "http://www.ncbi.nlm.nih.gov/pubmed/25851859", "http://www.ncbi.nlm.nih.gov/pubmed/28549783", "http://www.ncbi.nlm.nih.gov/pubmed/27456981"], "snippets": [{"offsetInBeginSection": 1339, "offsetInEndSection": 1466, "text": "In phase III trials, dinutuximab increased 2-year event-free survival and overall survival when compared to standard treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818"}, {"offsetInBeginSection": 1871, "offsetInEndSection": 2047, "text": "Ongoing research will determine if dinutuximab could be used earlier in treatment, in nonresponders to initial therapies, in combination with chemotherapy, or in other cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455"}, {"offsetInBeginSection": 491, "offsetInEndSection": 635, "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940913"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1128, "text": "The FDA and EMA approved dinutuximab (Unituxin(R)) in 2015 for the treatment of patients with HR-NB who achieved at least a partial response after multimodality therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26934530"}, {"offsetInBeginSection": 981, "offsetInEndSection": 1324, "text": "Computer-based randomisation with sequence generation defined by permuted block randomisation (block size two) was used to randomly assign patients (1:1) to irinotecan and temozolomide plus either temsirolimus or dinutuximab, stratified by disease category, previous exposure to anti-GD2 antibody therapy, and tumour MYCN amplification status.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28549783"}, {"offsetInBeginSection": 660, "offsetInEndSection": 841, "text": "Treatment for high-risk neuroblastoma includes induction chemotherapy, surgery, myeloablative chemotherapy with autologous hematopoietic stem cell transplant, and radiation therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818"}, {"offsetInBeginSection": 728, "offsetInEndSection": 900, "text": "Patients of any age were eligible at first designation of relapse or progression, or first designation of refractory disease, provided organ function requirements were met.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28549783"}, {"offsetInBeginSection": 3156, "offsetInEndSection": 3281, "text": "Irinotecan-temozolomide-dinutuximab shows notable anti-tumour activity in patients with relapsed or refractory neuroblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28549783"}, {"offsetInBeginSection": 825, "offsetInEndSection": 988, "text": "CONCLUSION: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455"}]}, {"id": "5ac24c9495d0062724000002", "body": "What is the ChIP-exo method used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28060339", "http://www.ncbi.nlm.nih.gov/pubmed/23026909", "http://www.ncbi.nlm.nih.gov/pubmed/24373287", "http://www.ncbi.nlm.nih.gov/pubmed/25249628", "http://www.ncbi.nlm.nih.gov/pubmed/27246337"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "The ChIP-exo Method: Identifying Protein-DNA Interactions with Near Base Pair Precision.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Chromatin immunoprecipitation (ChIP) is an indispensable tool in the fields of epigenetics and gene regulation that isolates specific protein-DNA interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 160, "offsetInEndSection": 306, "text": "ChIP coupled to high throughput sequencing (ChIP-seq) is commonly used to determine the genomic location of proteins that interact with chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 307, "offsetInEndSection": 431, "text": "However, ChIP-seq is hampered by relatively low mapping resolution of several hundred base pairs and high background signal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 432, "offsetInEndSection": 544, "text": "The ChIP-exo method is a refined version of ChIP-seq that substantially improves upon both resolution and noise.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 545, "offsetInEndSection": 775, "text": "The key distinction of the ChIP-exo methodology is the incorporation of lambda exonuclease digestion in the library preparation workflow to effectively footprint the left and right 5' DNA borders of the protein-DNA crosslink site.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 776, "offsetInEndSection": 848, "text": "The ChIP-exo libraries are then subjected to high throughput sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 986, "offsetInEndSection": 1138, "text": "Here, we describe the ChIP-exo method that we have optimized and streamlined for mammalian systems and next-generation sequencing-by-synthesis platform.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "ChIP-exo method for identifying genomic location of DNA-binding proteins with near-single-nucleotide accuracy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026909"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "This unit describes the ChIP-exo methodology, which combines chromatin immunoprecipitation (ChIP) with lambda exonuclease digestion followed by high-throughput sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026909"}]}, {"id": "5a74acd80384be9551000006", "body": "Are AAV vectors considered for the treatment of retinal dystrophies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21818300", "http://www.ncbi.nlm.nih.gov/pubmed/28596937", "http://www.ncbi.nlm.nih.gov/pubmed/21880665", "http://www.ncbi.nlm.nih.gov/pubmed/19373675", "http://www.ncbi.nlm.nih.gov/pubmed/24327302", "http://www.ncbi.nlm.nih.gov/pubmed/27416076", "http://www.ncbi.nlm.nih.gov/pubmed/27653967", "http://www.ncbi.nlm.nih.gov/pubmed/26609316", "http://www.ncbi.nlm.nih.gov/pubmed/15960597", "http://www.ncbi.nlm.nih.gov/pubmed/26015954"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "BACKGROUND: Gene transfer using adeno-associated viral (AAV) vectors has been successfully applied in the retina for the treatment of inherited retinal dystrophies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818300"}, {"offsetInBeginSection": 271, "offsetInEndSection": 502, "text": "Here we evaluated the ability of retinal-expressed microRNAs to restrict AAV-mediated transgene expression to specific retinal cell types that represent the main targets of common inherited blinding conditions.METHODOLOGY/PRINCIPAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818300"}, {"offsetInBeginSection": 790, "offsetInEndSection": 999, "text": "Our results demonstrate that miR-124 and miR-204 target sequences can efficiently restrict AAV2/5-mediated transgene expression to retinal pigment epithelium and photoreceptors, respectively, in mice and pigs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818300"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Harnessing the Potential of Human Pluripotent Stem Cells and Gene Editing for the Treatment of Retinal Degeneration.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596937"}, {"offsetInBeginSection": 11, "offsetInEndSection": 143, "text": "REVIEW: A major cause of visual disorders is dysfunction and/or loss of the light-sensitive cells of the retina, the photoreceptors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596937"}, {"offsetInBeginSection": 144, "offsetInEndSection": 293, "text": "To develop better treatments for patients, we need to understand how inherited retinal disease mutations result in the dysfunction of photoreceptors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596937"}, {"offsetInBeginSection": 294, "offsetInEndSection": 494, "text": "New advances in the field of stem cell and gene editing research offer novel ways to model retinal dystrophies in vitro and present opportunities to translate basic biological insights into therapies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596937"}, {"offsetInBeginSection": 495, "offsetInEndSection": 649, "text": "This brief review will discuss some of the issues that should be taken into account when carrying out disease modelling and gene editing of retinal cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596937"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1081, "text": "FINDINGS: Ground-breaking advances in differentiation of iPSCs into retinal organoids and methods to derive mature light sensitive photoreceptors from iPSCs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596937"}, {"offsetInBeginSection": 1082, "offsetInEndSection": 1224, "text": "Furthermore, single AAV systems for in vivo gene editing have been developed which makes retinal in vivo gene editing therapy a real prospect.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596937"}]}, {"id": "5ab2cc66fcf4565872000015", "body": "Cytochrome p450 CYP3A is induced by rifampicin  and compounds used to treat what virus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18799805", "http://www.ncbi.nlm.nih.gov/pubmed/15726657", "http://www.ncbi.nlm.nih.gov/pubmed/10620362", "http://www.ncbi.nlm.nih.gov/pubmed/23071008", "http://www.ncbi.nlm.nih.gov/pubmed/23974699", "http://www.ncbi.nlm.nih.gov/pubmed/11090943", "http://www.ncbi.nlm.nih.gov/pubmed/9413920", "http://www.ncbi.nlm.nih.gov/pubmed/10628745", "http://www.ncbi.nlm.nih.gov/pubmed/16432264", "http://www.ncbi.nlm.nih.gov/pubmed/26910068"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Cytochrome P450 3A4 (CYP3A4), the most abundant human cytochrome P450 in liver, participates in the metabolism of approximately 50% of clinically used drugs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799805"}, {"offsetInBeginSection": 687, "offsetInEndSection": 857, "text": "In TgCYP3A4/hPXR mice, CYP3A4 was strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799805"}, {"offsetInBeginSection": 858, "offsetInEndSection": 995, "text": "Consistent with CYP3A expression, hepatic CYP3A activity increased approximately 5-fold in TgCYP3A4/hPXR mice pretreated with rifampicin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799805"}, {"offsetInBeginSection": 996, "offsetInEndSection": 1232, "text": "Most antihuman immunodeficiency virus protease inhibitors are CYP3A substrates and their interactions with rifamycins are a source of major concern in patients coinfected with human immunodeficiency virus and Mycobacterium tuberculosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799805"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1696, "text": "In vivo, rifampicin pretreatment resulted in an approximately 80% decrease in the area under the serum amprenavir concentration-time curve in TgCYP3A4/hPXR mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799805"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15726657"}, {"offsetInBeginSection": 131, "offsetInEndSection": 311, "text": "CYP3A is of key importance in human drug metabolism, being involved in presystemic extraction of more than 50% of all drugs currently available and of various endogenous compounds.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15726657"}, {"offsetInBeginSection": 312, "offsetInEndSection": 489, "text": "Therefore, we compared the induction potential of UDCA with that of the prototypical inducer rifampicin in a human model study with the CYP3A substrates budesonide and cortisol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15726657"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1036, "text": "In parallel, urinary 6beta-hydroxycortisol, a validated marker of CYP3A induction, was determined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15726657"}, {"offsetInBeginSection": 1355, "offsetInEndSection": 1532, "text": "In contrast, administration of rifampicin markedly induced CYP3A metabolism, resulting in abolished budesonide plasma levels and high urinary excretion of 6beta-hydroxycortisol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15726657"}]}, {"id": "5ac0fccf19833b0d7b000007", "body": "What is the dardarin protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16750377"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Mutations in the LRRK2 gene, coding for dardarin, cause dominantly inherited Parkinson's disease (PD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 103, "offsetInEndSection": 204, "text": "Dardarin is a large protein, and mutations are found throughout the gene including the kinase domain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 312, "offsetInEndSection": 392, "text": "In this study, we noted two cellular phenotypes associated with mutant dardarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 393, "offsetInEndSection": 480, "text": "First, pathogenic mutations increase the tendency of dardarin to form inclusion bodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 858, "offsetInEndSection": 1000, "text": "We also show that dardarin protein is expressed within human midbrain neurons and that C-terminal epitopes are also found in some Lewy bodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 481, "offsetInEndSection": 577, "text": "Secondly, neurons and neuronal cell lines undergo cell death after expression of mutant protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 205, "offsetInEndSection": 311, "text": "However, it is not clear if kinase activity is important for the damaging effects of pathogenic mutations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 724, "offsetInEndSection": 857, "text": "This predicts that kinase inhibitors will be useful therapeutic agents in patients with LRRK2 mutations and, perhaps, in sporadic PD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}, {"offsetInBeginSection": 578, "offsetInEndSection": 723, "text": "Manipulating activity by replacing the kinase domain with a 'kinase-dead' version blocks inclusion body formation and strongly delays cell death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377"}]}, {"id": "58ec709aeda5a5767200000e", "body": "Does International Citicoline Trial on acUte Stroke trial supports efficacy of citicoline for stroke treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18637642", "http://www.ncbi.nlm.nih.gov/pubmed/22691567", "http://www.ncbi.nlm.nih.gov/pubmed/23600725", "http://www.ncbi.nlm.nih.gov/pubmed/27234918", "http://www.ncbi.nlm.nih.gov/pubmed/11706098", "http://www.ncbi.nlm.nih.gov/pubmed/19351232", "http://www.ncbi.nlm.nih.gov/pubmed/27072975", "http://www.ncbi.nlm.nih.gov/pubmed/10582983", "http://www.ncbi.nlm.nih.gov/pubmed/9305321", "http://www.ncbi.nlm.nih.gov/pubmed/12468781"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637642"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "The International Citicoline Trial in acUte Stroke is a sequential phase III study of the use of the drug citicoline in the treatment of acute ischaemic stroke, which was initiated in 2006 in 56 treatment centres.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637642"}, {"offsetInBeginSection": 214, "offsetInEndSection": 390, "text": "The primary objective of the trial is to demonstrate improved recovery of patients randomized to citicoline relative to those randomized to placebo after 12 weeks of follow-up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637642"}, {"offsetInBeginSection": 391, "offsetInEndSection": 628, "text": "The primary analysis will take the form of a global test combining the dichotomized results of assessments on three well-established scales: the Barthel Index, the modified Rankin scale and the National Institutes of Health Stroke Scale.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637642"}, {"offsetInBeginSection": 629, "offsetInEndSection": 1177, "text": "This approach was previously used in the analysis of the influential National Institute of Neurological Disorders and Stroke trial of recombinant tissue plasminogen activator in stroke.The purpose of this paper is to describe how this trial was designed, and in particular how the simultaneous objectives of taking into account three assessment scales, performing a series of interim analyses and conducting treatment allocation and adjusting the analyses to account for prognostic factors, including more than 50 treatment centres, were addressed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637642"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22691567"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "BACKGROUND: Citicoline is approved in some countries for the treatment of acute ischaemic stroke.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22691567"}, {"offsetInBeginSection": 165, "offsetInEndSection": 231, "text": "We sought to confirm the efficacy of citicoline in a larger trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22691567"}, {"offsetInBeginSection": 231, "offsetInEndSection": 428, "text": "METHODS: We undertook a randomised, placebo-controlled, sequential trial in patients with moderate-to-severe acute ischaemic stroke admitted at university hospitals in Germany, Portugal, and Spain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22691567"}, {"offsetInBeginSection": 429, "offsetInEndSection": 736, "text": "Using a centralised minimisation process, patients were randomly assigned in a 1:1 ratio to receive citicoline or placebo within 24 h after the onset of symptoms (1000 mg every 12 h intravenously during the first 3 days and orally thereafter for a total of 6 weeks [2\u00d7500 mg oral tablets given every 12 h]).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22691567"}]}, {"id": "5ace238e0340b9f05800000d", "body": "Which human chromosome is the product of fusion?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27423248", "http://www.ncbi.nlm.nih.gov/pubmed/3325883", "http://www.ncbi.nlm.nih.gov/pubmed/7284984", "http://www.ncbi.nlm.nih.gov/pubmed/28333343", "http://www.ncbi.nlm.nih.gov/pubmed/9310467", "http://www.ncbi.nlm.nih.gov/pubmed/15815621", "http://www.ncbi.nlm.nih.gov/pubmed/8364539", "http://www.ncbi.nlm.nih.gov/pubmed/3289649", "http://www.ncbi.nlm.nih.gov/pubmed/7786792", "http://www.ncbi.nlm.nih.gov/pubmed/10470089"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Chromosome-Specific Centromere Sequences Provide an Estimate of the Ancestral Chromosome 2 Fusion Event in Hominin Genomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27423248"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27423248"}, {"offsetInBeginSection": 339, "offsetInEndSection": 705, "text": "Unlike the site of fusion, which is enriched for sequences that are shared elsewhere in the human genome, the region of the nonfunctioning and degenerate ancestral centromere appears to share limited similarity with other sites in the human genome, thereby providing an opportunity to study this genomic arrangement in short, fragmented ancient DNA genomic datasets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27423248"}, {"offsetInBeginSection": 178, "offsetInEndSection": 371, "text": "These analyses reveal that the met kinase domain (located on human chromosome 7) possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3325883"}, {"offsetInBeginSection": 372, "offsetInEndSection": 592, "text": "The results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein, which is encoded by human chromosome 1, exhibits homology to laminin B1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3325883"}, {"offsetInBeginSection": 205, "offsetInEndSection": 372, "text": "We hypothesize that the near tetraploid chromosome number present in the tumor cells in both patients may be the product of fusion of two near diploid malignant cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7284984"}, {"offsetInBeginSection": 373, "offsetInEndSection": 532, "text": "Also it is speculated that some colorectal tumors with chromosomes ranging from the hypotriploid to the hypotetraploid levels may be the result of cell fusion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7284984"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Centromere Destiny in Dicentric Chromosomes: New Insights from the Evolution of Human Chromosome 2 Ancestral Centromeric Region.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28333343"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Dicentric chromosomes are products of genomic rearrangements that place two centromeres on the same chromosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28333343"}, {"offsetInBeginSection": 398, "offsetInEndSection": 631, "text": "Our understanding to date of dicentric chromosome formation, behavior and fate has been largely inferred from observational studies in plants and humans as well as artificially produced de novo dicentrics in yeast and in human cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28333343"}]}, {"id": "5a7d5580faa1ab7d2e00001a", "body": "What in vivo tau tracers are being used?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24833492", "http://www.ncbi.nlm.nih.gov/pubmed/28219440", "http://www.ncbi.nlm.nih.gov/pubmed/28587897", "http://www.ncbi.nlm.nih.gov/pubmed/24924676", "http://www.ncbi.nlm.nih.gov/pubmed/28750496", "http://www.ncbi.nlm.nih.gov/pubmed/27683159", "http://www.ncbi.nlm.nih.gov/pubmed/27334944", "http://www.ncbi.nlm.nih.gov/pubmed/26697966", "http://www.ncbi.nlm.nih.gov/pubmed/26802556", "http://www.ncbi.nlm.nih.gov/pubmed/25239654"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24833492"}, {"offsetInBeginSection": 526, "offsetInEndSection": 658, "text": "Selective PET radiotracers for amyloid-\u03b2 are already available, and potential tau tracers are emerging as new-generation biomarkers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24833492"}, {"offsetInBeginSection": 659, "offsetInEndSection": 798, "text": "An overview of the tau-PET radiotracer development scenario, focusing on tracers that are presently being examined in humans, is presented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24833492"}, {"offsetInBeginSection": 198, "offsetInEndSection": 324, "text": "Consequently, it is important to be able to accurately and specifically target tau deposits in vivo in the brains of patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219440"}, {"offsetInBeginSection": 325, "offsetInEndSection": 536, "text": "The advances of molecular imaging in the recent years have now led to the recent development of promising tau-specific tracers for positron emission tomography (PET), such as THK5317, THK5351, AV-1451, and PBB3.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219440"}, {"offsetInBeginSection": 537, "offsetInEndSection": 693, "text": "These tracers are now available for clinical assessment in patients with various tauopathies, including Alzheimer's disease, as well as in healthy subjects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219440"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1078, "text": "The variety and complexity of the different types of tau deposits in the different diseases, however, has resulted in quite a challenge for the development of tau PET tracers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219440"}, {"offsetInBeginSection": 1079, "offsetInEndSection": 1261, "text": "Extensive work remains in order to fully characterize the binding properties of the tau PET tracers, and to assess their usefulness as an early biomarker of the underlying pathology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219440"}, {"offsetInBeginSection": 0, "offsetInEndSection": 44, "text": "In vivo tau imaging: obstacles and progress.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24924676"}, {"offsetInBeginSection": 1055, "offsetInEndSection": 1169, "text": "A worldwide effort has focused on the development of imaging agents that will allow selective tau imaging in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24924676"}]}, {"id": "5ab90a79fcf456587200001b", "body": "What drug treatment can cause a spinal epidural hematoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22175167", "http://www.ncbi.nlm.nih.gov/pubmed/15043358", "http://www.ncbi.nlm.nih.gov/pubmed/11707724", "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "http://www.ncbi.nlm.nih.gov/pubmed/28614233", "http://www.ncbi.nlm.nih.gov/pubmed/27495842", "http://www.ncbi.nlm.nih.gov/pubmed/23351908", "http://www.ncbi.nlm.nih.gov/pubmed/18685937", "http://www.ncbi.nlm.nih.gov/pubmed/8447556", "http://www.ncbi.nlm.nih.gov/pubmed/21799620"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 39, "text": "[Risk management in spinal anesthesia].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22175167"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "More than one hundred years have passed since Bier first succeeded in spinal anesthesia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22175167"}, {"offsetInBeginSection": 170, "offsetInEndSection": 331, "text": "Spinal anesthesia requires both a simple technique and a small volume of drug, produces profound analgesia, and is devoid of systemic pharmacologic side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22175167"}, {"offsetInBeginSection": 332, "offsetInEndSection": 406, "text": "However, several complications after spinal anesthesia have been reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22175167"}, {"offsetInBeginSection": 493, "offsetInEndSection": 618, "text": "Those include cardiac arrest, meningitis, intracranial subdural hematoma, spinal epidural hematoma and cauda equina syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22175167"}, {"offsetInBeginSection": 782, "offsetInEndSection": 947, "text": "The prediction, early detection and prompt start of the treatment of the complications after spinal anesthesia are important to minimize the risk of adverse outcome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22175167"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Spinal epidural hematoma associated with oral anticoagulation therapy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043358"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Spontaneous spinal epidural hematoma is an uncommon cause of spinal cord compression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043358"}, {"offsetInBeginSection": 291, "offsetInEndSection": 511, "text": "Spontaneous spinal epidural hematoma should be suspected in any patient receiving anticoagulant agents who complains of local or referred spinal pain associated with limb weakness, sensory deficits, or urinary retention.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043358"}, {"offsetInBeginSection": 706, "offsetInEndSection": 913, "text": "Although primary management is the surgical evacuation of the spinal epidural hematoma via laminectomy, rare cases in which the patient is improving rapidly and progressively could be treated conservatively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043358"}]}, {"id": "5ac28c0c95d006272400000a", "body": "What is the basis of the Sp3 procedure used in proteomics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25358341", "http://www.ncbi.nlm.nih.gov/pubmed/28948796", "http://www.ncbi.nlm.nih.gov/pubmed/27668303"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "In order to obtain a systems-level understanding of a complex biological system, detailed proteome information is essential.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341"}, {"offsetInBeginSection": 125, "offsetInEndSection": 304, "text": "Despite great progress in proteomics technologies, thorough interrogation of the proteome from quantity-limited biological samples is hampered by inefficiencies during processing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341"}, {"offsetInBeginSection": 305, "offsetInEndSection": 459, "text": "To address these challenges, here we introduce a novel protocol using paramagnetic beads, termed Single-Pot Solid-Phase-enhanced Sample Preparation (SP3).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341"}, {"offsetInBeginSection": 460, "offsetInEndSection": 698, "text": "SP3 provides a rapid and unbiased means of proteomic sample preparation in a single tube that facilitates ultrasensitive analysis by outperforming existing protocols in terms of efficiency, scalability, speed, throughput, and flexibility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341"}, {"offsetInBeginSection": 699, "offsetInEndSection": 927, "text": "To illustrate these benefits, characterization of 1,000 HeLa cells and single Drosophila embryos is used to establish that SP3 provides an enhanced platform for profiling proteomes derived from sub-microgram amounts of material.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1330, "text": "Together, the findings of this work position SP3 as a superior protocol that facilitates exciting new directions in multiple areas of proteomics ranging from developmental biology to clinical applications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Evaluation of FASP, SP3, and iST Protocols for Proteomic Sample Preparation in the Low Microgram Range.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948796"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Efficient and reproducible sample preparation is a prerequisite for any robust and sensitive quantitative bottom-up proteomics workflow.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948796"}, {"offsetInBeginSection": 137, "offsetInEndSection": 347, "text": "Here, we performed an independent comparison between single-pot solid-phase-enhanced sample preparation (SP3), filter-aided sample preparation (FASP), and a commercial kit based on the in-StageTip (iST) method.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948796"}, {"offsetInBeginSection": 770, "offsetInEndSection": 852, "text": "In contrast, SP3 and iST provided high proteome coverage even in the low \u03bcg range.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948796"}]}, {"id": "5a896c26fcd1d6a10c000007", "body": "In which syndrome is the RPS19 gene most frequently mutated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24675553", "http://www.ncbi.nlm.nih.gov/pubmed/23990987", "http://www.ncbi.nlm.nih.gov/pubmed/21223253", "http://www.ncbi.nlm.nih.gov/pubmed/12351378", "http://www.ncbi.nlm.nih.gov/pubmed/18515656", "http://www.ncbi.nlm.nih.gov/pubmed/17053056", "http://www.ncbi.nlm.nih.gov/pubmed/21989989", "http://www.ncbi.nlm.nih.gov/pubmed/21435505", "http://www.ncbi.nlm.nih.gov/pubmed/15075082"], "snippets": [{"offsetInBeginSection": 352, "offsetInEndSection": 540, "text": "In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675553"}, {"offsetInBeginSection": 635, "offsetInEndSection": 721, "text": "Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675553"}, {"offsetInBeginSection": 895, "offsetInEndSection": 1216, "text": "The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675553"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1356, "text": "In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675553"}, {"offsetInBeginSection": 1357, "offsetInEndSection": 1422, "text": "Among these patients, RPS19 was the most frequently mutated gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675553"}, {"offsetInBeginSection": 1423, "offsetInEndSection": 1674, "text": "In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675553"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that is characterized by pure red-cell aplasia and associated physical deformities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990987"}, {"offsetInBeginSection": 163, "offsetInEndSection": 309, "text": "It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990987"}, {"offsetInBeginSection": 310, "offsetInEndSection": 421, "text": "Previous studies suggest that p53-dependent genes and pathways play important roles in RPS19-deficient embryos.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990987"}, {"offsetInBeginSection": 513, "offsetInEndSection": 722, "text": "In this study, we compared the whole genome RNA-Seq data of zebrafish embryos injected with RPS19 morpholino (RPS19 MO), RPS19 and p53 morpholino simultaneously (RPS19+p53 MO) and control morpholino (control).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990987"}]}, {"id": "5ab908d4fcf456587200001a", "body": "What is the alternative lengthening of telomeres?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26428317", "http://www.ncbi.nlm.nih.gov/pubmed/26022452", "http://www.ncbi.nlm.nih.gov/pubmed/20403221", "http://www.ncbi.nlm.nih.gov/pubmed/19154407", "http://www.ncbi.nlm.nih.gov/pubmed/27726944", "http://www.ncbi.nlm.nih.gov/pubmed/26769142", "http://www.ncbi.nlm.nih.gov/pubmed/24531712", "http://www.ncbi.nlm.nih.gov/pubmed/22575867", "http://www.ncbi.nlm.nih.gov/pubmed/18215414", "http://www.ncbi.nlm.nih.gov/pubmed/21574432"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 105, "offsetInEndSection": 197, "text": "Alternative lengthening of telomeres is a telomere-maintenance mechanism common in sarcomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 371, "offsetInEndSection": 567, "text": "We previously reported that alternative lengthening of telomeres and loss of ATRX expression were common in leiomyosarcoma, angiosarcoma, pleomorphic liposarcoma, and dedifferentiated liposarcoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 568, "offsetInEndSection": 766, "text": "In the present study, we screened an additional 245 sarcomas of other types to determine the prevalence of alternative lengthening of telomeres, loss of ATRX/DAXX expression, and their relationship.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 767, "offsetInEndSection": 981, "text": "Undifferentiated pleomorphic sarcomas were frequently alternative lengthening of telomeres positive (65%) and loss of ATRX was seen in approximately half of the alternative lengthening of telomeres-positive tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 982, "offsetInEndSection": 1099, "text": "Nineteen of 25 myxofibrosarcomas were alternative lengthening of telomeres-positive, but only one was ATRX deficient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1230, "text": "Three of 15 radiation-associated sarcomas were alternative lengthening of telomeres positive, but none of them was ATRX deficient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 1231, "offsetInEndSection": 1412, "text": "Alternative lengthening of telomeres and/or loss of ATRX were uncommon in malignant peripheral nerve sheath tumors, gastrointestinal stromal tumors, and embryonal rhabdomyosarcomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1541, "text": "By contrast, none of the 71 gene fusion-associated sarcomas was ATRX deficient or alternative lengthening of telomeres positive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}, {"offsetInBeginSection": 1739, "offsetInEndSection": 1904, "text": "By telomere-specific fluorescence in situ hybridization, 45% (138/308) were alternative lengthening of telomeres positive, 55% (76/138) of which were ATRX deficient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317"}]}, {"id": "5abcf010fcf4565872000023", "body": "What nerve is involved in carpal tunnel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27894853", "http://www.ncbi.nlm.nih.gov/pubmed/7235907", "http://www.ncbi.nlm.nih.gov/pubmed/19336461", "http://www.ncbi.nlm.nih.gov/pubmed/25206437", "http://www.ncbi.nlm.nih.gov/pubmed/25630774", "http://www.ncbi.nlm.nih.gov/pubmed/26014322", "http://www.ncbi.nlm.nih.gov/pubmed/7594983", "http://www.ncbi.nlm.nih.gov/pubmed/6231697", "http://www.ncbi.nlm.nih.gov/pubmed/23590784", "http://www.ncbi.nlm.nih.gov/pubmed/28718333"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Concurrent carpal tunnel syndrome and pronator syndrome: A retrospective study of 21 cases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "PURPOSE: Concurrent carpal tunnel syndrome and pronator syndrome are rarely considered and the proximal compression sites are easily overlooked.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 349, "offsetInEndSection": 535, "text": "If paresthesia involved the thenar eminence and proximal forearm pain was noted in cases of carpal tunnel syndrome, carpal tunnel syndrome combined with pronator syndrome was considered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 536, "offsetInEndSection": 613, "text": "Additionally, nocturnal paresthesia symptoms are absent in pronator syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 614, "offsetInEndSection": 716, "text": "Therefore, if nocturnal symptoms occurred in pronator syndrome, carpal tunnel syndrome was considered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 717, "offsetInEndSection": 785, "text": "We included concurrent carpal tunnel syndrome and pronator syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 947, "offsetInEndSection": 1093, "text": "However, recurrent carpal tunnel cases were treated with the open carpal tunnel release and open pronator decompression procedure in our hospital.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1422, "text": "RESULTS: We retrospectively reviewed 344 cases of sustained carpal tunnel syndrome or pronator syndrome from the medical records of our institution.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 1423, "offsetInEndSection": 1591, "text": "Of the 344 cases, 322 involved carpal tunnel syndrome alone, 1 involved pronator syndrome alone, and 21 involved carpal tunnel syndrome combined with pronator syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}, {"offsetInBeginSection": 1592, "offsetInEndSection": 1690, "text": "The 21 cases of carpal tunnel syndrome combined with pronator syndrome were included in our study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853"}]}, {"id": "5ad240f70340b9f058000015", "body": "Is human lysyl oxidase-like 2 a glycoprotein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20306300", "http://www.ncbi.nlm.nih.gov/pubmed/28112368", "http://www.ncbi.nlm.nih.gov/pubmed/25146937", "http://www.ncbi.nlm.nih.gov/pubmed/28350101", "http://www.ncbi.nlm.nih.gov/pubmed/21954900", "http://www.ncbi.nlm.nih.gov/pubmed/17018530", "http://www.ncbi.nlm.nih.gov/pubmed/27063404", "http://www.ncbi.nlm.nih.gov/pubmed/7706256", "http://www.ncbi.nlm.nih.gov/pubmed/23319596", "http://www.ncbi.nlm.nih.gov/pubmed/11334717"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20306300"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "The lysyl oxidase-like 2 (LOXL2) protein is a human paralogue of lysyl oxidase (LOX) that functions as an amine oxidase for formation of lysine-derived cross-links found in collagen and elastin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20306300"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "LOXL3-sv2, a novel variant of human lysyl oxidase-like 3 (LOXL3), functions as an amine oxidase.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28112368"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Human lysyl oxidase-like 3\u00a0(LOXL3) functions as a copper-dependent amine oxidase toward collagen and elastin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28112368"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1250, "text": "These findings indicate that the human LOXL3\u00a0gene encodes at least three variants, LOXL3, LOXL3-sv1 and\u00a0LOXL3-sv2, all of which function as amine oxidases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28112368"}, {"offsetInBeginSection": 0, "offsetInEndSection": 27, "text": "Human lysyl oxidase-like 2.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25146937"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Lysyl oxidase like-2 (LOXL2) belongs to the lysyl oxidase (LOX) family, which comprises Cu(2+)- and lysine tyrosylquinone (LTQ)-dependent amine oxidases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25146937"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "LOXL3-sv2, a novel variant of human lysyl oxidase-like 3 (LOXL3), functions as an amine oxidase.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28350101"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Human lysyl oxidase-like 3\u00a0(LOXL3) functions as a copper-dependent amine oxidase toward collagen and elastin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28350101"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1250, "text": "These findings indicate that the human LOXL3\u00a0gene encodes at least three variants, LOXL3, LOXL3-sv1 and\u00a0LOXL3-sv2, all of which function as amine oxidases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28350101"}]}, {"id": "5a86e6fafaa1ab7d2e000036", "body": "What is the nucleotide composition of the Lamin Associated Domains (LADs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25602132", "http://www.ncbi.nlm.nih.gov/pubmed/26359231", "http://www.ncbi.nlm.nih.gov/pubmed/25559185", "http://www.ncbi.nlm.nih.gov/pubmed/24717229", "http://www.ncbi.nlm.nih.gov/pubmed/23934658", "http://www.ncbi.nlm.nih.gov/pubmed/25784758"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Distinct features of lamin A-interacting chromatin domains mapped by ChIP-sequencing from sonicated or micrococcal nuclease-digested chromatin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "The nuclear lamina has been shown to interact with the genome through lamina-associated domains (LADs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 104, "offsetInEndSection": 265, "text": "LADs have been identified by DamID, a proximity labeling assay, and more recently by chromatin immunoprecipitation-sequencing (ChIP-seq) of A- and B-type lamins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 266, "offsetInEndSection": 370, "text": "LADs form megabase-size domains at the nuclear periphery, they are gene-poor and mostly heterochromatic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 371, "offsetInEndSection": 601, "text": "Here, we show that the mode of chromatin fragmentation for ChIP, namely bath sonication or digestion with micrococcal nuclease (MNase), leads to the discovery of common but also distinct sets of lamin-interacting domains, or LiDs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 602, "offsetInEndSection": 775, "text": "Using ChIP-seq, we show the existence of lamin A/C (LMNA) LiDs with distinct gene contents, histone composition enrichment and relationships to lamin B1-interacting domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 776, "offsetInEndSection": 999, "text": "The extent of genome coverage of lamin A/C (LMNA) LiDs in sonicated or MNase-digested chromatin is similar (\u223c730 megabases); however over half of these domains are uniquely detected in sonicated or MNase-digested chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 1298, "offsetInEndSection": 1540, "text": "Comparison of published LMNB1 DamID LADs with LMNB1 and LMNA LiDs identified here by ChIP-seq further shows that LMNA can associate with 'open' chromatin domains displaying euchromatin characteristics, and which are not associated with LMNB1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 1541, "offsetInEndSection": 1800, "text": "The differential genomic and epigenetic properties of lamin-interacting domains reflect the existence of distinct LiD populations identifiable in different chromatin contexts, including nuclease-accessible regions presumably localized in the nuclear interior.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Prepatterning of differentiation-driven nuclear lamin A/C-associated chromatin domains by GlcNAcylated histone H2B.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26359231"}]}, {"id": "5ac716810340b9f058000003", "body": "Name an lncRNA associated with dilated cardiomyopathy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26951817"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Myocardial Infarction-Associated Transcript, a Long Noncoding RNA, Is Overexpressed During Dilated Cardiomyopathy Due to Chronic Chagas Disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}, {"offsetInBeginSection": 123, "offsetInEndSection": 258, "text": "Dysregulation of the lncRNA known as myocardial infarction-associated transcript (MIAT) has been associated with myocardial infarction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}, {"offsetInBeginSection": 259, "offsetInEndSection": 340, "text": "Chagas disease causes a severe inflammatory dilated chronic cardiomyopathy (CCC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}, {"offsetInBeginSection": 382, "offsetInEndSection": 624, "text": "A whole-transcriptome analysis of heart biopsy specimens and formalin-fixed, paraffin-embedded samples revealed that MIAT was overexpressed in patients with CCC, compared with subjects with noninflammatory dilated cardiomyopathy and controls.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}, {"offsetInBeginSection": 672, "offsetInEndSection": 729, "text": "Results suggest that MIAT is a specific biomarker of CCC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Long noncoding RNAs (lncRNAs) modulate gene expression at the epigenetic, transcriptional, and posttranscriptional levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}, {"offsetInBeginSection": 341, "offsetInEndSection": 381, "text": "We investigated the role of MIAT in CCC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}, {"offsetInBeginSection": 625, "offsetInEndSection": 671, "text": "These results were confirmed in a mouse model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817"}]}, {"id": "5abcf108fcf4565872000025", "body": "What is myelin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28377211", "http://www.ncbi.nlm.nih.gov/pubmed/7650750", "http://www.ncbi.nlm.nih.gov/pubmed/24684721", "http://www.ncbi.nlm.nih.gov/pubmed/20186338", "http://www.ncbi.nlm.nih.gov/pubmed/25682762", "http://www.ncbi.nlm.nih.gov/pubmed/21401967", "http://www.ncbi.nlm.nih.gov/pubmed/2752082", "http://www.ncbi.nlm.nih.gov/pubmed/22102008", "http://www.ncbi.nlm.nih.gov/pubmed/2470784", "http://www.ncbi.nlm.nih.gov/pubmed/6191815"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Myelin content is an important marker for neuropathology and MRI generated myelin water fraction (MWF) has been shown to correlate well with myelin content.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 157, "offsetInEndSection": 344, "text": "However, because MWF is based on the amount of signal from myelin water, that is, the water trapped between the myelin lipid bilayers, the reading may depend heavily on myelin morphology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 345, "offsetInEndSection": 453, "text": "This is of special concern when there is a mix of intact myelin and myelin debris, as in the case of injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 454, "offsetInEndSection": 649, "text": "To investigate what MWF measures in the presence of debris, we compared MWF to transmission electron microscopy (TEM) derived myelin fraction that measures the amount of compact appearing myelin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 650, "offsetInEndSection": 830, "text": "A rat spinal cord injury model was used with time points at normal (normal myelin), 3 weeks post-injury (myelin debris), and 8 weeks post-injury (myelin debris, partially cleared).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 831, "offsetInEndSection": 1047, "text": "The myelin period between normal and 3 or 8 weeks post-injury cords did not differ significantly, suggesting that as long as the bilayer structure is intact, myelin debris has the same water content as intact myelin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 1048, "offsetInEndSection": 1227, "text": "The MWF also correlated strongly with the TEM-derived myelin fraction, suggesting that MWF measures the amount of compact appearing myelin in both intact myelin and myelin debris.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 1228, "offsetInEndSection": 1391, "text": "From the TEM images, it appears that as myelin degenerates, it tends to form large watery spaces within the myelin sheaths that are not classified as myelin water.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377211"}, {"offsetInBeginSection": 131, "offsetInEndSection": 279, "text": "The emphasis is on CNS myelin of adult mammals although both central nervous system (CNS) and peripheral nervous system (PNS) myelin are considered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7650750"}, {"offsetInBeginSection": 280, "offsetInEndSection": 356, "text": "The ability to prepare vesicle of myelin membrane has yet not been feasible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7650750"}]}, {"id": "5ad3013d0340b9f058000019", "body": "Can GDF15 be a biomarker for metformin treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27974345"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Growth Differentiation Factor 15 as a Novel Biomarker for Metformin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 180, "offsetInEndSection": 373, "text": "METHODS: A total of 237 biomarkers were assayed in baseline serum from 8,401 participants (2,317 receiving metformin) in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 374, "offsetInEndSection": 443, "text": "Regression models were used to identify biomarkers for metformin use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 443, "offsetInEndSection": 695, "text": "RESULTS: Growth differentiation factor 15 (GDF15) was strongly linked to metformin, such that the odds of metformin use per SD increase in level varied from 3.73 (95% CI 3.40, 4.09) to 3.94 (95% CI 3.59, 4.33) depending on the other included variables.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 771, "offsetInEndSection": 846, "text": "A 1.64 ng/mL higher GDF15 level predicted a 188-mg higher metformin dose (P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 847, "offsetInEndSection": 995, "text": "CONCLUSIONS: GDF15 levels are a biomarker for the use of metformin in people with dysglycemia, and its concentration reflects the dose of metformin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "OBJECTIVE: Metformin is a commonly used glucose-lowering drug.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 63, "offsetInEndSection": 179, "text": "However, apart from glycemic measures, no biomarker for its presence or dose has been identified.RESEARCH DESIGN AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}, {"offsetInBeginSection": 696, "offsetInEndSection": 770, "text": "For the remaining 25 linked biomarkers, the odds ranged from 0.71 to 1.24.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345"}]}, {"id": "5a8d8f39fcd1d6a10c000024", "body": "What is the TALE-iD method used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27940490", "http://www.ncbi.nlm.nih.gov/pubmed/23840477", "http://www.ncbi.nlm.nih.gov/pubmed/26854857", "http://www.ncbi.nlm.nih.gov/pubmed/24976123", "http://www.ncbi.nlm.nih.gov/pubmed/27811079", "http://www.ncbi.nlm.nih.gov/pubmed/26876161", "http://www.ncbi.nlm.nih.gov/pubmed/28074901", "http://www.ncbi.nlm.nih.gov/pubmed/23316790", "http://www.ncbi.nlm.nih.gov/pubmed/23869221", "http://www.ncbi.nlm.nih.gov/pubmed/23821439"], "snippets": [{"offsetInBeginSection": 778, "offsetInEndSection": 1139, "text": "Using different cell types and loci, computational modeling, and a methylation-based orthogonal validation method, \"TALE-iD\", we show that native interactions resemble cross-linked ones, but display improved signal-to-noise ratios and are more focal on regulatory elements and CTCF sites, while strictly abiding to topologically associating domain restrictions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "A simple and efficient method for assembling TALE protein based on plasmid library.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840477"}, {"offsetInBeginSection": 637, "offsetInEndSection": 816, "text": "Here, we described a simple and efficient method for generating customized TALE nucleases (TALENs) and TALE transcription factors (TALE-TFs) based on TALE repeat tetramer library.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840477"}, {"offsetInBeginSection": 1468, "offsetInEndSection": 1563, "text": "Sequencing results suggested that all TALE constructs were performed with high successful rate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840477"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Transcription activator-like effectors (TALEs) are extremely effective, single-molecule DNA-targeting molecular cursors used for locus-specific genome science applications, including high-precision molecular medicine and other genome engineering applications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26854857"}, {"offsetInBeginSection": 260, "offsetInEndSection": 439, "text": "TALEs are used in genome engineering for locus-specific DNA editing and imaging, as artificial transcriptional activators and repressors, and for targeted epigenetic modification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26854857"}, {"offsetInBeginSection": 625, "offsetInEndSection": 685, "text": "One bottleneck of broader TALE use is reagent accessibility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26854857"}, {"offsetInBeginSection": 771, "offsetInEndSection": 1062, "text": "Here we describe FusX, a streamlined Golden Gate TALE assembly system that (1) is backward compatible with popular TALE backbones, (2) is functionalized as a single-tube 3-day TALE assembly process, (3) requires only commonly used basic molecular biology reagents, and (4) is cost-effective.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26854857"}, {"offsetInBeginSection": 1409, "offsetInEndSection": 1570, "text": "To demonstrate, we use a highly accessible and commercially available liquid-handling robot to rapidly and accurately assemble TALEs using the FusX TALE toolkit.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26854857"}, {"offsetInBeginSection": 1571, "offsetInEndSection": 1751, "text": "Together, the FusX system accelerates TALE-based genomic science applications from basic science screening work for functional genomics testing and molecular medicine applications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26854857"}]}, {"id": "5aa395fcd6d6b54f79000007", "body": "Has rituximab been considered as a treatment for chronic fatigues syndrome? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22007328", "http://www.ncbi.nlm.nih.gov/pubmed/28243993", "http://www.ncbi.nlm.nih.gov/pubmed/28984295", "http://www.ncbi.nlm.nih.gov/pubmed/28164324", "http://www.ncbi.nlm.nih.gov/pubmed/21247220", "http://www.ncbi.nlm.nih.gov/pubmed/10589082", "http://www.ncbi.nlm.nih.gov/pubmed/28782884", "http://www.ncbi.nlm.nih.gov/pubmed/28235209", "http://www.ncbi.nlm.nih.gov/pubmed/28877546", "http://www.ncbi.nlm.nih.gov/pubmed/28856423"], "snippets": [{"offsetInBeginSection": 561, "offsetInEndSection": 772, "text": "Participants cited a range of etiologies and overlapping conditions including asthma, Reactive Airway Dysfunction Syndrome (RADS), Sick Building Syndrome (SBS), Chronic Fatigues Syndrome (CFS), and Fibromyalgia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22007328"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993"}, {"offsetInBeginSection": 8, "offsetInEndSection": 185, "text": "STATEMENT: The front-line management of patients with chronic lymphocytic leukemia (CLL) has evolved significantly in recent years due to introduction of novel, targeted agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1215, "text": "For those young, fit patients with high-risk disease and a contraindication to ibrutinib, FCR, or high-dose methylprednisolone and rituximab are options.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993"}, {"offsetInBeginSection": 1216, "offsetInEndSection": 1369, "text": "In regard to older, unfit patients, a careful assessment of their fitness and ability to tolerate treatment should be undertaken before starting therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993"}, {"offsetInBeginSection": 1668, "offsetInEndSection": 1773, "text": "For the low-risk patients, bendamustine and rituximab or obinutuzumab and chlorambucil can be considered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993"}, {"offsetInBeginSection": 1774, "offsetInEndSection": 1857, "text": "For the high-risk patients, treatment with rituximab and lenalidomide is an option.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993"}, {"offsetInBeginSection": 403, "offsetInEndSection": 576, "text": "Studies in animal models where a single copy of the syntenic 16p11.2 region has been deleted have revealed morphological, behavioral, and electrophysiological abnormalities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28984295"}, {"offsetInBeginSection": 577, "offsetInEndSection": 730, "text": "Previous studies suggested the possibility of some overlap in the mechanisms of pathophysiology in 16p11.2 microdeletion syndrome and fragile X syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28984295"}, {"offsetInBeginSection": 731, "offsetInEndSection": 859, "text": "Improvements in fragile X phenotypes have been observed following chronic treatment with R-baclofen, a selective agonist of GABA", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28984295"}]}, {"id": "5aa67b4fd6d6b54f7900000f", "body": "What disease is tinea ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21169831", "http://www.ncbi.nlm.nih.gov/pubmed/15050029", "http://www.ncbi.nlm.nih.gov/pubmed/12040364", "http://www.ncbi.nlm.nih.gov/pubmed/24739076", "http://www.ncbi.nlm.nih.gov/pubmed/8021081", "http://www.ncbi.nlm.nih.gov/pubmed/7742235", "http://www.ncbi.nlm.nih.gov/pubmed/19231646", "http://www.ncbi.nlm.nih.gov/pubmed/8821157", "http://www.ncbi.nlm.nih.gov/pubmed/134458", "http://www.ncbi.nlm.nih.gov/pubmed/19942789"], "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 354, "text": "REVIEW: The aim is to provide an overview on tinea imbricata, or Tokelau, a superficial mycosis caused by Trichophyton concentricum, a strictly anthropophilic dermatophyte with a well-defined geographic distribution and predisposing factors that include genetic, racial and immunologic susceptibility patterns and a specific environment.RECENT", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169831"}, {"offsetInBeginSection": 355, "offsetInEndSection": 689, "text": "FINDINGS: This review covers the most interesting aspects of the infrequent disease tinea imbricata, including the historical background, the epidemiologic aspects, highlighting the genetic and racial patterns of susceptibility to the acquisition of the disease, and the immunologic aspects that help to explain its clinical behavior.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169831"}, {"offsetInBeginSection": 690, "offsetInEndSection": 892, "text": "We also present a clinical description of the disease, the differential diagnosis and how currently some other emerging diseases such as syphilis in immunocompromised patients can mimic tinea imbricata.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169831"}, {"offsetInBeginSection": 893, "offsetInEndSection": 1126, "text": "The therapeutic options are still griseofulvin and nowadays terbinafine, but the access to the treatments in the endemic zones and the changes in habits of the affected population make control and prevention of the disease difficult.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169831"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Dermatology for the practicing allergist: Tinea pedis and its complications.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050029"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Tinea pedis is a chronic fungal infection of the feet, very often observed in patients who are immuno-suppressed or have diabetes mellitus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050029"}, {"offsetInBeginSection": 227, "offsetInEndSection": 310, "text": "Sometimes tinea infection may be mistaken for atopic dermatitis or allergic eczema.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050029"}, {"offsetInBeginSection": 311, "offsetInEndSection": 424, "text": "In other patients, tinea pedis may complicate allergy and asthma and may contribute to refractory atopic disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050029"}, {"offsetInBeginSection": 425, "offsetInEndSection": 591, "text": "Patients with recurrent cellulitis may be referred to the allergist/immunologist for an immune evaluation and discovered to have tinea pedis as a predisposing factor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050029"}, {"offsetInBeginSection": 882, "offsetInEndSection": 1039, "text": "Three groups of fungal pathogens, referred to as dermatophytes, have been shown to cause tinea pedis: Trychophyton sp, Epidermophyton sp, and Microsporum sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050029"}]}, {"id": "5ad4dd93133db5eb78000008", "body": "What is the clathrin triskelia structure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19925798", "http://www.ncbi.nlm.nih.gov/pubmed/22563470", "http://www.ncbi.nlm.nih.gov/pubmed/18502808", "http://www.ncbi.nlm.nih.gov/pubmed/7738035", "http://www.ncbi.nlm.nih.gov/pubmed/1587861", "http://www.ncbi.nlm.nih.gov/pubmed/7674375", "http://www.ncbi.nlm.nih.gov/pubmed/2571614", "http://www.ncbi.nlm.nih.gov/pubmed/23270814", "http://www.ncbi.nlm.nih.gov/pubmed/11943181", "http://www.ncbi.nlm.nih.gov/pubmed/10926122"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "AFM visualization of clathrin triskelia under fluid and in air.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19925798"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Atomic force microscopy (AFM) is used to characterize the structure and interactions of clathrin triskelia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19925798"}, {"offsetInBeginSection": 108, "offsetInEndSection": 248, "text": "Time sequence images of individual, wet triskelia resting on mica surfaces clearly demonstrate conformational fluctuations of the triskelia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19925798"}, {"offsetInBeginSection": 387, "offsetInEndSection": 605, "text": "Increased numbers of triskelion dimers and assembly intermediates, as well as structures having dimensions similar to those of clathrin cages, are observed when the triskelia were immersed in a low salt, low pH buffer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19925798"}, {"offsetInBeginSection": 272, "offsetInEndSection": 426, "text": "We herein introduce new bio-nanotechnology approaches for designing CNS contrast media based on the ubiquitous clathrin cell protein.METHODOLOGY/PRINCIPAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470"}, {"offsetInBeginSection": 427, "offsetInEndSection": 538, "text": "FINDINGS: The first approach utilizes three-legged clathrin triskelia modified to carry 81 gadolinium chelates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470"}, {"offsetInBeginSection": 539, "offsetInEndSection": 655, "text": "The second approach uses clathrin cages self-assembled from triskelia and designed to carry 432 gadolinium chelates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470"}, {"offsetInBeginSection": 656, "offsetInEndSection": 783, "text": "Clathrin triskelia and cages were characterized by size, structure, protein concentration, and chelate and gadolinium contents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1165, "text": "Clathrin nanoparticles can be constituted as triskelia (18.5 nm in size), and as cages assembled from them (55 nm).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1275, "text": "The mean chelate: clathrin heavy chain molar ratio was 27.04\u00b14.8: 1 for triskelia, and 4.2\u00b11.04: 1 for cages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470"}]}, {"id": "5ace37d50340b9f058000011", "body": "Which is the main reason for the increase in the incidence of cryptococcal disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16034947", "http://www.ncbi.nlm.nih.gov/pubmed/19009138", "http://www.ncbi.nlm.nih.gov/pubmed/19127040", "http://www.ncbi.nlm.nih.gov/pubmed/21982529", "http://www.ncbi.nlm.nih.gov/pubmed/17290547", "http://www.ncbi.nlm.nih.gov/pubmed/16011530", "http://www.ncbi.nlm.nih.gov/pubmed/14716388", "http://www.ncbi.nlm.nih.gov/pubmed/14617302", "http://www.ncbi.nlm.nih.gov/pubmed/19245939", "http://www.ncbi.nlm.nih.gov/pubmed/28483415"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "BACKGROUND: Cryptococcal disease is an opportunistic infection that causes significant morbidity and mortality in adults with HIV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947"}, {"offsetInBeginSection": 131, "offsetInEndSection": 250, "text": "Primary prophylaxis with antifungal interventions may decrease cryptococcal disease incidence and associated mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947"}, {"offsetInBeginSection": 250, "offsetInEndSection": 389, "text": "OBJECTIVES: To assess the efficacy of antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.SEARCH", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947"}, {"offsetInBeginSection": 1382, "offsetInEndSection": 1643, "text": "Key words used include: meningitis, cryptococcal, cryptococcus, cryptococcosis, acquired immunodeficiency syndrome, human immunodeficiency virus, prophylaxis, chemoprevention, antifungal agents, and the Cochrane screen for randomized controlled trials.SELECTION", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947"}, {"offsetInBeginSection": 1644, "offsetInEndSection": 1817, "text": "CRITERIA: Randomized controlled trials using antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV were selected.DATA COLLECTION AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947"}, {"offsetInBeginSection": 2211, "offsetInEndSection": 2394, "text": "CONCLUSIONS: Antifungal primary prophylaxis with either itraconazole or fluconazole is effective in reducing the incidence of cryptococcal disease in adults with advanced HIV disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "The objective of this article was to evaluate the epidemiology of cryptococcal meningitis in Rio de Janeiro State, Brazil, from 1994 to 2004.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009138"}, {"offsetInBeginSection": 142, "offsetInEndSection": 271, "text": "Six hundred and ninety-six cases of cryptococcal meningitis were reported, with a mean incidence of 0.45 per 100,000 inhabitants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009138"}, {"offsetInBeginSection": 496, "offsetInEndSection": 633, "text": "AIDS is the main predisposing condition for cryptococcal meningitis, and thus the profile of most patients mirrors that of HIV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009138"}]}, {"id": "5ab8fb5bfcf4565872000017", "body": "How is the nuclear localization of lncRNA mediated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24732794", "http://www.ncbi.nlm.nih.gov/pubmed/27198227", "http://www.ncbi.nlm.nih.gov/pubmed/26578588"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "A novel RNA motif mediates the strict nuclear localization of a long noncoding RNA.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732794"}, {"offsetInBeginSection": 150, "offsetInEndSection": 427, "text": "As many lncRNAs regulate nuclear events and thus must localize to nuclei, we analyzed the sequence requirements for nuclear localization in an intergenic lncRNA named BORG (BMP2-OP1-responsive gene), which is both spliced and polyadenylated but is strictly localized in nuclei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732794"}, {"offsetInBeginSection": 601, "offsetInEndSection": 863, "text": "Mutational analyses indicated that nuclear localization of BORG was mediated through a novel RNA motif consisting of the pentamer sequence AGCCC with sequence restrictions at positions -8 (T or A) and -3 (G or C) relative to the first nucleotide of the pentamer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732794"}, {"offsetInBeginSection": 864, "offsetInEndSection": 1092, "text": "Mutation of the motif to a scrambled sequence resulted in complete loss of nuclear localization, while addition of even a single copy of the motif to a cytoplasmically localized RNA was sufficient to impart nuclear localization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732794"}, {"offsetInBeginSection": 1093, "offsetInEndSection": 1300, "text": "Further, the presence of this motif in other cellular RNAs showed a direct correlation with nuclear localization, suggesting that the motif may act as a general nuclear localization signal for cellular RNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732794"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "HuR and GRSF1 modulate the nuclear export and mitochondrial localization of the lncRNA RMRP.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27198227"}, {"offsetInBeginSection": 167, "offsetInEndSection": 440, "text": "Using affinity RNA pull-down followed by mass spectrometry analysis, we found two RNA-binding proteins (RBPs), HuR (human antigen R) and GRSF1 (G-rich RNA sequence-binding factor 1), that associated with the nuclear DNA-encoded lncRNA RMRP and mobilized it to mitochondria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27198227"}, {"offsetInBeginSection": 441, "offsetInEndSection": 584, "text": "In cultured human cells, HuR bound RMRP in the nucleus and mediated its CRM1 (chromosome region maintenance 1)-dependent export to the cytosol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27198227"}, {"offsetInBeginSection": 585, "offsetInEndSection": 687, "text": "After RMRP was imported into mitochondria, GRSF1 bound RMRP and increased its abundance in the matrix.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27198227"}, {"offsetInBeginSection": 688, "offsetInEndSection": 849, "text": "Loss of GRSF1 lowered the mitochondrial levels of RMRP, in turn suppressing oxygen consumption rates and modestly reducing mitochondrial DNA replication priming.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27198227"}]}, {"id": "5aa67b6ad6d6b54f79000010", "body": "What is Paget's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7695525", "http://www.ncbi.nlm.nih.gov/pubmed/24160789", "http://www.ncbi.nlm.nih.gov/pubmed/17447970", "http://www.ncbi.nlm.nih.gov/pubmed/15389972", "http://www.ncbi.nlm.nih.gov/pubmed/6290548", "http://www.ncbi.nlm.nih.gov/pubmed/25025000", "http://www.ncbi.nlm.nih.gov/pubmed/3026195", "http://www.ncbi.nlm.nih.gov/pubmed/16429324", "http://www.ncbi.nlm.nih.gov/pubmed/8009241", "http://www.ncbi.nlm.nih.gov/pubmed/19032921"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Paget's disease of the breast: what the radiologist may expect to find.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7695525"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Paget's disease of the nipple is characterized by the presence of Paget's cells in the epidermis of the nipple or areola.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7695525"}, {"offsetInBeginSection": 122, "offsetInEndSection": 226, "text": "Two case reports of Paget's disease are described and used to highlight unusual features of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7695525"}, {"offsetInBeginSection": 227, "offsetInEndSection": 314, "text": "The literature on the radiographic and pathologic findings of this disease is reviewed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7695525"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Paget's disease of the nipple with parenchymal ductal carcinoma in situ is associated with worse prognosis than Paget's disease alone.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160789"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Paget's disease of the nipple is often found in conjunction with underlying ductal carcinoma in situ (DCIS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160789"}, {"offsetInBeginSection": 109, "offsetInEndSection": 209, "text": "In isolation, Paget's disease of the nipple, like DCIS, confers an excellent prognosis for survival.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160789"}, {"offsetInBeginSection": 210, "offsetInEndSection": 358, "text": "Our objective was to determine if Paget's disease identified with synchronous parenchymal DCIS has as favorable an outcome as Paget's disease alone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160789"}, {"offsetInBeginSection": 359, "offsetInEndSection": 543, "text": "We analyzed a prospectively maintained pathology database and medical records to identify all patients diagnosed with Paget's disease of the nipple between June 1996 and December 2011.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160789"}, {"offsetInBeginSection": 643, "offsetInEndSection": 847, "text": "Seventy-four patients were identified with Paget's disease: five (6%) with isolated Paget's of the nipple, 22 (30%) associated with parenchymal DCIS, and 47 (64%) associated with invasive cancer (\u00b1 DCIS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160789"}]}, {"id": "5a8980d2fcd1d6a10c00000d", "body": "Which is the main protein in brown adipose tissue (BAT) active in thermogenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24809334", "http://www.ncbi.nlm.nih.gov/pubmed/27339605", "http://www.ncbi.nlm.nih.gov/pubmed/19906816", "http://www.ncbi.nlm.nih.gov/pubmed/1763812", "http://www.ncbi.nlm.nih.gov/pubmed/22535970", "http://www.ncbi.nlm.nih.gov/pubmed/18407130", "http://www.ncbi.nlm.nih.gov/pubmed/21373720", "http://www.ncbi.nlm.nih.gov/pubmed/16464973", "http://www.ncbi.nlm.nih.gov/pubmed/27498420", "http://www.ncbi.nlm.nih.gov/pubmed/27641099"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Negative regulators of brown adipose tissue (BAT)-mediated thermogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24809334"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Brown adipose tissue (BAT) is specialized for energy expenditure, a process called adaptive thermogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24809334"}, {"offsetInBeginSection": 107, "offsetInEndSection": 239, "text": "PET-CT scans recently demonstrated the existence of metabolically active BAT in adult humans, which revitalized our interest in BAT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24809334"}, {"offsetInBeginSection": 368, "offsetInEndSection": 436, "text": "PGC1\u03b1 is the master regulator of UCP1-mediated thermogenesis in BAT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24809334"}, {"offsetInBeginSection": 777, "offsetInEndSection": 916, "text": "Here, we review the most important negative regulators of PGC1\u03b1/UCP1 signaling and their mechanism of action in BAT-mediated thermogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24809334"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Thermogenic activation represses autophagy in brown adipose tissue.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339605"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "BACKGROUND: Brown adipose tissue (BAT) thermogenesis is an adaptive process, essential for energy expenditure and involved in the control of obesity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339605"}, {"offsetInBeginSection": 150, "offsetInEndSection": 232, "text": "Obesity is associated with abnormally increased autophagy in white adipose tissue.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339605"}, {"offsetInBeginSection": 233, "offsetInEndSection": 397, "text": "Autophagy has been proposed as relevant for brown-vs-white adipocyte differentiation; however, its role in the response of BAT to thermogenic activation is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339605"}, {"offsetInBeginSection": 397, "offsetInEndSection": 526, "text": "METHODS: The effects of thermogenic activation on autophagy in BAT were analyzed in vivo by exposing mice to 24\u2009h cold condition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339605"}]}, {"id": "5a99566e1d1251d03b00000f", "body": "With which personality traits has the human monoamine oxidase A (MAOA) gene been associated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12566936", "http://www.ncbi.nlm.nih.gov/pubmed/16436187", "http://www.ncbi.nlm.nih.gov/pubmed/16110245", "http://www.ncbi.nlm.nih.gov/pubmed/29075213", "http://www.ncbi.nlm.nih.gov/pubmed/16360899", "http://www.ncbi.nlm.nih.gov/pubmed/19657584", "http://www.ncbi.nlm.nih.gov/pubmed/18845200", "http://www.ncbi.nlm.nih.gov/pubmed/19194374", "http://www.ncbi.nlm.nih.gov/pubmed/25794322", "http://www.ncbi.nlm.nih.gov/pubmed/12554604"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "A regulatory monoamine oxidase a promoter polymorphism and personality traits.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Monoamine oxidase type A (MAOA) has been implicated to be part of mechanisms underlying human temperament and psychiatric disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936"}, {"offsetInBeginSection": 133, "offsetInEndSection": 274, "text": "We hypothesised that a functional polymorphism in the 5' untranslated region of the MAOA gene is associated with specific personality traits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936"}, {"offsetInBeginSection": 275, "offsetInEndSection": 567, "text": "In 371 healthy Caucasians, we estimated personality traits by the use of the Karolinska Scales of Personality (KSP), Scandinavian Universities Scales of Personality, Health-Relevant 5-Factor Personality inventory, Temperament and Character Inventory and the revised NEO Personality Inventory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936"}, {"offsetInBeginSection": 568, "offsetInEndSection": 753, "text": "In the same subjects, we analysed the genotype of a polymorphic region consisting of a variable number of a 30-bp repeat sequence located approximately 1.2 kb upstream of the MAOA gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936"}, {"offsetInBeginSection": 927, "offsetInEndSection": 1099, "text": "We conclude that the structure of this MAOA promoter region does not have a large impact on the expression of personality characteristics in the present Swedish population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Structural variation of the monoamine oxidase A gene promoter repeat polymorphism in nonhuman primates.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16436187"}, {"offsetInBeginSection": 0, "offsetInEndSection": 377, "text": "By conferring allele-specific transcriptional activity on the monoamine oxidase A (MAOA) gene in humans, length variation of a repetitive sequence [(variable number of tandem repeat (VNTR)] in the MAOA promoter influences a constellation of personality traits related to aggressive and antisocial behavior and increases the risk of neurodevelopmental and psychiatric disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16436187"}, {"offsetInBeginSection": 378, "offsetInEndSection": 499, "text": "Here, we have analyzed the presence and variability of this MAOA promoter repeat in several species of nonhuman primates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16436187"}, {"offsetInBeginSection": 1232, "offsetInEndSection": 1479, "text": "The extent of variability of the MAOA promoter repeat in both rhesus monkeys and humans supports the notion that there may be a relationship between functional MAOA expression and aggression-related traits in humans and rhesus macaque populations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16436187"}]}, {"id": "5ab9032afcf4565872000018", "body": "Does oncogene-induced DNA replication stress inhibit genomic instability?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20177397", "http://www.ncbi.nlm.nih.gov/pubmed/27725641", "http://www.ncbi.nlm.nih.gov/pubmed/25959793", "http://www.ncbi.nlm.nih.gov/pubmed/21311564", "http://www.ncbi.nlm.nih.gov/pubmed/26292731", "http://www.ncbi.nlm.nih.gov/pubmed/23204322", "http://www.ncbi.nlm.nih.gov/pubmed/21641882", "http://www.ncbi.nlm.nih.gov/pubmed/24845676", "http://www.ncbi.nlm.nih.gov/pubmed/27160911", "http://www.ncbi.nlm.nih.gov/pubmed/20098673"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Genomic instability--an evolving hallmark of cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20177397"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Genomic instability is a characteristic of most cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20177397"}, {"offsetInBeginSection": 57, "offsetInEndSection": 213, "text": "In hereditary cancers, genomic instability results from mutations in DNA repair genes and drives cancer development, as predicted by the mutator hypothesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20177397"}, {"offsetInBeginSection": 214, "offsetInEndSection": 488, "text": "In sporadic (non-hereditary) cancers the molecular basis of genomic instability remains unclear, but recent high-throughput sequencing studies suggest that mutations in DNA repair genes are infrequent before therapy, arguing against the mutator hypothesis for these cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20177397"}, {"offsetInBeginSection": 489, "offsetInEndSection": 846, "text": "Instead, the mutation patterns of the tumour suppressor TP53 (which encodes p53), ataxia telangiectasia mutated (ATM) and cyclin-dependent kinase inhibitor 2A (CDKN2A; which encodes p16INK4A and p14ARF) support the oncogene-induced DNA replication stress model, which attributes genomic instability and TP53 and ATM mutations to oncogene-induced DNA damage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20177397"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Increased global transcription activity as a mechanism of replication stress in cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725641"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Cancer is a disease associated with genomic instability that often results from oncogene activation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725641"}, {"offsetInBeginSection": 101, "offsetInEndSection": 165, "text": "This in turn leads to hyperproliferation and replication stress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725641"}, {"offsetInBeginSection": 166, "offsetInEndSection": 278, "text": "However, the molecular mechanisms that underlie oncogene-induced replication stress are still poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725641"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Recurrent genomic instability in cancer is attributed to positive selection and/or the sensitivity of specific genomic regions to breakage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959793"}]}, {"id": "5aa6800ad6d6b54f79000011", "body": "Is Brucella abortus the organism that causes brucillosis known to cause spontaneous abortions in humans?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25566611", "http://www.ncbi.nlm.nih.gov/pubmed/17296251", "http://www.ncbi.nlm.nih.gov/pubmed/23942901", "http://www.ncbi.nlm.nih.gov/pubmed/16739129", "http://www.ncbi.nlm.nih.gov/pubmed/23837364", "http://www.ncbi.nlm.nih.gov/pubmed/4295848", "http://www.ncbi.nlm.nih.gov/pubmed/10941733", "http://www.ncbi.nlm.nih.gov/pubmed/25480485", "http://www.ncbi.nlm.nih.gov/pubmed/20117540", "http://www.ncbi.nlm.nih.gov/pubmed/4882024"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Mouse cytokine profile skewed towards Th2 in pregnancy during infection with Brucella abortus S19 strain.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566611"}, {"offsetInBeginSection": 154, "offsetInEndSection": 290, "text": "Brucellosis is an intracellular bacterium that elicits the Th1 response and is known to cause spontaneous abortion in mammalian species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566611"}, {"offsetInBeginSection": 291, "offsetInEndSection": 449, "text": "This study sought to determine if Brucella infection causes spontaneous abortion by causing the circulating cytokine profile be Th1 dominant during pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566611"}, {"offsetInBeginSection": 450, "offsetInEndSection": 584, "text": "Forty-eight Swiss white mice were used in this murine model and the S19 strain of Brucella abortus was used in as the infective agent.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566611"}, {"offsetInBeginSection": 585, "offsetInEndSection": 748, "text": "Pregnant mice in the test group were injected intraperitoneally with 10(5-8) CFU of Brucella and cytokine profile evaluated over the three trimesters of pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566611"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17296251"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Brucella abortus, a facultative intracellular pathogen, is of tremendous zoonotic importance because of its ability to induce spontaneous abortion in cattle and other livestock.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17296251"}, {"offsetInBeginSection": 178, "offsetInEndSection": 295, "text": "It is also known to cause persistent undulant fever, endocarditis, arthritis, osteomyelitis and meningitis in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17296251"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Abortion and premature birth in cattle following vaccination with Brucella abortus strain RB51.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23942901"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Brucella abortus RB51 is the vaccine strain currently licensed for immunizing cattle against brucellosis in the United States.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23942901"}]}, {"id": "5abd3707fcf456587200002d", "body": "Is the petrous bone used in ancient DNA sampling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28129388", "http://www.ncbi.nlm.nih.gov/pubmed/28625158", "http://www.ncbi.nlm.nih.gov/pubmed/26086078"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Comparing Ancient DNA Preservation in Petrous Bone and Tooth Cementum.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Large-scale genomic analyses of ancient human populations have become feasible partly due to refined sampling methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388"}, {"offsetInBeginSection": 119, "offsetInEndSection": 255, "text": "The inner part of petrous bones and the cementum layer in teeth roots are currently recognized as the best substrates for such research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388"}, {"offsetInBeginSection": 256, "offsetInEndSection": 434, "text": "We present a comparative analysis of DNA preservation in these two substrates obtained from the same human skulls, across a range of different ages and preservation environments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388"}, {"offsetInBeginSection": 435, "offsetInEndSection": 617, "text": "Both substrates display significantly higher endogenous DNA content (average of 16.4% and 40.0% for teeth and petrous bones, respectively) than parietal skull bone (average of 2.2%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388"}, {"offsetInBeginSection": 618, "offsetInEndSection": 723, "text": "Despite sample-to-sample variation, petrous bone overall performs better than tooth cementum (p = 0.001).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "A minimally-invasive method for sampling human petrous bones from the cranial base for ancient DNA analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625158"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Ancient DNA (aDNA) research involves invasive and destructive sampling procedures that are often incompatible with anthropological, anatomical, and bioarcheological analyses requiring intact skeletal remains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625158"}, {"offsetInBeginSection": 209, "offsetInEndSection": 495, "text": "The osseous labyrinth inside the petrous bone has been shown to yield higher amounts of endogenous DNA than any other skeletal element; however, accessing this labyrinth in cases of a complete or reconstructed skull involves causing major structural damage to the cranial vault or base.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625158"}, {"offsetInBeginSection": 731, "offsetInEndSection": 943, "text": "We assessed this method by comparing the aDNA results from one petrous bone processed using our novel method to its pair, which was processed using established protocols for sampling disarticulated petrous bones.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625158"}]}, {"id": "5abc9157fcf456587200001e", "body": "What is \"enhancer hijacking\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27869826", "http://www.ncbi.nlm.nih.gov/pubmed/25043047", "http://www.ncbi.nlm.nih.gov/pubmed/29059320", "http://www.ncbi.nlm.nih.gov/pubmed/26229090"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27869826"}, {"offsetInBeginSection": 235, "offsetInEndSection": 476, "text": "Here we present a framework for inferring cancer-related gene overexpression resulting from CRE reorganization (e.g., enhancer hijacking) by integrating SCNAs, gene expression data and information on topologically associating domains (TADs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27869826"}, {"offsetInBeginSection": 751, "offsetInEndSection": 880, "text": "We additionally pursued cancer-type-specific analyses and uncovered IGF2 as a target for enhancer hijacking in colorectal cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27869826"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25043047"}, {"offsetInBeginSection": 737, "offsetInEndSection": 902, "text": "Somatic structural variants juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, including super-enhancers, instigating oncogenic activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25043047"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1131, "text": "Our results, supported by evidence from mouse models, identify GFI1 and GFI1B as prominent medulloblastoma oncogenes and implicate 'enhancer hijacking' as an efficient mechanism driving oncogene activation in a childhood cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25043047"}, {"offsetInBeginSection": 154, "offsetInEndSection": 346, "text": "Importantly, such variants could affect enhancer regulation by changing transcription factor bindings or enhancer hijacking, and in turn, make an essential contribution to disease progression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059320"}, {"offsetInBeginSection": 347, "offsetInEndSection": 589, "text": "To facilitate better usage of published data and exploring enhancer deregulation in various human diseases, we created DiseaseEnhancer (http://biocc.hrbmu.edu.cn/DiseaseEnhancer/), a manually curated database for disease-associated enhancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059320"}, {"offsetInBeginSection": 1312, "offsetInEndSection": 1503, "text": "We identify novel mechanisms of enhancer-driven regulation of the oncogenes MYC and BCL6, and show that the BCL6 locus can serve as an enhancer donor in an \"enhancer hijacking\" translocation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26229090"}, {"offsetInBeginSection": 1081, "offsetInEndSection": 1172, "text": "Our work provides novel insights regarding enhancer-driven oncogene activation in lymphoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26229090"}]}, {"id": "5ab9050bfcf4565872000019", "body": "What is break induced replication?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28427283", "http://www.ncbi.nlm.nih.gov/pubmed/25329304", "http://www.ncbi.nlm.nih.gov/pubmed/11030337", "http://www.ncbi.nlm.nih.gov/pubmed/12660252", "http://www.ncbi.nlm.nih.gov/pubmed/17671506", "http://www.ncbi.nlm.nih.gov/pubmed/21183718", "http://www.ncbi.nlm.nih.gov/pubmed/26055704", "http://www.ncbi.nlm.nih.gov/pubmed/28732309", "http://www.ncbi.nlm.nih.gov/pubmed/20479284", "http://www.ncbi.nlm.nih.gov/pubmed/6275090"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Break induced replication in eukaryotes: mechanisms, functions, and consequences.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427283"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Break-induced replication (BIR) is an important pathway specializing in repair of one-ended double-strand DNA breaks (DSBs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427283"}, {"offsetInBeginSection": 125, "offsetInEndSection": 219, "text": "This type of DSB break typically arises at collapsed replication forks or at eroded telomeres.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427283"}, {"offsetInBeginSection": 377, "offsetInEndSection": 590, "text": "This synthesis is drastically different from S-phase replication in that instead of a replication fork, BIR proceeds via a migrating bubble and is associated with conservative inheritance of newly synthesized DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427283"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Break-induced replication requires DNA damage-induced phosphorylation of Pif1 and leads to telomere lengthening.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25329304"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Broken replication forks result in DNA breaks that are normally repaired via homologous recombination or break induced replication (BIR).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25329304"}, {"offsetInBeginSection": 138, "offsetInEndSection": 411, "text": "Mild insufficiency in the replicative ligase Cdc9 in budding yeast Saccharomyces cerevisiae resulted in a population of cells with persistent DNA damage, most likely due to broken replication forks, constitutive activation of the DNA damage checkpoint and longer telomeres.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25329304"}, {"offsetInBeginSection": 603, "offsetInEndSection": 819, "text": "The Mec1-Rad53 induced phosphorylation of Pif1, previously found necessary for inhibition of telomerase at double strand breaks, was also important for the role of Pif1 in BIR and telomere elongation in cdc9-1 cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25329304"}, {"offsetInBeginSection": 132, "offsetInEndSection": 297, "text": "DNA double-strand breaks are associated with the termination of chromosomal replication; therefore, we directly tested the effect of DNA breaks on Tn7 transposition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11030337"}, {"offsetInBeginSection": 298, "offsetInEndSection": 467, "text": "When DNA double-strand breaks are induced at specific sites in the chromosome, Tn7 transposition is stimulated and insertions are directed proximal to the induced break.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11030337"}]}, {"id": "5aac543bfcf4565872000004", "body": "What biologic process in the body is associated with Mast cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22706316", "http://www.ncbi.nlm.nih.gov/pubmed/17386403", "http://www.ncbi.nlm.nih.gov/pubmed/22906983", "http://www.ncbi.nlm.nih.gov/pubmed/9354811", "http://www.ncbi.nlm.nih.gov/pubmed/6184614", "http://www.ncbi.nlm.nih.gov/pubmed/10359893", "http://www.ncbi.nlm.nih.gov/pubmed/16141514", "http://www.ncbi.nlm.nih.gov/pubmed/17468237", "http://www.ncbi.nlm.nih.gov/pubmed/17062134", "http://www.ncbi.nlm.nih.gov/pubmed/6178551"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Insulin-containing lipogenic stimuli suppress mast cell degranulation potential and up-regulate lipid body biogenesis and eicosanoid secretion in a PPAR\u03b3-independent manner.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 110, "offsetInEndSection": 248, "text": "Here, we test the hypothesis that insulin may regulate lipid body content in mast cells and hence, modify their proinflammatory potential.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 328, "offsetInEndSection": 454, "text": "Lipid body accumulation in mast cells is associated with enhanced levels of leukotriene-synthesizing enzymes (LTC4S and 5-LO).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 455, "offsetInEndSection": 552, "text": "Increased basal and antigen-stimulated release of LTC4 is observed in insulin-treated mast cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 553, "offsetInEndSection": 806, "text": "Concomitantly, the insulin-containing lipogenic stimulus induces a phenotypic change in mast cells, where this enhancement in leukotriene levels is accompanied by a marked down-regulation in secretory granule content and release in response to stimulus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 807, "offsetInEndSection": 1075, "text": "Mast cells exposed to insulin exhibit altered scatter and fluorescence properties, accumulating in a SSC(lo)FSC(hi) population that exhibits decreased BS staining and degranulation responses and is enriched in NR-positive lipid bodies and eicosanoid synthesis enzymes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 1076, "offsetInEndSection": 1299, "text": "Lipid body accumulation in mast cells is mechanistically distinct from the process in adipocytes; for example, it is independent of PPAR\u03b3 up-regulation and does not involve significant accumulation of conjugated glycerides.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 1300, "offsetInEndSection": 1433, "text": "Thus, chronic exposure to metabolic stimuli, such as insulin, may be a determinant of the proinflammatory potential of the mast cell.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Different approaches to study mast cell functions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17386403"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Mast cells have long been known to play a detrimental role in the pathogenesis of IgE-associated allergic disorders by their ability to release a wide variety of pro-inflammatory mediators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17386403"}]}, {"id": "5abd44b1fcf4565872000030", "body": "List proteins with HEAT repeats", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19777061", "http://www.ncbi.nlm.nih.gov/pubmed/11042144", "http://www.ncbi.nlm.nih.gov/pubmed/11491282", "http://www.ncbi.nlm.nih.gov/pubmed/23895768", "http://www.ncbi.nlm.nih.gov/pubmed/25435324", "http://www.ncbi.nlm.nih.gov/pubmed/14970380", "http://www.ncbi.nlm.nih.gov/pubmed/24053231", "http://www.ncbi.nlm.nih.gov/pubmed/27802131", "http://www.ncbi.nlm.nih.gov/pubmed/15099583", "http://www.ncbi.nlm.nih.gov/pubmed/20060908"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Highly sensitive detection of individual HEAT and ARM repeats with HHpred and COACH.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "BACKGROUND: HEAT and ARM repeats occur in a large number of eukaryotic proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 81, "offsetInEndSection": 182, "text": "As these repeats are often highly diverged, the prediction of HEAT or ARM domains can be challenging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 333, "offsetInEndSection": 578, "text": "However, methods using single sequence queries do not have the sensitivity required to deal with more divergent repeats and, when applied to proteins with known structures, in some cases failed to detect a single repeat.METHODOLOGY AND PRINCIPAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 579, "offsetInEndSection": 764, "text": "FINDINGS: Testing algorithms which use multiple sequence alignments as queries, we found two of them, HHpred and COACH, to detect HEAT and ARM repeats with greatly enhanced sensitivity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1172, "text": "When we applied a new protocol using both HHpred and COACH to these structures, it detected 82% of HEAT repeats and 90% of ARM repeats, with the minimum for a given protein of 57% for HEAT repeats and 60% for ARM repeats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 1173, "offsetInEndSection": 1323, "text": "Application to bona fide HEAT and ARM proteins or domains indicated that similar numbers can be expected for the full complement of HEAT/ARM proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 1324, "offsetInEndSection": 1456, "text": "A systematic screen of the Protein Data Bank for false positive hits revealed their number to be low, in particular for ARM repeats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 1457, "offsetInEndSection": 1563, "text": "Double false positive hits for a given protein were rare for HEAT and not at all observed for ARM repeats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}, {"offsetInBeginSection": 1904, "offsetInEndSection": 2037, "text": "SIGNIFICANCE: A protocol is presented for the identification of individual HEAT or ARM repeats which is straightforward to implement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061"}]}, {"id": "5abc974bfcf456587200001f", "body": "Is recursive splicing more common in short introns?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27965595", "http://www.ncbi.nlm.nih.gov/pubmed/15802507", "http://www.ncbi.nlm.nih.gov/pubmed/25970244", "http://www.ncbi.nlm.nih.gov/pubmed/25970246"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Cutting a Long Intron Short: Recursive Splicing and Its Implications.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965595"}, {"offsetInBeginSection": 649, "offsetInEndSection": 843, "text": "Recent work in human and fruitfly tissues revealed that long introns are extensively processed cotranscriptionally and in a stepwise manner, before their two flanking exons are spliced together.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965595"}, {"offsetInBeginSection": 844, "offsetInEndSection": 1029, "text": "This process, called \"recursive splicing,\" often involves non-canonical splicing elements positioned deep within introns, and different mechanisms for its deployment have been proposed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965595"}, {"offsetInBeginSection": 1030, "offsetInEndSection": 1218, "text": "Still, the very existence and widespread nature of recursive splicing offers a new regulatory layer in the transcript maturation pathway, which may also have implications in human disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965595"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Subdivision of large introns in Drosophila by recursive splicing at nonexonic elements.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Many genes with important roles in development and disease contain exceptionally long introns, but special mechanisms for their expression have not been investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507"}, {"offsetInBeginSection": 167, "offsetInEndSection": 364, "text": "We present bioinformatic, phylogenetic, and experimental evidence in Drosophila for a mechanism that subdivides many large introns by recursive splicing at nonexonic elements and alternative exons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Genome-wide identification of zero nucleotide recursive splicing in Drosophila.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25970244"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Recursive splicing is a process in which large introns are removed in multiple steps by re-splicing at ratchet points--5' splice sites recreated after splicing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25970244"}, {"offsetInBeginSection": 161, "offsetInEndSection": 354, "text": "Recursive splicing was first identified in the Drosophila Ultrabithorax (Ubx) gene and only three additional Drosophila genes have since been experimentally shown to undergo recursive splicing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25970244"}]}, {"id": "5ac0a82d19833b0d7b000003", "body": "In what percentage of skeletal muscle fibers is dystrophin expression restored after PPMO- mediated exon skipping?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28373570", "http://www.ncbi.nlm.nih.gov/pubmed/24942628", "http://www.ncbi.nlm.nih.gov/pubmed/20924363", "http://www.ncbi.nlm.nih.gov/pubmed/19796077", "http://www.ncbi.nlm.nih.gov/pubmed/8213828", "http://www.ncbi.nlm.nih.gov/pubmed/19277018", "http://www.ncbi.nlm.nih.gov/pubmed/21851223"], "snippets": [{"offsetInBeginSection": 203, "offsetInEndSection": 395, "text": "Exon skipping via synthetic phosphorodiamidate morpholino oligomers (PMOs) represents one of the most promising therapeutic options, yet PMOs have shown very little efficacy in cardiac muscle.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28373570"}, {"offsetInBeginSection": 396, "offsetInEndSection": 607, "text": "To increase therapeutic potency in cardiac muscle, we tested a next-generation morpholino: arginine-rich, cell-penetrating peptide-conjugated PMOs (PPMOs) in the canine X-linked muscular dystrophy in Japan (CXMD", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28373570"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24942628"}, {"offsetInBeginSection": 407, "offsetInEndSection": 701, "text": "In this study, we examined the effect of peptide-conjugated PMO (PPMO)-mediated exon skipping on disease progression of utrophin-dystrophin-deficient mice (dko) of four age groups (21-29, 30-39, 40-49 and 50+ days), representing diseases from early stage to advanced stage with severe kyphosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24942628"}, {"offsetInBeginSection": 730, "offsetInEndSection": 848, "text": "administration of the PPMO restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24942628"}, {"offsetInBeginSection": 1272, "offsetInEndSection": 1446, "text": "However, restoration of high levels of dystrophin expression failed to prevent disease progression to the mice receiving treatment when disease was already at advanced stage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24942628"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924363"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Antisense-induced exon skipping can restore the open reading frame, and thus correct the dystrophin deficiency that causes Duchenne muscular dystrophy (DMD), a lethal muscle wasting condition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924363"}, {"offsetInBeginSection": 279, "offsetInEndSection": 425, "text": "However, it is still not known what percentage of dystrophin-positive fibers and what level of expression is necessary for functional improvement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924363"}, {"offsetInBeginSection": 505, "offsetInEndSection": 757, "text": "To achieve a significant variation in dystrophin expression, we locally administered into tibialis anterior muscles various doses of a phosphorodiamidate morpholino oligomer (PMO) designed to skip the mutated exon 23 from the mRNA of murine dystrophin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924363"}]}, {"id": "5aac5469fcf4565872000005", "body": "What are 7 symptoms of yellow fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12410495", "http://www.ncbi.nlm.nih.gov/pubmed/8599063", "http://www.ncbi.nlm.nih.gov/pubmed/19869938", "http://www.ncbi.nlm.nih.gov/pubmed/19868337", "http://www.ncbi.nlm.nih.gov/pubmed/16498293", "http://www.ncbi.nlm.nih.gov/pubmed/559399", "http://www.ncbi.nlm.nih.gov/pubmed/9402373", "http://www.ncbi.nlm.nih.gov/pubmed/20300380", "http://www.ncbi.nlm.nih.gov/pubmed/28358796", "http://www.ncbi.nlm.nih.gov/pubmed/11000957"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "A Belgian traveler who acquired yellow fever in the Gambia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12410495"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "A 47-year-old Belgian woman acquired yellow fever during a 1-week vacation in The Gambia; she had never been vaccinated against yellow fever.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12410495"}, {"offsetInBeginSection": 142, "offsetInEndSection": 233, "text": "She died of massive gastrointestinal bleeding 7 days after the onset of the first symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12410495"}, {"offsetInBeginSection": 234, "offsetInEndSection": 482, "text": "This dramatic case demonstrates that it is important for persons to be vaccinated against yellow fever before they travel to countries where yellow fever is endemic, even if the country, like The Gambia, does not require travelers to be vaccinated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12410495"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Jungle yellow fever: clinical and laboratorial studies emphasizing viremia on a human case.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8599063"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The authors report the clinical, laboratorial and epidemiological aspects of a human case of jungle yellow fever.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8599063"}, {"offsetInBeginSection": 114, "offsetInEndSection": 257, "text": "The patient suffered from fever, chills, sweating, headaches, backaches, myalgia, epigastric pains, nausea, vomiting, diarrhea and prostration.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8599063"}, {"offsetInBeginSection": 258, "offsetInEndSection": 362, "text": "He was unvaccinated and had been working in areas where cases of jungle yellow fever had been confirmed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8599063"}, {"offsetInBeginSection": 363, "offsetInEndSection": 427, "text": "Investigations concerning the yellow fever virus were performed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8599063"}, {"offsetInBeginSection": 869, "offsetInEndSection": 984, "text": "The yellow fever virus, recovered from the two first samples and the virus titration, showed high level of viremia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8599063"}]}, {"id": "5ac07b67dd95b2cd42000001", "body": "Is Lysyl oxidase crosslinking collagen?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12918034", "http://www.ncbi.nlm.nih.gov/pubmed/8116", "http://www.ncbi.nlm.nih.gov/pubmed/2870873", "http://www.ncbi.nlm.nih.gov/pubmed/906929", "http://www.ncbi.nlm.nih.gov/pubmed/8096378", "http://www.ncbi.nlm.nih.gov/pubmed/4531019", "http://www.ncbi.nlm.nih.gov/pubmed/2890532", "http://www.ncbi.nlm.nih.gov/pubmed/26918", "http://www.ncbi.nlm.nih.gov/pubmed/22633114", "http://www.ncbi.nlm.nih.gov/pubmed/9524359"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Enhancing mechanical properties of tissue-engineered constructs via lysyl oxidase crosslinking activity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12918034"}, {"offsetInBeginSection": 105, "offsetInEndSection": 361, "text": "In this study, we utilized lysyl oxidase (LO) to enzymatically crosslink extracellular matrix (ECM) proteins, particularly collagen and elastin, to enhance the mechanical integrity of the ECM and thereby impart mechanical strength to the engineered tissue.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12918034"}, {"offsetInBeginSection": 857, "offsetInEndSection": 1098, "text": "When smooth muscle cells transfected with lysyl oxidase were seeded in collagen gels, the tensile strength and elastic modulus in these constructs increased by approximately two-fold compared to constructs seeded with mock-transfected VSMCs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12918034"}, {"offsetInBeginSection": 1254, "offsetInEndSection": 1487, "text": "Compositional analysis of the ECM deposited by the transformed cells showed similar collagen and elastin levels, and cell proliferation rates were similar as well, thus attributing increased mechanical properties to ECM crosslinking.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12918034"}, {"offsetInBeginSection": 0, "offsetInEndSection": 311, "text": "Aldehyde-deficient non-crosslinked collagen obtained from lathyritic rats and collagen from penicillamine-treated rats, which is not deficient in aldehydes but the crosslinking of which is also inhibited, were implanted into the peritoneal cavity of hypophysectomized rats using the diffusion chamber technique.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8116"}, {"offsetInBeginSection": 312, "offsetInEndSection": 480, "text": "The enzyme lysyl oxidase which catalyses the aldehyde formation in certain lysyl residues of collagen and elastin was extracted from the skin of hypophysectomized rats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8116"}, {"offsetInBeginSection": 650, "offsetInEndSection": 817, "text": "The result showed that the aldehyde deficient collagen did not crosslink while in the hypophysectomized animal indicating the lack of active lysyl oxidase in the rats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8116"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Skin lysyl oxidase activity is not rate limiting for collagen crosslinking in the glucocorticoid-treated rat.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2870873"}, {"offsetInBeginSection": 289, "offsetInEndSection": 411, "text": "The decreased lysyl oxidase activity was accompanied by a forty-nine percent decrease of acetic acid extractable collagen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2870873"}, {"offsetInBeginSection": 556, "offsetInEndSection": 777, "text": "These data indicate that although skin lysyl oxidase activity is decreased by glucocorticoid treatment, the crosslinking of acid extracted collagen as measured by the alpha/beta ratio and collagen solubility is increased.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2870873"}]}, {"id": "5abc9c1efcf4565872000020", "body": "How are deletion breakpoints defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1684331", "http://www.ncbi.nlm.nih.gov/pubmed/1741389", "http://www.ncbi.nlm.nih.gov/pubmed/16293123", "http://www.ncbi.nlm.nih.gov/pubmed/11001932", "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "http://www.ncbi.nlm.nih.gov/pubmed/9326327", "http://www.ncbi.nlm.nih.gov/pubmed/10631140", "http://www.ncbi.nlm.nih.gov/pubmed/19484265", "http://www.ncbi.nlm.nih.gov/pubmed/17351135", "http://www.ncbi.nlm.nih.gov/pubmed/12297986"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "The albino-deletion complex of the mouse: molecular mapping of deletion breakpoints that define regions necessary for development of the embryonic and extraembryonic ectoderm.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1684331"}, {"offsetInBeginSection": 314, "offsetInEndSection": 472, "text": "The region of chromosome 7 containing these two genes has now been accessed at the molecular level by cloning two of the deletion breakpoint-fusion fragments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1684331"}, {"offsetInBeginSection": 473, "offsetInEndSection": 614, "text": "The c2YPSj breakpoints were isolated by cloning an EcoRI fragment containing a copy of an albino region-specific repeat unique to c2YPSj DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1684331"}, {"offsetInBeginSection": 615, "offsetInEndSection": 782, "text": "Similarly, the c11DSD breakpoints were isolated by cloning a c11DSD EcoRI fragment detected by a unique-sequence probe mapping proximal to the albino-coat-color locus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1684331"}, {"offsetInBeginSection": 694, "offsetInEndSection": 879, "text": "Here we report the use of a probe derived from a deletion breakpoint fusion fragment cloned from c24R75M/c24R75M DNA to clone a breakpoint fusion fragment caused by the c14CoS deletion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1741389"}, {"offsetInBeginSection": 1225, "offsetInEndSection": 1465, "text": "Therefore, the Fah gene maps within or proximal to the hsdr-1 locus, as defined by deletion breakpoints, and disruption of this gene may be partially or completely responsible for the phenotypes associated with the hsdr-1 deletion syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1741389"}, {"offsetInBeginSection": 282, "offsetInEndSection": 499, "text": "Subsequently, the deletion of exon 2 of the copper metabolism domain containing 1 (COMMD1) gene (formerly MURR1) was shown to be the major cause of copper toxicosis, although the deletion breakpoints were not defined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293123"}, {"offsetInBeginSection": 500, "offsetInEndSection": 684, "text": "In this investigation, polymerase chain reaction (PCR)-based techniques and sequencing were used to isolate the deletion breakpoints, utilizing the newly available dog genome sequence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293123"}, {"offsetInBeginSection": 685, "offsetInEndSection": 836, "text": "The breakpoints were positioned at 65.3091 and 65.3489 Mb of dog chromosome 10, in intron 1 and intron 2 of COMMD1 respectively, a deletion of 39.7 kb.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293123"}, {"offsetInBeginSection": 837, "offsetInEndSection": 965, "text": "The two breakpoints share sequence homology suggesting that homologous recombination may have been responsible for the deletion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293123"}]}, {"id": "5ac7185f0340b9f058000004", "body": "Which cellular functions are affected by lncRNA H19 in the heart?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27317124", "http://www.ncbi.nlm.nih.gov/pubmed/29036538", "http://www.ncbi.nlm.nih.gov/pubmed/27895893", "http://www.ncbi.nlm.nih.gov/pubmed/26853553", "http://www.ncbi.nlm.nih.gov/pubmed/28790415", "http://www.ncbi.nlm.nih.gov/pubmed/27796346", "http://www.ncbi.nlm.nih.gov/pubmed/27307343", "http://www.ncbi.nlm.nih.gov/pubmed/27040767", "http://www.ncbi.nlm.nih.gov/pubmed/28063931", "http://www.ncbi.nlm.nih.gov/pubmed/28881833"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Long noncoding RNA dysregulation in ischemic heart failure.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "BACKGROUND: Long noncoding RNAs (lncRNAs) are non-protein coding transcripts regulating a variety of physiological and pathological functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 143, "offsetInEndSection": 212, "text": "However, their implication in heart failure is still largely unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 213, "offsetInEndSection": 334, "text": "The aim of this study is to identify and characterize lncRNAs deregulated in patients affected by ischemic heart failure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 504, "offsetInEndSection": 719, "text": "Further validations were performed in left ventricle samples derived from explanted hearts of end-stage heart failure patients and in a mouse model of cardiac hypertrophy, obtained by transverse aortic constriction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 720, "offsetInEndSection": 800, "text": "Peripheral blood mononuclear cells of heart failure patients were also analyzed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 801, "offsetInEndSection": 872, "text": "LncRNA distribution in the heart was assessed by in situ hybridization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 873, "offsetInEndSection": 1036, "text": "Function of the deregulated lncRNA was explored analyzing the expression of the neighbor mRNAs and by gene ontology analysis of the correlating coding transcripts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 1036, "offsetInEndSection": 1177, "text": "RESULTS: Fourteen lncRNAs were significantly modulated in non end-stage heart failure patients, identifying a heart failure lncRNA signature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1333, "text": "Nine of these lncRNAs (CDKN2B-AS1/ANRIL, EGOT, H19, HOTAIR, LOC285194/TUSC7, RMRP, RNY5, SOX2-OT and SRA1) were also confirmed in end-stage failing hearts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124"}]}, {"id": "5aae651ffcf456587200000d", "body": "What is the function of penicillinase, also known as beta lactamase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/806305", "http://www.ncbi.nlm.nih.gov/pubmed/3541135", "http://www.ncbi.nlm.nih.gov/pubmed/3877980", "http://www.ncbi.nlm.nih.gov/pubmed/2406875", "http://www.ncbi.nlm.nih.gov/pubmed/9624479", "http://www.ncbi.nlm.nih.gov/pubmed/6448580", "http://www.ncbi.nlm.nih.gov/pubmed/11399858", "http://www.ncbi.nlm.nih.gov/pubmed/6803835", "http://www.ncbi.nlm.nih.gov/pubmed/9158769", "http://www.ncbi.nlm.nih.gov/pubmed/4985545"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "[Identification of the beta lactamase R-TEM of Pseudomonas aeruginosa].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/806305"}, {"offsetInBeginSection": 78, "offsetInEndSection": 160, "text": "aeruginosa resistant to classical beta lactam antibiotics including carbenicillin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/806305"}, {"offsetInBeginSection": 212, "offsetInEndSection": 501, "text": "In both cases, we have shown the simultaneous biosynthesis of two enzymes: an inducible and chromosome cephalosporinase frequently found in this germ, and a constitutive beta lactamase, with a penicillinase activity which has been identified with the extrachromosomic beta lactamase R-TEM.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/806305"}, {"offsetInBeginSection": 502, "offsetInEndSection": 766, "text": "These two enzymes have been separated by affinity chromatography, characterized by their kinetic constants given by computerized microacidimetry, and their isoelectric points which are respectively 9.2 for the cephalosporinase and 5.40 for the penicillinase R-TEM.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/806305"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Mechanisms of beta-lactam resistance in anaerobic bacteria.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3541135"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "The known mechanisms of beta-lactam resistance in anaerobic bacteria involve production of beta-lactamases, alteration of penicillin-binding proteins, and blocking of the penetration of beta-lactams through the outer membranes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3541135"}, {"offsetInBeginSection": 228, "offsetInEndSection": 316, "text": "The most important factor in beta-lactam resistance is the production of beta-lactamase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3541135"}, {"offsetInBeginSection": 317, "offsetInEndSection": 416, "text": "beta-Lactamases in various Bacteroides, Fusobacterium, and Clostridium species have been described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3541135"}, {"offsetInBeginSection": 417, "offsetInEndSection": 566, "text": "beta-Lactam resistance in Bacteroides fragilis is most commonly mediated by the production of beta-lactamase, primarily of the cephalosporinase type.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3541135"}, {"offsetInBeginSection": 567, "offsetInEndSection": 684, "text": "Studies have also shown that B. fragilis can produce a penicillinase that inactivates piperacillin and carbenicillin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3541135"}]}, {"id": "5ac0817cd0c506ce46000001", "body": "Is p53 a transcription factor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7651386", "http://www.ncbi.nlm.nih.gov/pubmed/9690516", "http://www.ncbi.nlm.nih.gov/pubmed/1944276", "http://www.ncbi.nlm.nih.gov/pubmed/29125602", "http://www.ncbi.nlm.nih.gov/pubmed/9215863", "http://www.ncbi.nlm.nih.gov/pubmed/7478550", "http://www.ncbi.nlm.nih.gov/pubmed/8862400", "http://www.ncbi.nlm.nih.gov/pubmed/21042708", "http://www.ncbi.nlm.nih.gov/pubmed/9572492", "http://www.ncbi.nlm.nih.gov/pubmed/17762884"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 52, "offsetInEndSection": 134, "text": "Part of the protective response to this damage is the increased expression of p53.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 135, "offsetInEndSection": 241, "text": "p53, a transcription factor, controls the expression of genes, leading to cell cycle arrest and apoptosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 403, "offsetInEndSection": 556, "text": "In this communication, we show that the transforming growth factor alpha (TGF-alpha) gene is a direct target for p53-mediated transcriptional activation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 557, "offsetInEndSection": 695, "text": "In a stable cell line containing an inducible p53 construct, p53 induction leads to a threefold accumulation of the native TGF-alpha mRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 696, "offsetInEndSection": 911, "text": "IN cotransfection assays using a TGF-alpha promoter reporter construct, we show that expression of wild-type but not mutant p53 increases transcriptional activity of the TGF-alpha promoter by approximately 2.5-fold.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1085, "text": "In vitro, wild-type p53 binds to a consensus binding site found in the proximal portion of the promoter, and this sequence is necessary for the p53 transcriptional response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 1086, "offsetInEndSection": 1196, "text": "Furthermore, this element confers p53 induction to the otherwise nonresponsive adenovirus major late promoter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1402, "text": "In addition to these results, we found that the TGF-alpha promoter contains a nonconsensus but functional TATA box-binding protein-binding site approximately 30 bp upstream of the transcription start site.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1546, "text": "Although p53 can repress transcription from promoters containing a TATA box, the nonconsensus TGF-alpha TATA motif is resistant to this effect.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386"}]}, {"id": "5abc9ecffcf4565872000021", "body": "Where do mitochondrial DNA deletion breakpoints tend to occur?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25124333", "http://www.ncbi.nlm.nih.gov/pubmed/25193669", "http://www.ncbi.nlm.nih.gov/pubmed/22661583", "http://www.ncbi.nlm.nih.gov/pubmed/9128755", "http://www.ncbi.nlm.nih.gov/pubmed/15313545", "http://www.ncbi.nlm.nih.gov/pubmed/22529999", "http://www.ncbi.nlm.nih.gov/pubmed/16432145", "http://www.ncbi.nlm.nih.gov/pubmed/12090301", "http://www.ncbi.nlm.nih.gov/pubmed/7605803", "http://www.ncbi.nlm.nih.gov/pubmed/9375854"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Association of G-quadruplex forming sequences with human mtDNA deletion breakpoints.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "BACKGROUND: Mitochondrial DNA (mtDNA) deletions cause disease and accumulate during aging, yet our understanding of the molecular mechanisms underlying their formation remains rudimentary.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333"}, {"offsetInBeginSection": 189, "offsetInEndSection": 444, "text": "Guanine-quadruplex (GQ) DNA structures are associated with nuclear DNA instability in cancer; recent evidence indicates they can also form in mitochondrial nucleic acids, suggesting that these non-B DNA structures could be associated with mtDNA deletions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333"}, {"offsetInBeginSection": 1073, "offsetInEndSection": 1320, "text": "We analyzed the position of each motif set relative to either 5' or 3' unique mtDNA deletion breakpoints, and found that intrastrand QFP sequences, but not ddi QFP sequences, showed significant association with mtDNA deletion breakpoint locations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333"}, {"offsetInBeginSection": 1321, "offsetInEndSection": 1457, "text": "Moreover, a large proportion of these QFP sequences occur at smaller distances to breakpoints relative to distribution-matched controls.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333"}, {"offsetInBeginSection": 1733, "offsetInEndSection": 1862, "text": "Notably, the most frequent deletion breakpoints, including those of the \"common deletion\", are bounded by 2G QFP sequence motifs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333"}, {"offsetInBeginSection": 1862, "offsetInEndSection": 2069, "text": "CONCLUSIONS: The potential for GQ to influence mitochondrial genome stability supports a high-priority investigation of these structures and their regulation in normal and pathological mitochondrial biology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "DNA sequences proximal to human mitochondrial DNA deletion breakpoints prevalent in human disease form G-quadruplexes, a class of DNA structures inefficiently unwound by the mitochondrial replicative Twinkle helicase.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25193669"}, {"offsetInBeginSection": 89, "offsetInEndSection": 347, "text": "It is thought that stalling of the mitochondrial replication machinery during DNA synthesis is a prominent source of mitochondrial genome instability; however, the precise molecular determinants of defective mitochondrial replication are not well understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25193669"}, {"offsetInBeginSection": 823, "offsetInEndSection": 1002, "text": "Circular dichroism and UV spectral analysis demonstrated that mitochondrial G-rich sequences near deletion breakpoints prevalent in human disease form G-quadruplex DNA structures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25193669"}]}, {"id": "5ac721230340b9f058000005", "body": "Name 4 circular RNA molecules associated with carcinogenesis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28185365", "http://www.ncbi.nlm.nih.gov/pubmed/28342987", "http://www.ncbi.nlm.nih.gov/pubmed/9154796", "http://www.ncbi.nlm.nih.gov/pubmed/27429839", "http://www.ncbi.nlm.nih.gov/pubmed/29081691", "http://www.ncbi.nlm.nih.gov/pubmed/26874353", "http://www.ncbi.nlm.nih.gov/pubmed/19010924", "http://www.ncbi.nlm.nih.gov/pubmed/850304", "http://www.ncbi.nlm.nih.gov/pubmed/28253710", "http://www.ncbi.nlm.nih.gov/pubmed/8692851"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Circular RNAs (circRNAs) are a class of new-found RNA molecules that have a special covalent loop structure without a 5' cap and 3' tail.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185365"}, {"offsetInBeginSection": 388, "offsetInEndSection": 600, "text": "By serving as sponges of microRNAs, interacting with long non-coding RNAs, mRNA, or proteins, circRNAs regulate gene expression at transcriptional and post-transcriptional levels and contribute to carcinogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185365"}, {"offsetInBeginSection": 731, "offsetInEndSection": 886, "text": "An in-depth study of circRNA will provide a better understanding of carcinogenesis and assist in developing clinical diagnostic and therapeutic strategies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28342987"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9154796"}, {"offsetInBeginSection": 345, "offsetInEndSection": 516, "text": "Remarkably, circular RNA transcripts synthesized by the joining of the donor and acceptor splice sites of the same exon were detected in human epidermis for exons 4 and 5.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9154796"}, {"offsetInBeginSection": 813, "offsetInEndSection": 1100, "text": "In rat testis, a similar analysis allowed the detection of a circular RNA molecule composed of exons 6 and 7 of the androgen binding protein (ABP) gene, with the donor splice site of exon 7 joined to the acceptor splice site of exon 6, and of an ABP mRNA which had skipped exons 6 and 7.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9154796"}, {"offsetInBeginSection": 1101, "offsetInEndSection": 1342, "text": "These results apparently substantiate the hypothesis that alternative pre-mRNA splicing has the potential to generate not only mRNAs that lack one or more exons but also circular RNA molecules that are composed of the exons that are skipped.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9154796"}, {"offsetInBeginSection": 1343, "offsetInEndSection": 1534, "text": "However, additional 2C18 circular species containing various combinations of exons were also detected in human epidermis, and an exon 6-skipped ABP mRNA molecule was identified in rat testis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9154796"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1741, "text": "This observation is interpreted as indicative that at low frequency, numerous circular RNA formation and exon skipping events may occur, allowing the joining of a variety of different combinations of exons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9154796"}, {"offsetInBeginSection": 162, "offsetInEndSection": 286, "text": "They are usually stable, abundant, conserved RNA molecules and often exhibit tissue/developmental-stage specific expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27429839"}]}, {"id": "5ab147edfcf4565872000013", "body": "The Mantoux test detects what latent infection/disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22527447", "http://www.ncbi.nlm.nih.gov/pubmed/17663901", "http://www.ncbi.nlm.nih.gov/pubmed/16307510", "http://www.ncbi.nlm.nih.gov/pubmed/17158278", "http://www.ncbi.nlm.nih.gov/pubmed/12238571", "http://www.ncbi.nlm.nih.gov/pubmed/1983096", "http://www.ncbi.nlm.nih.gov/pubmed/16956501", "http://www.ncbi.nlm.nih.gov/pubmed/19831558", "http://www.ncbi.nlm.nih.gov/pubmed/10524588", "http://www.ncbi.nlm.nih.gov/pubmed/18579028"], "snippets": [{"offsetInBeginSection": 1052, "offsetInEndSection": 1110, "text": "In 11 patients both QFT-G and Mantoux tests were positive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527447"}, {"offsetInBeginSection": 1167, "offsetInEndSection": 1243, "text": "Significantly, no patient with a positive Mantoux had a negative QFT-G test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527447"}, {"offsetInBeginSection": 1876, "offsetInEndSection": 2021, "text": "It was more sensitive than the Mantoux test and is not significantly affected by previous treatment with systemic steroids or immunosuppressives.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527447"}, {"offsetInBeginSection": 725, "offsetInEndSection": 892, "text": "RESULTS: School exposures were identified and underwent the Mantoux skin test (142 students in years 1, 2, 3, and 4 of compulsory secondary education and 22 teachers).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663901"}, {"offsetInBeginSection": 893, "offsetInEndSection": 971, "text": "The Mantoux test was positive in 68 students (48 %) and seven teachers (32 %).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663901"}, {"offsetInBeginSection": 1106, "offsetInEndSection": 1244, "text": "A further two students, identified as contacts, were studied in another center and also started treatment for active tuberculosis disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663901"}, {"offsetInBeginSection": 1545, "offsetInEndSection": 1624, "text": "Latent tuberculosis treatment was recommended in all Mantoux-positive contacts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663901"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16307510"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Tuberculosis is responsible for more then 2 million deaths worldwide each year and vies with HIV as the world's most fatal infectious disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16307510"}, {"offsetInBeginSection": 143, "offsetInEndSection": 322, "text": "In many developing countries, attempts to control the spread of infection rely solely on identification and treatment of those with active disease, ignoring subclinical infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16307510"}]}, {"id": "5ac08478d0c506ce46000002", "body": "What is the aim of  perfoming a \"cycloheximide chase assay\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29082276", "http://www.ncbi.nlm.nih.gov/pubmed/27167179", "http://www.ncbi.nlm.nih.gov/pubmed/19151744"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Analysis of Protein Stability by the Cycloheximide Chase Assay.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29082276"}, {"offsetInBeginSection": 328, "offsetInEndSection": 452, "text": "Here we present a full cycloheximide chase assay in our laboratory using a lung adenocarcinoma cell line, CL1-5, as a model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29082276"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167179"}, {"offsetInBeginSection": 444, "offsetInEndSection": 648, "text": "This article describes the use of cycloheximide chase followed by western blotting to specifically analyze protein degradation in the model unicellular eukaryote, Saccharomyces cerevisiae (budding yeast).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167179"}, {"offsetInBeginSection": 649, "offsetInEndSection": 755, "text": "In this procedure, yeast cells are incubated in the presence of the translational inhibitor cycloheximide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167179"}, {"offsetInBeginSection": 756, "offsetInEndSection": 870, "text": "Aliquots of cells are collected immediately after and at specific time points following addition of cycloheximide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167179"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1172, "text": "The cycloheximide chase procedure permits visualization of the degradation kinetics of the steady state population of a variety of cellular proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167179"}, {"offsetInBeginSection": 729, "offsetInEndSection": 840, "text": "The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19151744"}, {"offsetInBeginSection": 1646, "offsetInEndSection": 1799, "text": "Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19151744"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Comparison of protein stability in eukaryotic cells has been achieved by cycloheximide, which is an inhibitor of protein biosynthesis due to its prevention in translational elongation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29082276"}]}, {"id": "5abcf6b9fcf4565872000027", "body": "What is caused by the ectopic expression of CTCF?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11507042", "http://www.ncbi.nlm.nih.gov/pubmed/19369356", "http://www.ncbi.nlm.nih.gov/pubmed/21465478", "http://www.ncbi.nlm.nih.gov/pubmed/22724006", "http://www.ncbi.nlm.nih.gov/pubmed/15941718", "http://www.ncbi.nlm.nih.gov/pubmed/14980504", "http://www.ncbi.nlm.nih.gov/pubmed/28862757", "http://www.ncbi.nlm.nih.gov/pubmed/26929370", "http://www.ncbi.nlm.nih.gov/pubmed/26268681", "http://www.ncbi.nlm.nih.gov/pubmed/24725430"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 0, "offsetInEndSection": 354, "text": "The 11-zinc finger protein CCTC-binding factor (CTCF) employs different sets of zinc fingers to form distinct complexes with varying CTCF- target sequences (CTSs) that mediate the repression or activation of gene expression and the creation of hormone-responsive gene silencers and of diverse vertebrate enhancer-blocking elements (chromatin insulators).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 355, "offsetInEndSection": 505, "text": "To determine how these varying effects would integrate in vivo, we engineered a variety of expression systems to study effects of CTCF on cell growth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 506, "offsetInEndSection": 655, "text": "Here we show that ectopic expression of CTCF in many cell types inhibits cell clonogenicity by causing profound growth retardation without apoptosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 656, "offsetInEndSection": 831, "text": "In asynchronous cultures, the cell-cycle profile of CTCF-expressing cells remained unaltered, which suggested that progression through the cycle was slowed at multiple points.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 832, "offsetInEndSection": 929, "text": "Although conditionally induced CTCF caused the S-phase block, CTCF can also arrest cell division.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 930, "offsetInEndSection": 1013, "text": "Viable CTCF-expressing cells could be maintained without dividing for several days.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 1014, "offsetInEndSection": 1315, "text": "While MYC is the well-characterized CTCF target, the inhibitory effects of CTCF on cell growth could not be ascribed solely to repression of MYC, suggesting that additional CTS-driven genes involved in growth-regulatory circuits, such as p19ARF, are likely to contribute to CTCF-induced growth arrest.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 1316, "offsetInEndSection": 1506, "text": "These findings indicate that CTCF may regulate cell-cycle progression at multiple steps within the cycle, and add to the growing evidence for the function of CTCF as a tumor suppressor gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Cell cycle control of Kaposi's sarcoma-associated herpesvirus latency transcription by CTCF-cohesin interactions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356"}]}, {"id": "5ab2cdc5fcf4565872000016", "body": "Is sternotomy closure done using either a sternal ZipFix\u2122 implant  or conventional steel wire following cardiac surgery?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23624983", "http://www.ncbi.nlm.nih.gov/pubmed/26290838", "http://www.ncbi.nlm.nih.gov/pubmed/29075945", "http://www.ncbi.nlm.nih.gov/pubmed/16967378", "http://www.ncbi.nlm.nih.gov/pubmed/20494064"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "A new cable-tie-based sternal closure device: infectious considerations.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "OBJECTIVES: To determine the difference in sternal infection and other infectious events between conventional wire and cable-tie-based closure techniques post-sternotomy in a collective of patients after cardiac surgery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983"}, {"offsetInBeginSection": 220, "offsetInEndSection": 432, "text": "METHODS: The sternal ZipFix\u2122 (ZF) system consists of a biocompatible poly-ether-ether-ketone (PEEK) cable-tie that surrounds the sternum through the intercostal space and provides a large implant-to-bone contact.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983"}, {"offsetInBeginSection": 433, "offsetInEndSection": 550, "text": "Between 1 February 2011 and 31 January 2012, 680 cardiac operations were performed via sternotomy at our institution.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983"}, {"offsetInBeginSection": 551, "offsetInEndSection": 788, "text": "After the exclusion of operations for active endocarditis and early mortality within 7 days, 95 patients were exclusively closed with ZF and could be compared with 498 who were closed with conventional wires (CWs) during the same period.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983"}, {"offsetInBeginSection": 1665, "offsetInEndSection": 1786, "text": "CONCLUSIONS: Our study underlines a neutral effect of the sternal ZipFix\u2122 system in patients regarding sternal infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983"}, {"offsetInBeginSection": 1787, "offsetInEndSection": 1859, "text": "Postoperative complications are similar in both sternal closure methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Multifilament Cable Wire versus Conventional Wire for Sternal Closure in Patients Undergoing Major Cardiac Surgery.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290838"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "BACKGROUND: Stainless steel wiring remains the most popular technique for primary sternal closure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290838"}, {"offsetInBeginSection": 99, "offsetInEndSection": 308, "text": "Recently, a multifilament cable wiring system (Pioneer Surgical Technology Inc., Marquette, MI, USA) was introduced for sternal closure and has gained wide acceptance due to its superior resistance to tension.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290838"}]}, {"id": "5ac09a7b19833b0d7b000001", "body": "Where is the EpCam protein mainly located?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21115857", "http://www.ncbi.nlm.nih.gov/pubmed/23026194", "http://www.ncbi.nlm.nih.gov/pubmed/26054340", "http://www.ncbi.nlm.nih.gov/pubmed/16054130"], "snippets": [{"offsetInBeginSection": 157, "offsetInEndSection": 400, "text": "Recently, germline deletions affecting the epithelial cell adhesion molecule (EPCAM) gene located upstream of MSH2 were identified as a novel mutational mechanism causing Lynch syndrome by epigenetic inactivation of the respective MSH2 allele.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115857"}, {"offsetInBeginSection": 401, "offsetInEndSection": 586, "text": "Immunohistochemical analysis of MMR protein expression is a hallmark of Lynch syndrome diagnostics, but it cannot distinguish between EPCAM deletion carriers and MSH2 mutation carriers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115857"}, {"offsetInBeginSection": 587, "offsetInEndSection": 717, "text": "We hypothesized that EPCAM protein expression might be altered in tumors from patients with a germline EPCAM deletion.PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115857"}, {"offsetInBeginSection": 1172, "offsetInEndSection": 1299, "text": "In contrast, EPCAM expression was positive in all cancers from patients with germline alterations affecting MSH2 but not EPCAM.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115857"}, {"offsetInBeginSection": 1375, "offsetInEndSection": 1514, "text": "CONCLUSION: These results indicate that loss of EPCAM protein expression is frequent in tumors from patients with EPCAM germline deletions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115857"}, {"offsetInBeginSection": 156, "offsetInEndSection": 323, "text": "Recently, a new mechanism involving the epithelial cell adhesion molecule (EPCAM)/TACSTD1 gene has been shown to be responsible in cases with abnormal MSH2 expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026194"}, {"offsetInBeginSection": 324, "offsetInEndSection": 477, "text": "Of interest, 3' exons deletions of the EPCAM gene, which is located upstream of MSH2 in chromosome 2, are associated with MSH2 promoter hypermethylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026194"}, {"offsetInBeginSection": 478, "offsetInEndSection": 563, "text": "EPCAM protein, expressed in epithelial tissues, is encoded by the EPCAM/TACSTD1 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026194"}, {"offsetInBeginSection": 564, "offsetInEndSection": 773, "text": "Our study's aim was to explore EPCAM expression in colorectal carcinomas of MSH2-associated LS cases to evaluate the usefulness of EPCAM protein expression in the algorithm approach to LS population screening.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026194"}, {"offsetInBeginSection": 1136, "offsetInEndSection": 1279, "text": "Of the 19 colorectal carcinomas, EPCAM expression loss was seen in only 5 tumors, all of them from patients showing a germ-line EPCAM deletion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026194"}]}, {"id": "5ac24f7595d0062724000003", "body": "Is transcription of eRNA bidirectional?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23728302", "http://www.ncbi.nlm.nih.gov/pubmed/25810254", "http://www.ncbi.nlm.nih.gov/pubmed/25348400", "http://www.ncbi.nlm.nih.gov/pubmed/24778216", "http://www.ncbi.nlm.nih.gov/pubmed/25561718", "http://www.ncbi.nlm.nih.gov/pubmed/25934506", "http://www.ncbi.nlm.nih.gov/pubmed/27932455"], "snippets": [{"offsetInBeginSection": 94, "offsetInEndSection": 289, "text": "In addition to widespread transcription of long non-coding RNAs (lncRNAs) in mammalian cells, bidirectional ncRNAs are transcribed on enhancers, and are thus referred to as enhancer RNAs (eRNAs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728302"}, {"offsetInBeginSection": 405, "offsetInEndSection": 608, "text": "Here we report that in human breast cancer cells 17\u03b2-oestradiol (E2)-bound oestrogen receptor \u03b1 (ER-\u03b1) causes a global increase in eRNA transcription on enhancers adjacent to E2-upregulated coding genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728302"}, {"offsetInBeginSection": 844, "offsetInEndSection": 1059, "text": "Cohesin, present on many ER-\u03b1-regulated enhancers even before ligand treatment, apparently contributes to E2-dependent gene activation, at least in part by stabilizing E2/ER-\u03b1/eRNA-induced enhancer-promoter looping.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728302"}, {"offsetInBeginSection": 834, "offsetInEndSection": 954, "text": "Knockdown of the more distal eRNA led to a drop in Cga mRNA levels, initially without effect on the forward eRNA levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810254"}, {"offsetInBeginSection": 955, "offsetInEndSection": 1061, "text": "With time, however, the repression on the Cga increased, and the forward eRNA levels were suppressed also.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810254"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1161, "text": "We demonstrate that the interaction of the enhancer with the promoter is lost after eRNA knockdown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810254"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1381, "text": "Dramatic changes also were seen in the chromatin, with an increase in total histone H3 occupancy throughout this region and a virtual loss of histone H3 Lys 4 trimethylation at the promoter following the eRNA knockdown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810254"}, {"offsetInBeginSection": 1569, "offsetInEndSection": 1741, "text": "Thus, the Cga eRNA mediates the physical interaction between these genomic regions and determines the chromatin structure of the proximal promoter to allow gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810254"}, {"offsetInBeginSection": 210, "offsetInEndSection": 300, "text": "However, it remains unclear how tightly coupled eRNA production is with enhancer activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348400"}, {"offsetInBeginSection": 740, "offsetInEndSection": 967, "text": "This enhancer exhibits intimately linked virus-inducible enhancer and bidirectional promoter activity that is largely dependent on a conserved Interferon Stimulated Response Element and robustly generates virus inducible eRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348400"}]}, {"id": "5abbe429fcf456587200001c", "body": "What is the drug target for Eliquis (Apixaban)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23649961", "http://www.ncbi.nlm.nih.gov/pubmed/24624626", "http://www.ncbi.nlm.nih.gov/pubmed/26298448", "http://www.ncbi.nlm.nih.gov/pubmed/23305476", "http://www.ncbi.nlm.nih.gov/pubmed/23821689", "http://www.ncbi.nlm.nih.gov/pubmed/28008269", "http://www.ncbi.nlm.nih.gov/pubmed/27984753", "http://www.ncbi.nlm.nih.gov/pubmed/25195485", "http://www.ncbi.nlm.nih.gov/pubmed/22533680", "http://www.ncbi.nlm.nih.gov/pubmed/26369819"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "The current mainstay of treatment of thrombotic APS is long-term anticoagulation with oral vitamin K antagonists (VKA) such as warfarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649961"}, {"offsetInBeginSection": 137, "offsetInEndSection": 244, "text": "However, the use of warfarin is problematic, particularly in patients with antiphospholipid syndrome (APS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649961"}, {"offsetInBeginSection": 245, "offsetInEndSection": 458, "text": "The new oral anticoagulants (NOAC) include dabigatran etexilate (Pradaxa\u00ae), a direct thrombin inhibitor, and rivaroxaban (Xarelto\u00ae), Apixaban (Eliquis) and Edoxaban (Lixiana\u00ae), which are direct anti-Xa inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649961"}, {"offsetInBeginSection": 459, "offsetInEndSection": 702, "text": "Unlike warfarin, these agents do not interact with dietary constituents and alcohol, have few reported drug interactions, and monitoring of their anticoagulant intensity is not routinely required due to their predictable anticoagulant effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649961"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448"}, {"offsetInBeginSection": 6, "offsetInEndSection": 175, "text": "OBJECTIVE: Rivaroxaban and apixaban are part of a new group of oral anticoagulants targeting factor Xa and approved by the Food and Drug Administration in 2011 and 2012.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448"}, {"offsetInBeginSection": 391, "offsetInEndSection": 484, "text": "This study characterizes the clinical effect in patients exposed to rivaroxaban and apixaban.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448"}, {"offsetInBeginSection": 580, "offsetInEndSection": 748, "text": "Cases were initially identified by a search of the poison centers' databases for case mentions involving a human exposure to Xarelto, rivaroxaban, Eliquis, or apixaban.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448"}, {"offsetInBeginSection": 1899, "offsetInEndSection": 1972, "text": "Bleeding was reported in\u00a015 patients (7%): 11 rivaroxaban and 4 apixaban.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448"}, {"offsetInBeginSection": 2388, "offsetInEndSection": 2475, "text": "Blood products were used in 7 rivaroxaban patients (1 suicide) and 3 apixaban patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448"}]}, {"id": "5ac0a36f19833b0d7b000002", "body": "What is an exosome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26725667", "http://www.ncbi.nlm.nih.gov/pubmed/24462375", "http://www.ncbi.nlm.nih.gov/pubmed/27599779", "http://www.ncbi.nlm.nih.gov/pubmed/23376832", "http://www.ncbi.nlm.nih.gov/pubmed/27348448", "http://www.ncbi.nlm.nih.gov/pubmed/21618876", "http://www.ncbi.nlm.nih.gov/pubmed/21713679", "http://www.ncbi.nlm.nih.gov/pubmed/26341056", "http://www.ncbi.nlm.nih.gov/pubmed/27756426", "http://www.ncbi.nlm.nih.gov/pubmed/16087368"], "snippets": [{"offsetInBeginSection": 691, "offsetInEndSection": 843, "text": "We selected lactadherin as an exosome tropic protein and developed it as a fusion protein with Gaussia luciferase to label exosomes for in vivo imaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26725667"}, {"offsetInBeginSection": 1268, "offsetInEndSection": 1381, "text": "We also examined the effect of exosome isolation methods on their physicochemical and pharmacokinetic properties.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26725667"}, {"offsetInBeginSection": 1592, "offsetInEndSection": 1773, "text": "The gradient method is more time-consuming than others; therefore the development of a more efficient method for exosome isolation will advance the development of exosome-based DDS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26725667"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24462375"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1112, "text": "RESULTS: Exosome release from normal human mammary epithelial cells and breast cancer cells is regulated by the presence of exosomes, derived from their own cells, in the extracellular environment of the cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24462375"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Quantification of plasma exosome is a potential prognostic marker for esophageal squamous cell carcinoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27599779"}, {"offsetInBeginSection": 53, "offsetInEndSection": 268, "text": "Although its contents (e.g., proteins and microRNAs) have been focused on in cancer research, particularly as potential diagnostic markers, the exosome behavior and methods for exosome quantification remain unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27599779"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1064, "text": "The relationship between exosome quantification and the patient clinical characteristics was assessed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27599779"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1459, "text": "Although there was no correlation between the tumor progression and the exosome levels, exosome number was the independent prognostic marker and low levels of exosome predicted a poor prognosis (P=0.03).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27599779"}, {"offsetInBeginSection": 1608, "offsetInEndSection": 1716, "text": "In conclusion, exosomal protein content is influenced by the cell source and stimulus for exosome formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376832"}]}, {"id": "5ac3699f0340b9f058000001", "body": "Are human enhancers or promoters evolving faster?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21282711", "http://www.ncbi.nlm.nih.gov/pubmed/8931987", "http://www.ncbi.nlm.nih.gov/pubmed/12610136", "http://www.ncbi.nlm.nih.gov/pubmed/8417365", "http://www.ncbi.nlm.nih.gov/pubmed/1668145", "http://www.ncbi.nlm.nih.gov/pubmed/28116828", "http://www.ncbi.nlm.nih.gov/pubmed/18367463", "http://www.ncbi.nlm.nih.gov/pubmed/8508026", "http://www.ncbi.nlm.nih.gov/pubmed/21326370", "http://www.ncbi.nlm.nih.gov/pubmed/21457775"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Comparative genomic analysis of the Streptococcus dysgalactiae species group: gene content, molecular adaptation, and promoter evolution.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282711"}, {"offsetInBeginSection": 1215, "offsetInEndSection": 1328, "text": "Promoters were primarily evolving under purifying selection but with certain categories of genes evolving faster.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282711"}, {"offsetInBeginSection": 1436, "offsetInEndSection": 1675, "text": "Overall, these results suggest that adaptation to changing environments and new hosts in the SD species group has involved the acquisition of key virulence genes along with selection of orthologous protein-coding loci and operon promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282711"}, {"offsetInBeginSection": 115, "offsetInEndSection": 302, "text": "In transgenic mice, the upstream pN and the downstream pH promoters are ubiquitous, whereas the pM promoter, located between pN and pH, is activated specifically in fast skeletal muscles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8931987"}, {"offsetInBeginSection": 541, "offsetInEndSection": 717, "text": "In the present study, we use the transgenic mice model to further investigate the contribution of these two regulatory elements to the overall control of these three promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8931987"}, {"offsetInBeginSection": 0, "offsetInEndSection": 317, "text": "To determine the effect of the human cytomegalovirus (CMV) major immediate-early (MIE) enhancer or promoter on the efficiency of viral replication in permissive human cells, we constructed recombinant viruses with their human MIE promoter, enhancer, and promoter plus enhancer replaced with the murine CMV components.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136"}, {"offsetInBeginSection": 668, "offsetInEndSection": 903, "text": "The effect of the human CMV enhancer substitution with the murine CMV enhancer was also demonstrated in different cell types by using recombinant virus with the UL127 promoter, driving the expression of green fluorescent protein (GFP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136"}, {"offsetInBeginSection": 904, "offsetInEndSection": 1028, "text": "After an MOI of 1, GFP expression was high with the human CMV enhancer and significantly lower with the murine CMV enhancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136"}, {"offsetInBeginSection": 1266, "offsetInEndSection": 1433, "text": "Proximal and distal chimeras of the human and murine enhancers also replicated less efficiently at a low MOI and expressed lower levels of GFP from the UL127 promoter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136"}, {"offsetInBeginSection": 1434, "offsetInEndSection": 1587, "text": "These experiments demonstrate that the entire human CMV enhancer has evolved for the efficient expression of the viral IE and early genes in human cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136"}]}, {"id": "5abbfd97fcf456587200001d", "body": "What is the Formalin test used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17166125", "http://www.ncbi.nlm.nih.gov/pubmed/19762763", "http://www.ncbi.nlm.nih.gov/pubmed/2247320", "http://www.ncbi.nlm.nih.gov/pubmed/16492837", "http://www.ncbi.nlm.nih.gov/pubmed/19168051", "http://www.ncbi.nlm.nih.gov/pubmed/15105218", "http://www.ncbi.nlm.nih.gov/pubmed/18799335", "http://www.ncbi.nlm.nih.gov/pubmed/15172765", "http://www.ncbi.nlm.nih.gov/pubmed/11226110", "http://www.ncbi.nlm.nih.gov/pubmed/9431444"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Is the second phase of the formalin test useful to predict activity in chronic constriction injury models?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "This study presents data of several reference drugs in rats and gerbils for both the second phase of the formalin test and the cold allodynia in animals with a constriction injury of the sciatic nerve.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 202, "offsetInEndSection": 295, "text": "A pharmacological validation of the formalin test and the CCI model in gerbils was performed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 296, "offsetInEndSection": 461, "text": "It was evaluated whether the second phase of the formalin test could be used as a pharmacological screening to predict outcome in the cold plate test in CCI animals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 541, "offsetInEndSection": 710, "text": "For the formalin test, animals were injected in the right hind paw (5% formalin rat: 0.05 microl; gerbil: 0.01 microl) and flinching and licking or biting were recorded.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 989, "offsetInEndSection": 1184, "text": "Clonidine tends to have more activity in the second phase of the formalin test, whereas baclofen, tramadol, amitryptiline, ketamine and topiramate demonstrate to be more active in the cold plate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1479, "text": "Tramadol and CP-96345 tend to have more activity in the second phase of the formalin test, whereas morphine, SR-48968, SR-142801 and R116301 demonstrates to be more active in the cold plate test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 1480, "offsetInEndSection": 1725, "text": "In the present acute test conditions, there is a correlation in the pharmacological activity in rats and gerbils for the tested compounds a correlation between the second phase of the formalin test and the cold allodynia in CCI animals is found.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Licking decreases phosphorylation of extracellular signal-regulated kinase in the dorsal horn of the spinal cord after a formalin test.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762763"}, {"offsetInBeginSection": 209, "offsetInEndSection": 301, "text": "We investigated, in a formalin test, whether pERK of the dorsal horn is affected by licking.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762763"}]}, {"id": "5ac2776195d0062724000006", "body": "List diseases caused by protein glutamine expanded repeats", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9932422", "http://www.ncbi.nlm.nih.gov/pubmed/9536080", "http://www.ncbi.nlm.nih.gov/pubmed/21933837", "http://www.ncbi.nlm.nih.gov/pubmed/11200958", "http://www.ncbi.nlm.nih.gov/pubmed/8980137", "http://www.ncbi.nlm.nih.gov/pubmed/8202492", "http://www.ncbi.nlm.nih.gov/pubmed/19692580", "http://www.ncbi.nlm.nih.gov/pubmed/9536081", "http://www.ncbi.nlm.nih.gov/pubmed/10434299", "http://www.ncbi.nlm.nih.gov/pubmed/7604023"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9932422"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Eight diseases are now known to be caused by an expansion mutation of the trinucleotide repeat CAG encoding glutamine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9932422"}, {"offsetInBeginSection": 119, "offsetInEndSection": 267, "text": "Each disease is caused by a CAG expansion in a different gene, and the genes bear no similarity to each other except for the presence of the repeat.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9932422"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1269, "text": "Recent findings have now established the presence of such aggregates in selected regions of brain from affected individuals, in transgenic mice expressing expanded repeats, and in isolated cells transfected with expanded repeats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9932422"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9536080"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Huntington's disease (HD) is caused by expansion of a glutamine repeat in huntingtin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9536080"}, {"offsetInBeginSection": 319, "offsetInEndSection": 448, "text": "Aggregation of expanded polyglutamine is thought to be a common pathological mechanism in HD and other glutamine repeat diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9536080"}, {"offsetInBeginSection": 449, "offsetInEndSection": 546, "text": "It is not clear how the length of the repeats is correlated with formation of protein aggregates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9536080"}, {"offsetInBeginSection": 547, "offsetInEndSection": 834, "text": "By expressing a series of huntingtin constructs encoding various glutamine repeats (23-150 units) in cultured cells we observed N-terminal fragments of huntingtin (amino acids 1-67 and 1-212), but not full-length huntingtins, with glutamine repeats >/=66 units formed protein aggregates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9536080"}, {"offsetInBeginSection": 907, "offsetInEndSection": 1071, "text": "This study suggests that various N-terminal fragments of mutant huntingtin can form aggregates and that aggregation is prompted by lengthening the glutamine repeat.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9536080"}]}, {"id": "5ac37afc0340b9f058000002", "body": "What type of sequences do enhancers evolve from?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25956793", "http://www.ncbi.nlm.nih.gov/pubmed/21593416", "http://www.ncbi.nlm.nih.gov/pubmed/28760812", "http://www.ncbi.nlm.nih.gov/pubmed/21798176", "http://www.ncbi.nlm.nih.gov/pubmed/2134678", "http://www.ncbi.nlm.nih.gov/pubmed/1668145", "http://www.ncbi.nlm.nih.gov/pubmed/21151964", "http://www.ncbi.nlm.nih.gov/pubmed/24218638", "http://www.ncbi.nlm.nih.gov/pubmed/15014138", "http://www.ncbi.nlm.nih.gov/pubmed/29035697"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 40, "text": "What does it take to evolve an enhancer?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956793"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "There is widespread interest today in understanding enhancers, which are regulatory elements typically harboring several transcription factor binding sites and mediating the combinatorial effect of transcription factors on gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956793"}, {"offsetInBeginSection": 419, "offsetInEndSection": 585, "text": "Existing approaches to cis-regulatory evolution have often ignored the combinatorial nature and varied biochemical mechanisms of gene regulation encoded in enhancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956793"}, {"offsetInBeginSection": 848, "offsetInEndSection": 1039, "text": "We estimated the time necessary to evolve, from genomic background, enhancers capable of driving complex gene expression patterns similar to those involved in early development in Drosophila.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956793"}, {"offsetInBeginSection": 1282, "offsetInEndSection": 1378, "text": "To our knowledge, this is the first estimate of waiting times for realistic enhancers to evolve.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956793"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Evolutionary origin of a novel gene expression pattern through co-option of the latent activities of existing regulatory sequences.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21593416"}, {"offsetInBeginSection": 243, "offsetInEndSection": 332, "text": "Here, we sought to explore the molecular genetic mechanisms by which new enhancers arise.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21593416"}, {"offsetInBeginSection": 1283, "offsetInEndSection": 1474, "text": "We suggest that the novel optic lobe enhancer evolved by exploiting the cryptic activity of extant regulatory sequences, and this may reflect a general mechanism whereby new enhancers evolve.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21593416"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Transcriptional enhancers are regions of DNA that drive precise patterns of gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28760812"}, {"offsetInBeginSection": 93, "offsetInEndSection": 339, "text": "Although many studies have elucidated how individual enhancers can evolve, most of this work has focused on what are called 'minimal' enhancers, the smallest DNA regions that drive expression that approximates an aspect of native gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28760812"}]}, {"id": "5abcf66afcf4565872000026", "body": "What is Dupuytren's contracture?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22872850", "http://www.ncbi.nlm.nih.gov/pubmed/21992150", "http://www.ncbi.nlm.nih.gov/pubmed/21935843", "http://www.ncbi.nlm.nih.gov/pubmed/10409813", "http://www.ncbi.nlm.nih.gov/pubmed/20676061", "http://www.ncbi.nlm.nih.gov/pubmed/6130030", "http://www.ncbi.nlm.nih.gov/pubmed/18080603", "http://www.ncbi.nlm.nih.gov/pubmed/1769989", "http://www.ncbi.nlm.nih.gov/pubmed/26152183", "http://www.ncbi.nlm.nih.gov/pubmed/1616255"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "The Surgical Release of Dupuytren's Contracture Using Multiple Transverse Incisions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Dupuytren's contracture is a condition commonly encountered by hand surgeons, although it is rare in the Asian population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 123, "offsetInEndSection": 259, "text": "Various surgical procedures for Dupuytren's contracture have been reported, and the outcomes vary according to the treatment modalities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 260, "offsetInEndSection": 396, "text": "We report the treatment results of segmental fasciectomies with multiple transverse incisions for patients with Dupuytren's contracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 397, "offsetInEndSection": 583, "text": "The cases of seven patients who underwent multiple segmental fasciectomies with multiple transverse incisions for Dupuytren's contracture from 2006 to 2011 were reviewed retrospectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 584, "offsetInEndSection": 812, "text": "Multiple transverse incisions to the severe contracture sites were performed initially, and additional incisions to the metacarpophalangeal (MCP) joints, and the proximal interphalangeal (PIP) joints were performed if necessary.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 1146, "offsetInEndSection": 1281, "text": "Multiple transverse incisions for Dupuytren's contracture are technically challenging, and require a high skill level of hand surgeons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 1374, "offsetInEndSection": 1503, "text": "Therefore, segmental fasciectomies with multiple transverse incisions can be a good treatment option for Dupuytren's contracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872850"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Dupuytren's contracture: a retrospective database analysis to determine hospitalizations in the Netherlands.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21992150"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "BACKGROUND: Dupuytren's contracture is a condition of the palmar fascia involving contractures of the fascia and skin in the hand.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21992150"}]}, {"id": "5ad243e30340b9f058000016", "body": "What is the function of LOX proteins in the ECM?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17931358", "http://www.ncbi.nlm.nih.gov/pubmed/26024311", "http://www.ncbi.nlm.nih.gov/pubmed/24348049", "http://www.ncbi.nlm.nih.gov/pubmed/19592613", "http://www.ncbi.nlm.nih.gov/pubmed/16085123"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Active lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin activation and migration in invasive astrocytes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 115, "offsetInEndSection": 243, "text": "However, the function of ECM components and signalling between a permissive ECM and invasive astrocytes is not fully understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 244, "offsetInEndSection": 403, "text": "We have recently reported the ECM enzyme, lysyl oxidase (LOX), in the central nervous system and observed up-regulation of LOX in anaplastic astrocytoma cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 404, "offsetInEndSection": 645, "text": "While the catalytic function of LOX is essential for cross-linking of ECM proteins, we also reported that LOX induced invasive and metastatic properties in breast tumour epithelial cells through hydrogen peroxide-mediated FAK/Src activation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 646, "offsetInEndSection": 801, "text": "In this study, we tested the hypothesis that active LOX is expressed in anaplastic astrocytes and promotes FAK activation and invasive/migratory behaviour.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 802, "offsetInEndSection": 950, "text": "Results demonstrate that increased expression and activity of LOX positively correlated with invasive phenotype of malignant astrocytoma cell lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1190, "text": "Immunohistochemistry detected increased LOX within tumour cells and ECM in grade I-IV astrocytic neoplasm compared with normal brain and coincidence of increased LOX with the loss of glial fibrillary acidic protein in higher-grade tumours.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 1191, "offsetInEndSection": 1486, "text": "Increased active LOX in invasive astrocytes was accompanied by phosphorylation of FAK[Tyr576] and paxillin[Tyr118]; furthermore, both FAK and paxillin tyrosine phosphorylation were diminished by beta-aminopropionitrile inhibition of LOX activity and depletion of H(2)O(2) via catalase treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 1487, "offsetInEndSection": 1688, "text": "Additionally, we provide evidence that in astrocytes, LOX is likely processed by bone morphogenic protein-1 and LOX activity might be further stimulated by the expression of fibronectin in these cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}, {"offsetInBeginSection": 1689, "offsetInEndSection": 1818, "text": "These results demonstrate an important LOX-mediated mechanism that promotes migratory/invasive behaviour of malignant astrocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358"}]}, {"id": "5ace12be0340b9f058000007", "body": "Which gene is responsible for proper speech development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20571508", "http://www.ncbi.nlm.nih.gov/pubmed/26980647", "http://www.ncbi.nlm.nih.gov/pubmed/15884233", "http://www.ncbi.nlm.nih.gov/pubmed/17574010", "http://www.ncbi.nlm.nih.gov/pubmed/18554997", "http://www.ncbi.nlm.nih.gov/pubmed/22644823", "http://www.ncbi.nlm.nih.gov/pubmed/27771768", "http://www.ncbi.nlm.nih.gov/pubmed/25269856", "http://www.ncbi.nlm.nih.gov/pubmed/17565757"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Chiari I malformation, delayed gross motor skills, severe speech delay, and epileptiform discharges in a child with FOXP1 haploinsufficiency.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508"}, {"offsetInBeginSection": 282, "offsetInEndSection": 381, "text": "These findings suggest the possibility that FOXP1 may also contribute to proper speech development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508"}, {"offsetInBeginSection": 443, "offsetInEndSection": 605, "text": "Recently, a child was reported who presented with a 3p13-14.1 deletion of four genes, including FOXP1, and a constellation of deficits that included speech delay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508"}, {"offsetInBeginSection": 686, "offsetInEndSection": 806, "text": "This patient presented with speech and motor developmental delays, a Chiari I malformation, and epileptiform discharges.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508"}, {"offsetInBeginSection": 807, "offsetInEndSection": 936, "text": "The nature of the speech deficit is different from the primary oromotor verbal dyspraxia found in patients with FOXP2 deficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508"}, {"offsetInBeginSection": 937, "offsetInEndSection": 1049, "text": "The patient's developmental deficits may support a role for FOXP1 in the development of verbal and motor skills.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "The FOXP2 gene is important for the development of proper speech motor control in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26980647"}, {"offsetInBeginSection": 90, "offsetInEndSection": 191, "text": "However, the role of the gene in general vocal behavior in other mammals, including mice, is unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26980647"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "[Influence of selected family environment factors on the child's speech development].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884233"}, {"offsetInBeginSection": 286, "offsetInEndSection": 369, "text": "The basis of such process is always the possibility of the intercourse with speech.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884233"}]}, {"id": "5abcf755fcf4565872000028", "body": "Please list 3 diseases treated with Valtrex(valacyclovir)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28089147", "http://www.ncbi.nlm.nih.gov/pubmed/15043175", "http://www.ncbi.nlm.nih.gov/pubmed/28961065", "http://www.ncbi.nlm.nih.gov/pubmed/24736271", "http://www.ncbi.nlm.nih.gov/pubmed/21404597", "http://www.ncbi.nlm.nih.gov/pubmed/9589847", "http://www.ncbi.nlm.nih.gov/pubmed/24284060", "http://www.ncbi.nlm.nih.gov/pubmed/9514622", "http://www.ncbi.nlm.nih.gov/pubmed/19841603"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Descriptions of barriers to self-care by persons with comorbid chronic diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043175"}, {"offsetInBeginSection": 297, "offsetInEndSection": 416, "text": "OBJECTIVE: Our objective was to identify perceived barriers to self-care among patients with comorbid chronic diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043175"}, {"offsetInBeginSection": 1498, "offsetInEndSection": 1648, "text": "Self-management interventions may need to address interactions between chronic conditions as well as skills necessary to care for individual diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043175"}, {"offsetInBeginSection": 296, "offsetInEndSection": 544, "text": "Diseases defined by mitochondrial dysfunction have also expanded from rare monogenic disorders in a strict sense to now also include many common polygenic diseases, including metabolic, cardiovascular, neurodegenerative, and neuromuscular diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961065"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Christoph Steininger and colleagues explore how multiple infectious, autoimmune, metabolic, and neoplastic diseases have been associated with changes in the intestinal microbiome, although a cause-effect relationship is often difficult to establish.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24736271"}, {"offsetInBeginSection": 284, "offsetInEndSection": 473, "text": "As patients with asthma get older, their medication regimen can become even more complex with the development of numerous other age-related diseases requiring their own list of medications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9589847"}, {"offsetInBeginSection": 474, "offsetInEndSection": 722, "text": "Diseases of the joints, diseases of the eye, cardiovascular disease, neurological disease and urological problems represent the most common conditions that patients develop, at times needing medications which might interfere with asthma management.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9589847"}, {"offsetInBeginSection": 218, "offsetInEndSection": 300, "text": "Platelets are an important biomarker source, especially for neurological diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284060"}, {"offsetInBeginSection": 428, "offsetInEndSection": 630, "text": "We first screened a healthy population (n=137), aged between 18 and 104years, to find proteins with small coefficients of total variation (CVtot), herein termed low biological variation proteins (LBVP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284060"}, {"offsetInBeginSection": 881, "offsetInEndSection": 1031, "text": "The least variable protein, calculated over all 238 individuals, was 14-3-3 gamma, with a CVtot of 9.3%, showing no gender, age or disease dependency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284060"}]}, {"id": "5ad35933133db5eb78000001", "body": "Is the protein pelota a ribosomal rescue factor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27493551", "http://www.ncbi.nlm.nih.gov/pubmed/25061210", "http://www.ncbi.nlm.nih.gov/pubmed/9584085"], "snippets": [{"offsetInBeginSection": 271, "offsetInEndSection": 398, "text": "In eukaryotes, Pelota (Dom34 in yeast) and Hbs1 are responsible for solving general problems of ribosomal stall in translation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493551"}, {"offsetInBeginSection": 399, "offsetInEndSection": 521, "text": "In archaea, aPelota and aEF1\u03b1, homologous to Pelota and Hbs1, respectively, are considered to be involved in that process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493551"}, {"offsetInBeginSection": 308, "offsetInEndSection": 571, "text": "Here, we discover that loss of GTPBP2, a novel binding partner of the ribosome recycling protein Pelota, in mice with a mutation in a tRNA gene that is specifically expressed in the central nervous system causes ribosome stalling and widespread neurodegeneration.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25061210"}, {"offsetInBeginSection": 572, "offsetInEndSection": 716, "text": "Our results not only define GTPBP2 as a ribosome rescue factor but also unmask the disease potential of mutations in nuclear-encoded tRNA genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25061210"}, {"offsetInBeginSection": 677, "offsetInEndSection": 788, "text": "A Drosophila homolog of Dom34p, pelota, is required for the proper coordination of meiosis and spermatogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9584085"}, {"offsetInBeginSection": 789, "offsetInEndSection": 979, "text": "Heterologous expression of pelota in dom34delata mutants restores wild-type growth and differentiation, suggesting conservation of function between the eukaryotic members of the gene family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9584085"}, {"offsetInBeginSection": 627, "offsetInEndSection": 771, "text": "In this review, we focus on the functional roles of Dom34/aPelota and Hbs1/aEF1\u03b1 in ribosome rescue, based on recent structural studies of them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493551"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Recent structural studies on Dom34/aPelota and Hbs1/aEF1\u03b1: important factors for solving general problems of ribosomal stall in translation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493551"}, {"offsetInBeginSection": 171, "offsetInEndSection": 270, "text": "Then, ribosomes are rescued from the aberrant mRNA, and the aberrant mRNA is subsequently degraded.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493551"}, {"offsetInBeginSection": 318, "offsetInEndSection": 448, "text": "RPS30A, which encodes ribosomal protein S30, was identified in a screen for high-copy suppressors of the dom34delta growth defect.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9584085"}]}, {"id": "5ace17c30340b9f058000009", "body": "Which olfactory gene senses androsterone?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26140380", "http://www.ncbi.nlm.nih.gov/pubmed/23321429", "http://www.ncbi.nlm.nih.gov/pubmed/23230501", "http://www.ncbi.nlm.nih.gov/pubmed/8043710", "http://www.ncbi.nlm.nih.gov/pubmed/18808328", "http://www.ncbi.nlm.nih.gov/pubmed/20221768", "http://www.ncbi.nlm.nih.gov/pubmed/25091523", "http://www.ncbi.nlm.nih.gov/pubmed/1737068", "http://www.ncbi.nlm.nih.gov/pubmed/23721465", "http://www.ncbi.nlm.nih.gov/pubmed/9566734"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Dexamethasone affects mouse olfactory mucosa gene expression and attenuates genes related to neurite outgrowth.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26140380"}, {"offsetInBeginSection": 1038, "offsetInEndSection": 1176, "text": "RESULTS: Between the WK2 and Ctrl groups, 3351 genes were differentially expressed, of which 236 genes were related to olfactory function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26140380"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The relationship between oral contraceptive use and sensitivity to olfactory stimuli.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321429"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "The present study examined differences in olfactory sensitivity between 16 naturally cycling (NC) women and 17 women taking monophasic oral contraceptives (OCs) to six odors: lemon, peppermint, rose, musk, androstenone and androsterone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321429"}, {"offsetInBeginSection": 395, "offsetInEndSection": 527, "text": "NC women in the periovulatory phase were significantly more sensitive to androstenone, androsterone, and musk than women taking OCs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321429"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Evaluation of the effect of upper complete denture on gustatory and olfactory senses.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23230501"}, {"offsetInBeginSection": 71, "offsetInEndSection": 292, "text": "Clinical experience suggests that complete denture wearers have various disorders in their gustatory and olfactory senses due to disturbance of airways between the oral and nasal cavities caused by upper complete denture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23230501"}, {"offsetInBeginSection": 293, "offsetInEndSection": 438, "text": "The purpose of this study was to evaluate the effect of upper complete denture on gustatory and olfactory senses in denture wearers.MATERIALS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23230501"}, {"offsetInBeginSection": 439, "offsetInEndSection": 683, "text": "METHODS: In this study, gustatory and olfactory senses in 30 patients (15 men and 15 women with a mean age of 52.93 \u00b1 12.97 years) were evaluated three times: before complete denture insertion, three days after insertion and 1 month after that.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23230501"}, {"offsetInBeginSection": 684, "offsetInEndSection": 883, "text": "Sucrose, citric acid, NaCl solution and distilled water (in two samples) were used to evaluate gustatory evalu-ation while mint- and cinnamon-flavored chewing gums were used for olfactory evaluation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23230501"}]}, {"id": "5abd13e1fcf4565872000029", "body": "Where in the body would the navicular bone be found?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20525052", "http://www.ncbi.nlm.nih.gov/pubmed/2681808", "http://www.ncbi.nlm.nih.gov/pubmed/28099198", "http://www.ncbi.nlm.nih.gov/pubmed/9622323", "http://www.ncbi.nlm.nih.gov/pubmed/10029187", "http://www.ncbi.nlm.nih.gov/pubmed/27588043", "http://www.ncbi.nlm.nih.gov/pubmed/27298914", "http://www.ncbi.nlm.nih.gov/pubmed/24788547", "http://www.ncbi.nlm.nih.gov/pubmed/24719271", "http://www.ncbi.nlm.nih.gov/pubmed/9776073"], "snippets": [{"offsetInBeginSection": 235, "offsetInEndSection": 461, "text": "HYPOTHESES: There would be: 1) a correlation between histopathology and MRI findings; and 2) a relationship between MR abnormalities at the origin and the insertion of the DSIL, between insertion and body; and origin and body.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20525052"}, {"offsetInBeginSection": 552, "offsetInEndSection": 667, "text": "MR abnormalities of the DSIL, its origin on the navicular bone and its insertion on the distal phalanx were graded.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20525052"}, {"offsetInBeginSection": 956, "offsetInEndSection": 1273, "text": "RESULTS: There were significant correlations between the presence of a cystic structure in the distal third of the navicular bone, or a distal border fragment, or increased signal intensity in fat suppressed images at the insertion of the DSIL on the distal phalanx and the histological grade of the body of the DSIL.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20525052"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1873, "text": "There were significant associations between a cystic structure in the distal third of the navicular bone and the presence of either a distal border fragment or entheseous new bone at the insertion of the DSIL, swelling of the DSIL and increased signal intensity in the DSIL in fat suppressed images; between distal elongation of the flexor border of the navicular bone and the presence of one or more distal border fragments and between swelling of the body of the DSIL and irregularity of its palmar border or increased signal intensity in fat suppressed images in the DSIL.CONCLUSIONS AND CLINICAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20525052"}, {"offsetInBeginSection": 1874, "offsetInEndSection": 2142, "text": "RELEVANCE: The presence of a cystic structure in the distal third of the navicular bone detected using MRI, a distal border fragment or increased signal intensity at the insertion of the DSIL are suggestive of significant alterations in the infrastructure of the DSIL.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20525052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Fractures of the body of the tarsal navicular bone: case reports and literature review.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2681808"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Four patients sustaining tarsal navicular body fractures are presented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2681808"}, {"offsetInBeginSection": 423, "offsetInEndSection": 568, "text": "Favorable results are obtained in a vertical two-part fracture, by an open reduction and internal fixation of the tarsal navicular body fracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2681808"}, {"offsetInBeginSection": 569, "offsetInEndSection": 657, "text": "In highly comminuted fractures, talo-navicular-cuneiform arthrodesis can be carried out.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2681808"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Osteomyelitis of the accessory and body of the navicular bone: a case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099198"}]}, {"id": "5a9d9ab94e03427e73000003", "body": "Is Cystatin D a biomarker?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27861242", "http://www.ncbi.nlm.nih.gov/pubmed/26066476", "http://www.ncbi.nlm.nih.gov/pubmed/29087712", "http://www.ncbi.nlm.nih.gov/pubmed/21151566", "http://www.ncbi.nlm.nih.gov/pubmed/22350134", "http://www.ncbi.nlm.nih.gov/pubmed/19444952", "http://www.ncbi.nlm.nih.gov/pubmed/21918259", "http://www.ncbi.nlm.nih.gov/pubmed/24713815", "http://www.ncbi.nlm.nih.gov/pubmed/24266750", "http://www.ncbi.nlm.nih.gov/pubmed/22795897"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "OBJECTIVE: The study aims to determine whether cystatin C is associated with HIV disease and HIV-associated neurocognitive impairment (NCI).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27861242"}, {"offsetInBeginSection": 322, "offsetInEndSection": 436, "text": "Cystatin C, a biomarker of kidney functioning that has been linked to poor health outcomes, was measured in blood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27861242"}, {"offsetInBeginSection": 660, "offsetInEndSection": 881, "text": "CONCLUSIONS: Our results confirm that HIV+ older adults have higher cystatin C than HIV- older adults and further identify that cystatin C may be associated with NCI in this population, particularly if they use tenofovir.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27861242"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Cystatin C as a biomarker for estimating glomerular filtration rate.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476"}, {"offsetInBeginSection": 321, "offsetInEndSection": 455, "text": "Contemporary research suggests that cystatin C may be an improved alternative to creatinine for inclusion in GFR estimating equations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476"}, {"offsetInBeginSection": 456, "offsetInEndSection": 583, "text": "The purpose of this article is to evaluate the benefits and limitations of using cystatin C as a biomarker of filtration.RECENT", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476"}, {"offsetInBeginSection": 584, "offsetInEndSection": 673, "text": "FINDINGS: Cystatin C has fewer non-GFR determinants, when compared with serum creatinine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476"}, {"offsetInBeginSection": 674, "offsetInEndSection": 787, "text": "Use of serum cystatin C avoids the limitations related to both diet and muscle mass that affect serum creatinine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476"}, {"offsetInBeginSection": 788, "offsetInEndSection": 944, "text": "Cystatin C may be more accurate than serum creatinine in estimating GFR, and is more strongly associated with all-cause mortality and cardiovascular events.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476"}, {"offsetInBeginSection": 944, "offsetInEndSection": 1024, "text": "SUMMARY: Cystatin C has some advantages over serum creatinine in estimating GFR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476"}]}, {"id": "5ace19420340b9f05800000a", "body": "Which gene is responsible for red hair?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12876664", "http://www.ncbi.nlm.nih.gov/pubmed/9302268", "http://www.ncbi.nlm.nih.gov/pubmed/28024137", "http://www.ncbi.nlm.nih.gov/pubmed/2363420"], "snippets": [{"offsetInBeginSection": 238, "offsetInEndSection": 386, "text": "The majority of affected individuals develop some cutaneous melanin; this is predominantly seen as yellow/blond hair, whereas fewer have brown hair.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12876664"}, {"offsetInBeginSection": 628, "offsetInEndSection": 775, "text": "Sequence variation in the melanocortin-1 receptor (MC1R) gene is associated with red hair in the normal population, but red hair is unusual in OCA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12876664"}, {"offsetInBeginSection": 776, "offsetInEndSection": 840, "text": "We identified eight probands with OCA who had red hair at birth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12876664"}, {"offsetInBeginSection": 841, "offsetInEndSection": 1114, "text": "Mutations in the P gene were responsible for classic phenotype of oculocutaneous albinism type 2 (OCA2) in all eight, and mutations in the MC1R gene were responsible for the red (rather than yellow/blond) hair in the six of eight who continued to have red hair after birth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12876664"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9302268"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "The association between MSHR coding region variation and hair colour in humans has been examined by genotyping 25 red haired and 62 non-red Caucasians, all of whom were 12 years of age and members of a twin pair study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9302268"}, {"offsetInBeginSection": 335, "offsetInEndSection": 588, "text": "The previously reported Val92Met allele shows no association with hair colour, but the three alleles Arg151Cys, Arg160Trp and Asp294His were associated with red hair and one Val60Leu variant was most frequent in fair/blonde and light brown hair colours.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9302268"}, {"offsetInBeginSection": 589, "offsetInEndSection": 666, "text": "Variant MSHR genotypes are associated with lighter skin types and red hair (P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9302268"}, {"offsetInBeginSection": 0, "offsetInEndSection": 28, "text": "[Secrets of the red-headed].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28024137"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Only 1-2% of people is red-headed but in the Russian Udmurt Republic or United Kingdom they can be met more often.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28024137"}]}, {"id": "5abd5a62fcf4565872000031", "body": "Which bacteria was EcoRI, restriction endonuclease isolated from?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10573394", "http://www.ncbi.nlm.nih.gov/pubmed/2695392", "http://www.ncbi.nlm.nih.gov/pubmed/6263856", "http://www.ncbi.nlm.nih.gov/pubmed/1979278", "http://www.ncbi.nlm.nih.gov/pubmed/403933", "http://www.ncbi.nlm.nih.gov/pubmed/6265073", "http://www.ncbi.nlm.nih.gov/pubmed/8246264", "http://www.ncbi.nlm.nih.gov/pubmed/18183461", "http://www.ncbi.nlm.nih.gov/pubmed/776705", "http://www.ncbi.nlm.nih.gov/pubmed/8760442"], "snippets": [{"offsetInBeginSection": 259, "offsetInEndSection": 473, "text": "The isolates were initially classified according to their restriction endonuclease profiles using HindIII and EcoRI restriction endonucleases and further characterised by rRNA gene restriction patterns (ribotypes).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10573394"}, {"offsetInBeginSection": 628, "offsetInEndSection": 769, "text": "The strains were divided with HindIII and EcoRI ribopatterns into ten and nine clusters at the similarity level of 65% and 50%, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10573394"}, {"offsetInBeginSection": 863, "offsetInEndSection": 968, "text": "Only one isolate was identified as Lactobacillus plantarum and no Carnobacterium strains were discovered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10573394"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Comparison of the nucleotide and amino acid sequences of the RsrI and EcoRI restriction endonucleases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2695392"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The RsrI endonuclease, a type-II restriction endonuclease (ENase) found in Rhodobacter sphaeroides, is an isoschizomer of the EcoRI ENase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2695392"}, {"offsetInBeginSection": 139, "offsetInEndSection": 359, "text": "A clone containing an 11-kb BamHI fragment was isolated from an R. sphaeroides genomic DNA library by hybridization with synthetic oligodeoxyribonucleotide probes based on the N-terminal amino acid (aa) sequence of RsrI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2695392"}, {"offsetInBeginSection": 547, "offsetInEndSection": 644, "text": "A 50% identity exists within a 266-aa overlap between the deduced aa sequences of RsrI and EcoRI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2695392"}, {"offsetInBeginSection": 645, "offsetInEndSection": 746, "text": "Regions of 75-100% aa sequence identity correspond to key structural and functional regions of EcoRI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2695392"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Ten plasmids were isolated as covalently closed circular deoxyribonucleic acid from antibiotic-resistant thermophilic bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6263856"}, {"offsetInBeginSection": 547, "offsetInEndSection": 645, "text": "The restriction endonuclease cleavage maps of the two plasmids, pTB19 and pTB20, were constructed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6263856"}]}, {"id": "5a9da37e4e03427e73000004", "body": "What is Mendelian randomization?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26291580", "http://www.ncbi.nlm.nih.gov/pubmed/26201704", "http://www.ncbi.nlm.nih.gov/pubmed/19432981", "http://www.ncbi.nlm.nih.gov/pubmed/23199790", "http://www.ncbi.nlm.nih.gov/pubmed/20978399", "http://www.ncbi.nlm.nih.gov/pubmed/19674341", "http://www.ncbi.nlm.nih.gov/pubmed/16410347", "http://www.ncbi.nlm.nih.gov/pubmed/20616999", "http://www.ncbi.nlm.nih.gov/pubmed/19174578", "http://www.ncbi.nlm.nih.gov/pubmed/27486138"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26291580"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "OBJECTIVE: Mendelian randomization is a popular technique for assessing and estimating the causal effects of risk factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26291580"}, {"offsetInBeginSection": 590, "offsetInEndSection": 765, "text": "RESULTS: A list of guidelines based on the 'Bradford Hill criteria' for judging the plausibility of a causal finding from an applied Mendelian randomization study is provided.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26291580"}, {"offsetInBeginSection": 766, "offsetInEndSection": 983, "text": "We also give a framework for performing and interpreting investigations performed in the style of Mendelian randomization, but where the choice of genetic variants is statistically, rather than biologically motivated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26291580"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1091, "text": "Such analyses should not be assigned the same evidential weight as a Mendelian randomization investigation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26291580"}, {"offsetInBeginSection": 1091, "offsetInEndSection": 1259, "text": "CONCLUSION: We discuss the role of such investigations (in the style of Mendelian randomization), and what they add to our understanding of potential causal mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26291580"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Mendelian Randomization versus Path Models: Making Causal Inferences in Genetic Epidemiology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201704"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "OBJECTIVE: The term Mendelian randomization is popular in the current literature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201704"}, {"offsetInBeginSection": 82, "offsetInEndSection": 227, "text": "The first aim of this work is to describe the idea of Mendelian randomization studies and the assumptions required for drawing valid conclusions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201704"}, {"offsetInBeginSection": 228, "offsetInEndSection": 353, "text": "The second aim is to contrast Mendelian randomization and path modeling when different 'omics' levels are considered jointly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201704"}]}, {"id": "5ace1a590340b9f05800000b", "body": "What percentage of Homo sapiens DNA is of Neanderthal origin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17146600", "http://www.ncbi.nlm.nih.gov/pubmed/17110569", "http://www.ncbi.nlm.nih.gov/pubmed/10788336", "http://www.ncbi.nlm.nih.gov/pubmed/27429943", "http://www.ncbi.nlm.nih.gov/pubmed/18768141", "http://www.ncbi.nlm.nih.gov/pubmed/21404232", "http://www.ncbi.nlm.nih.gov/pubmed/21078988"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Evaluating Neanderthal genetics and phylogeny.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17146600"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "The retrieval of Neanderthal (Homo neanderthalsensis) mitochondrial DNA is thought to be among the most significant ancient DNA contributions to date, allowing conflicting hypotheses on modern human (Homo sapiens) evolution to be tested directly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17146600"}, {"offsetInBeginSection": 247, "offsetInEndSection": 407, "text": "Recently, however, both the authenticity of the Neanderthal sequences and their phylogenetic position outside contemporary human diversity have been questioned.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17146600"}, {"offsetInBeginSection": 408, "offsetInEndSection": 669, "text": "Using Bayesian inference and the largest dataset to date, we find strong support for a monophyletic Neanderthal clade outside the diversity of contemporary humans, in agreement with the expectations of the Out-of-Africa replacement model of modern human origin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17146600"}, {"offsetInBeginSection": 670, "offsetInEndSection": 867, "text": "From average pairwise sequence differences, we obtain support for claims that the first published Neanderthal sequence may include errors due to postmortem damage in the template molecules for PCR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17146600"}, {"offsetInBeginSection": 868, "offsetInEndSection": 1139, "text": "In contrast, we find that recent results implying that the Neanderthal sequences are products of PCR artifacts are not well supported, suffering from inadequate experimental design and a presumably high percentage (>68%) of chimeric sequences due to \"jumping PCR\" events.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17146600"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Sequencing and analysis of Neanderthal genomic DNA.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110569"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Our knowledge of Neanderthals is based on a limited number of remains and artifacts from which we must make inferences about their biology, behavior, and relationship to ourselves.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110569"}, {"offsetInBeginSection": 181, "offsetInEndSection": 380, "text": "Here, we describe the characterization of these extinct hominids from a new perspective, based on the development of a Neanderthal metagenomic library and its high-throughput sequencing and analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110569"}, {"offsetInBeginSection": 381, "offsetInEndSection": 674, "text": "Several lines of evidence indicate that the 65,250 base pairs of hominid sequence so far identified in the library are of Neanderthal origin, the strongest being the ascertainment of sequence identities between Neanderthal and chimpanzee at sites where the human genomic sequence is different.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110569"}]}, {"id": "5ac0f7b919833b0d7b000006", "body": "What are the 3 antidotes for anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors, as of November 2017.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26378211", "http://www.ncbi.nlm.nih.gov/pubmed/25485923", "http://www.ncbi.nlm.nih.gov/pubmed/27082776", "http://www.ncbi.nlm.nih.gov/pubmed/28314985", "http://www.ncbi.nlm.nih.gov/pubmed/12516682", "http://www.ncbi.nlm.nih.gov/pubmed/23953907", "http://www.ncbi.nlm.nih.gov/pubmed/19351313", "http://www.ncbi.nlm.nih.gov/pubmed/28471371", "http://www.ncbi.nlm.nih.gov/pubmed/27626268", "http://www.ncbi.nlm.nih.gov/pubmed/21254900"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 56, "offsetInEndSection": 185, "text": "Treatment with anticoagulants in patients with atrial fibrillation reduces embolic complications of the disease including stroke.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 381, "offsetInEndSection": 623, "text": "Inhibition of clotting factor Xa has been evaluated as a potential target for anticoagulation therapy with the hypothesis that using target-specific therapy will alleviate some of the dosing variability observed with the vitamin K antagonist.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 624, "offsetInEndSection": 718, "text": "Three factor Xa inhibitors are currently indicated for use in nonvalvular atrial fibrillation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 719, "offsetInEndSection": 822, "text": "Similar to the vitamin K antagonist, warfarin, all of the factor Xa inhibitors are administered orally.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1124, "text": "The therapeutic dose of factor Xa inhibitors vary based on renal function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1282, "text": "Unlike warfarin, there are no currently available antidotes for the factor Xa inhibitors although this is an area of interest for current and future studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 1283, "offsetInEndSection": 1428, "text": "In the event of a life-threatening bleed there are established management strategies to reverse the bleeding effects of the factor Xa inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are US Food and Drug Administration (FDA)-approved target-specific oral anticoagulants (TSOACs) that have emerged onto the market for use in some indications similar to those for warfarin; in addition, edoxaban is seeking FDA approval.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25485923"}, {"offsetInBeginSection": 709, "offsetInEndSection": 858, "text": "As anticoagulants, they are all associated with a risk of bleeding, and, unfortunately, there are no approved antidotes for reversal of these agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25485923"}]}, {"id": "5a9da59c4e03427e73000005", "body": "What is PNPPP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26551787", "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "http://www.ncbi.nlm.nih.gov/pubmed/21747892", "http://www.ncbi.nlm.nih.gov/pubmed/24201366"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Effect of genetic and environmental factors on protein biomarkers for common non-communicable disease and use of personally normalized plasma protein profiles (PNPPP).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26551787"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1050, "text": "PdeM is a monomer of 29.3 kDa, which exhibits optimum activity at 25\u00b0C and pH 8.5, but low affinity for bis(pNPP) as well as pNPPP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120"}, {"offsetInBeginSection": 1827, "offsetInEndSection": 1913, "text": "PdeM, thus, is a novel representative of new subclass of class III phosphodiesterases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120"}, {"offsetInBeginSection": 165, "offsetInEndSection": 531, "text": "In the + MP transgenic plants, as compared with non-transgenic and - MP plants, higher hydrolytic activities were found on the following substrates: bis-(nitrophenyl)-phosphate (BPNPP, phosphodiesterase), p-nitrophenyl-(phenyl)-phosphate (PNPPP, nucleotidephosphodiesterase) and thymidine-3'-monophosphate p-nitrophenyl ester (T3MPP; 3'nucleotide phosphodiesterase.)", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201366"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Clerodendron capitatum (Willd) (family: verbenaceae) is locally named as Gung and used traditionally to treat erectile dysfunction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747892"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "OBJECTIVE: To study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (PNPPP) controlling for non-disease-related variance.MATERIALS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26551787"}, {"offsetInBeginSection": 233, "offsetInEndSection": 357, "text": "The relaxation effect of this plant was tested on phenylephrine precontracted rabbit corpus cavernosum smooth muscle (CCSM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747892"}, {"offsetInBeginSection": 1400, "offsetInEndSection": 1522, "text": "Although Mn2+ was required for the activity of PdeM, but addition of metals (Mn2+ or Fe3+) did not induce oligomerization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120"}, {"offsetInBeginSection": 514, "offsetInEndSection": 717, "text": "CONCLUSION: PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26551787"}, {"offsetInBeginSection": 728, "offsetInEndSection": 918, "text": "Bioinformatic, biochemical and biophysical characterization of PdeM further revealed some of the characteristic features of the phosphodiesterases belonging to newly described subclass IIIB.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120"}]}, {"id": "5ace20fa0340b9f05800000c", "body": "Which genes are responsible for the high-altitude adaptation of Tibetans?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25501874", "http://www.ncbi.nlm.nih.gov/pubmed/20961960", "http://www.ncbi.nlm.nih.gov/pubmed/28585439", "http://www.ncbi.nlm.nih.gov/pubmed/26053282", "http://www.ncbi.nlm.nih.gov/pubmed/22503288", "http://www.ncbi.nlm.nih.gov/pubmed/20838600", "http://www.ncbi.nlm.nih.gov/pubmed/28585440", "http://www.ncbi.nlm.nih.gov/pubmed/23874230", "http://www.ncbi.nlm.nih.gov/pubmed/27501156", "http://www.ncbi.nlm.nih.gov/pubmed/23666208"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Two functional loci in the promoter of EPAS1 gene involved in high-altitude adaptation of Tibetans.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501874"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "EPAS1 involves in the hypoxic response and is suggested to be responsible for the genetic adaptation of high-altitude hypoxia in Tibetans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501874"}, {"offsetInBeginSection": 198, "offsetInEndSection": 404, "text": "In this study, a single nucleotide polymorphism rs56721780:G>C and an insertion/deletion (indel) polymorphism -742 indel in the promoter region showed divergence between Tibetans and non-Tibetan lowlanders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501874"}, {"offsetInBeginSection": 569, "offsetInEndSection": 720, "text": "It demonstrated that the C allele of rs56721780:G>C decreased the binding of IKZF1, leading to the attenuated transcriptional repression of EPAS1 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501874"}, {"offsetInBeginSection": 838, "offsetInEndSection": 1041, "text": "Further functional analysis revealed that lysyl oxidase (LOX) gene, which was reported to be responsible for extracellular matrix protein cross-linking of amnion previously, was a direct target of EPAS1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501874"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "A genome-wide search for signals of high-altitude adaptation in Tibetans.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20961960"}, {"offsetInBeginSection": 0, "offsetInEndSection": 267, "text": "Genetic studies of Tibetans, an ethnic group with a long-lasting presence on the Tibetan Plateau which is known as the highest plateau in the world, may offer a unique opportunity to understand the biological adaptations of human beings to high-altitude environments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20961960"}, {"offsetInBeginSection": 268, "offsetInEndSection": 460, "text": "We conducted a genome-wide study of 1,000,000 genetic variants in 46 Tibetans (TBN) and 92 Han Chinese (HAN) for identifying the signals of high-altitude adaptations (HAAs) in Tibetan genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20961960"}, {"offsetInBeginSection": 559, "offsetInEndSection": 729, "text": "EGLN1 (or HIFPH2, MIM 606425) and EPAS1 (or HIF2A, MIM 603349), both related to hypoxia-inducible factor, were found most differentiated in the two regions, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20961960"}, {"offsetInBeginSection": 1186, "offsetInEndSection": 1319, "text": "All of our population genomic and statistical analyses indicate that EPAS1 and EGLN1 are most likely responsible for HAA of Tibetans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20961960"}]}, {"id": "5a74eaa50384be955100000b", "body": "What part of the body is affected by mesotheliomia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22879850", "http://www.ncbi.nlm.nih.gov/pubmed/16163658", "http://www.ncbi.nlm.nih.gov/pubmed/17509761", "http://www.ncbi.nlm.nih.gov/pubmed/26007284", "http://www.ncbi.nlm.nih.gov/pubmed/869834", "http://www.ncbi.nlm.nih.gov/pubmed/25274322", "http://www.ncbi.nlm.nih.gov/pubmed/24531623", "http://www.ncbi.nlm.nih.gov/pubmed/16051171", "http://www.ncbi.nlm.nih.gov/pubmed/23204474", "http://www.ncbi.nlm.nih.gov/pubmed/11058423"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Systemic lupus erythematosus (SLE) is a chronic, multifaceted autoimmune inflammatory disease that can affect any part of the body.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22879850"}, {"offsetInBeginSection": 628, "offsetInEndSection": 764, "text": "Symptoms vary from person to person, and may come and go, depend on what part of the body is affected, can be mild, moderate, or severe.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22879850"}, {"offsetInBeginSection": 1369, "offsetInEndSection": 1616, "text": "These movements appear in the non-affected part of the body throughout cerebrovascular disease evolution, and which could be caused by maintained hypersolicitation of the unaffected part of the body and the neuroplastic process following a stroke.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16163658"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Body perception disturbance: a contribution to pain in complex regional pain syndrome (CRPS).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509761"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "In spite of pain in the CRPS limb, clinical observations show patients pay little attention to, and fail to care for, their affected limb as if it were not part of their body.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509761"}, {"offsetInBeginSection": 421, "offsetInEndSection": 595, "text": "Twenty-seven participants who met the IASP CRPS classification were interviewed using qualitative methods to explore feelings and perceptions about their affected body parts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509761"}, {"offsetInBeginSection": 684, "offsetInEndSection": 865, "text": "Participants revealed bizarre perceptions about a part of their body and expressed a desperate desire to amputate this part despite the prospect of further pain and functional loss.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509761"}, {"offsetInBeginSection": 946, "offsetInEndSection": 1039, "text": "Anatomical parts of the CRPS limb were erased in mental representations of the affected area.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509761"}, {"offsetInBeginSection": 1144, "offsetInEndSection": 1244, "text": "These feelings were about the CRPS limb only as the remaining unaffected body was felt to be normal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509761"}, {"offsetInBeginSection": 157, "offsetInEndSection": 321, "text": "METHOD: Participants completed an online questionnaire including 15 demographic questions, 7 work-related and 8 injury-related questions for 9 different body parts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26007284"}]}, {"id": "5a9db99ffd02ddc336000001", "body": "Is CXCL7 a chemokine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20652876", "http://www.ncbi.nlm.nih.gov/pubmed/28245630", "http://www.ncbi.nlm.nih.gov/pubmed/28368308", "http://www.ncbi.nlm.nih.gov/pubmed/26233476", "http://www.ncbi.nlm.nih.gov/pubmed/18707017", "http://www.ncbi.nlm.nih.gov/pubmed/23136963", "http://www.ncbi.nlm.nih.gov/pubmed/20022386", "http://www.ncbi.nlm.nih.gov/pubmed/12193731", "http://www.ncbi.nlm.nih.gov/pubmed/29038657", "http://www.ncbi.nlm.nih.gov/pubmed/20652010"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Chondrogenic differentiation of human mesenchymal stem cells in micro-masses is impaired by high doses of the chemokine CXCL7.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20652876"}, {"offsetInBeginSection": 151, "offsetInEndSection": 303, "text": "The aim of our study was to analyse the effect of CXCL7, a chemokine that has the capacity to recruit MSCs, on the chondrogenic differentiation of MSCs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20652876"}, {"offsetInBeginSection": 304, "offsetInEndSection": 509, "text": "Bone marrow-derived MSCs were cultured in high-density micro-masses under serum-free conditions and were co-stimulated with 0-100 nM CXCL7 in the presence of 10 ng/ml transforming growth factor-\u03b23 (TGF\u03b23).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20652876"}, {"offsetInBeginSection": 1259, "offsetInEndSection": 1451, "text": "As assessed by histological staining, MSCs showed a significantly reduced deposition of proteoglycan and a mildly mineralized matrix when stimulated with TGF\u03b23 in the presence of 100 nM CXCL7.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20652876"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Structural Basis of Native CXCL7 Monomer Binding to CXCR2 Receptor N-Domain and Glycosaminoglycan Heparin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28245630"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "CXCL7, a chemokine highly expressed in platelets, orchestrates neutrophil recruitment during thrombosis and related pathophysiological processes by interacting with CXCR2 receptor and sulfated glycosaminoglycans (GAG).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28245630"}, {"offsetInBeginSection": 219, "offsetInEndSection": 372, "text": "CXCL7 exists as monomers and dimers, and dimerization (~50 \u03bcM) and CXCR2 binding (~10 nM) constants indicate that CXCL7 is a potent agonist as a monomer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28245630"}, {"offsetInBeginSection": 373, "offsetInEndSection": 494, "text": "Currently, nothing is known regarding the structural basis by which receptor and GAG interactions mediate CXCL7 function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28245630"}, {"offsetInBeginSection": 1201, "offsetInEndSection": 1369, "text": "Further, this is the first study that describes the structural basis of receptor and GAG interactions of a native monomer of the neutrophil-activating chemokine family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28245630"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Chemokine CXCL7 Heterodimers: Structural Insights, CXCR2 Receptor Function, and Glycosaminoglycan Interactions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368308"}]}, {"id": "5ace2d600340b9f05800000e", "body": "What phenotype is associated with the V60L mutation in the human MC1R gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25794181", "http://www.ncbi.nlm.nih.gov/pubmed/24045876", "http://www.ncbi.nlm.nih.gov/pubmed/15972726", "http://www.ncbi.nlm.nih.gov/pubmed/20876876", "http://www.ncbi.nlm.nih.gov/pubmed/26103569", "http://www.ncbi.nlm.nih.gov/pubmed/16567973", "http://www.ncbi.nlm.nih.gov/pubmed/17616515"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Prediction of the damage-associated non-synonymous single nucleotide polymorphisms in the human MC1R gene.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794181"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The melanocortin 1 receptor (MC1R) is involved in the control of melanogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794181"}, {"offsetInBeginSection": 80, "offsetInEndSection": 221, "text": "Polymorphisms in this gene have been associated with variation in skin and hair color and with elevated risk for the development of melanoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794181"}, {"offsetInBeginSection": 222, "offsetInEndSection": 421, "text": "Here we used 11 computational tools based on different approaches to predict the damage-associated non-synonymous single nucleotide polymorphisms (nsSNPs) in the coding region of the human MC1R gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794181"}, {"offsetInBeginSection": 732, "offsetInEndSection": 1244, "text": "The R variants D84E, R142H, R151C, I155T, R160W and D294H were classified as damaging by the majority of the tools while the r variants V60L, V92M and R163Q have been predicted as neutral in most of the programs The combination of the prediction tools results in 14 nsSNPs indicated as the most damaging mutations in MC1R (L48P, R67W, H70Y, P72L, S83P, R151H, S172I, L206P, T242I, G255R, P256S, C273Y, C289R and R306H); C273Y showed to be highly damaging in SIFT, Polyphen-2, MutPred, PANTHER and PROVEAN scores.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794181"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1509, "text": "The computational analysis proved capable of identifying the potentially damaging nsSNPs in MC1R, which are candidates for further laboratory studies of the functional and pharmacological significance of the alterations in the receptor and the phenotypic outcomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794181"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Simultaneous purifying selection on the ancestral MC1R allele and positive selection on the melanoma-risk allele V60L in south Europeans.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045876"}, {"offsetInBeginSection": 174, "offsetInEndSection": 331, "text": "This atypical observation has been interpreted as the result of purifying selection due to functional constraint on MC1R in high UV-B radiation environments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045876"}, {"offsetInBeginSection": 332, "offsetInEndSection": 596, "text": "By analyzing 3,142 human MC1R alleles from different regions of Spain in the context of additional haplotypic information from the 1000 Genomes (1000G) Project data, we show that purifying selection is also strong in southern Europe, but not so in northern Europe.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045876"}, {"offsetInBeginSection": 597, "offsetInEndSection": 683, "text": "Furthermore, we show that purifying and positive selection act simultaneously on MC1R.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045876"}]}, {"id": "5aae6499fcf456587200000c", "body": "What is BORSA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28893360", "http://www.ncbi.nlm.nih.gov/pubmed/2261916", "http://www.ncbi.nlm.nih.gov/pubmed/20880412", "http://www.ncbi.nlm.nih.gov/pubmed/21337531", "http://www.ncbi.nlm.nih.gov/pubmed/15770100", "http://www.ncbi.nlm.nih.gov/pubmed/21875361", "http://www.ncbi.nlm.nih.gov/pubmed/17108271", "http://www.ncbi.nlm.nih.gov/pubmed/2069374", "http://www.ncbi.nlm.nih.gov/pubmed/26064878", "http://www.ncbi.nlm.nih.gov/pubmed/18630132"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) - a more common problem than expected?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893360"}, {"offsetInBeginSection": 896, "offsetInEndSection": 1065, "text": "Under conditions used to elicit intrinsic methicillin resistance in Staphylococcus aureus, a large percentage of BORSA appeared resistant to amoxicillin/clavulanic acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2261916"}, {"offsetInBeginSection": 1066, "offsetInEndSection": 1175, "text": "This clearly shows that BORSA may be misidentified as MRSA while heteroresistant MRSA may appear to be BORSA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2261916"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "Since it is unknown whether \u03b2-lactam antimicrobial agents can be used effectively against borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical BORSA isolates was evaluated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412"}, {"offsetInBeginSection": 302, "offsetInEndSection": 521, "text": "Time-kill experiments with oxacillin were performed and the results compared with those obtained with vancomycin, daptomycin and linezolid against BORSA with oxacillin MICs \u22654 mg/L and BORSA with oxacillin MICs \u22642 mg/L.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412"}, {"offsetInBeginSection": 660, "offsetInEndSection": 894, "text": "Oxacillin killing activity was attenuated against BORSA compared with ATCC 29213 since the pharmacodynamic parameters revealed that the potency of oxacillin was markedly reduced (c. ten-fold) against BORSA with oxacillin MICs \u22654 mg/L.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412"}, {"offsetInBeginSection": 895, "offsetInEndSection": 991, "text": "pBORa53-like plasmid-containing BORSA with oxacillin MICs \u22642 mg/L showed markedly more regrowth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412"}, {"offsetInBeginSection": 992, "offsetInEndSection": 1158, "text": "In conclusion, oxacillin was non-effective in the eradication of either (i) BORSA with oxacillin MICs \u22654 mg/L or (ii) \u03b2-lactamase-hyperproducing BORSA (MICs \u22642 mg/L).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1301, "text": "Further investigation into \u03b2-lactam dosing strategies against different BORSA strains is warranted in order to avoid possible therapy failure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412"}, {"offsetInBeginSection": 883, "offsetInEndSection": 941, "text": "Eighteen children (53%) grew BORSA in their index culture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21337531"}]}, {"id": "5a9e202bde7cb99d40000002", "body": "Which method is Proseek based on?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25987887", "http://www.ncbi.nlm.nih.gov/pubmed/19040730", "http://www.ncbi.nlm.nih.gov/pubmed/28936257"], "snippets": [{"offsetInBeginSection": 1279, "offsetInEndSection": 1488, "text": "RESULTS: Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887"}, {"offsetInBeginSection": 474, "offsetInEndSection": 654, "text": "Among 92 proteins in the Proseek Multiplex Oncology Iv2 panel, 87 were above the limit of detection (LOD) in liquid plasma and 56 among 92 above LOD in plasma applied to FTA cards.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1038, "text": "Our results demonstrate that samples applied to the indicating FTA elute micro card\u2122 are amendable to protein analyses, given that a sensitive protein detection assay is used.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257"}, {"offsetInBeginSection": 332, "offsetInEndSection": 494, "text": "Multiplex Ligation-dependent Probe Amplification (MLPA) is a targeted method to assess copy number differences for up to 40 genomic loci in one single experiment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19040730"}, {"offsetInBeginSection": 882, "offsetInEndSection": 1166, "text": "EDTA plasma samples (1\u00a0\u03bcL) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek\u00ae Multiplex Oncology I proximity extension assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887"}, {"offsetInBeginSection": 655, "offsetInEndSection": 737, "text": "Washing and protein elution protocols were compared to identify an optimal method.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "BACKGROUND: Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887"}, {"offsetInBeginSection": 0, "offsetInEndSection": 44, "text": "ProSeeK: a web server for MLPA probe design.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19040730"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "The indicating FTA elute micro card\u2122 has been developed to collect and stabilize the nucleic acid in biological samples and is widely used in human and veterinary medicine and other disciplines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257"}, {"offsetInBeginSection": 738, "offsetInEndSection": 862, "text": "Liquid-based cytology samples showed a lower number of proteins above LOD than FTA cards with vaginal fluid samples applied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257"}]}, {"id": "5ace34eb0340b9f058000010", "body": "Which genes are associated with Epidermolysis Bullosa Simplex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9406827", "http://www.ncbi.nlm.nih.gov/pubmed/12655565", "http://www.ncbi.nlm.nih.gov/pubmed/23894602", "http://www.ncbi.nlm.nih.gov/pubmed/19797037", "http://www.ncbi.nlm.nih.gov/pubmed/11851893", "http://www.ncbi.nlm.nih.gov/pubmed/10494094", "http://www.ncbi.nlm.nih.gov/pubmed/9036937", "http://www.ncbi.nlm.nih.gov/pubmed/20199538", "http://www.ncbi.nlm.nih.gov/pubmed/25354580", "http://www.ncbi.nlm.nih.gov/pubmed/7561171"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "A novel mutation in the helix termination peptide of keratin 5 causing epidermolysis bullosa simplex Dowling-Meara.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Epidermolysis bullosa simplex Dowling-Meara (MIM# 1317600) is the most severe of the three common epidermolysis bullosa simplex subtypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827"}, {"offsetInBeginSection": 138, "offsetInEndSection": 360, "text": "In addition to the palmoplantar distribution seen in other epidermolysis bullosa simplex subtypes, extensive herpetiform blistering spontaneously develops on the trunk and limbs and may lead to scarring or milia formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827"}, {"offsetInBeginSection": 361, "offsetInEndSection": 569, "text": "The keratin 5 and keratin 14 genes encode proteins that form the primary structural components of the basal epidermal keratinocytes, mutations in either of these genes can cause epidermolysis bullosa simplex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827"}, {"offsetInBeginSection": 570, "offsetInEndSection": 670, "text": "In this study we sequenced these genes in a family with epidermolysis bullosa simplex Dowling-Meara.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827"}, {"offsetInBeginSection": 859, "offsetInEndSection": 1004, "text": "This mutation adds to those previously reported and provides further evidence of phenotype-genotype correlation in epidermolysis bullosa simplex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Mutation analysis of the entire keratin 5 and 14 genes in patients with epidermolysis bullosa simplex and identification of novel mutations.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655565"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Epidermolysis bullosa simplex is a group of blistering skin disorders caused by defects in one of the keratin genes, KRT5 and KRT14.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655565"}, {"offsetInBeginSection": 485, "offsetInEndSection": 691, "text": "In two patients, with the Koebner and the Weber-Cockayne subtypes of epidermolysis bullosa simplex respectively, we could, however, not identify any mutation in one of the hotspot domains of KRT5 and KRT14.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655565"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894602"}]}, {"id": "5aafc37afcf4565872000010", "body": "What is the function of HDAC  proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27345839", "http://www.ncbi.nlm.nih.gov/pubmed/26927903", "http://www.ncbi.nlm.nih.gov/pubmed/17786239", "http://www.ncbi.nlm.nih.gov/pubmed/10220385", "http://www.ncbi.nlm.nih.gov/pubmed/10869435", "http://www.ncbi.nlm.nih.gov/pubmed/26232305", "http://www.ncbi.nlm.nih.gov/pubmed/22621256", "http://www.ncbi.nlm.nih.gov/pubmed/15050820", "http://www.ncbi.nlm.nih.gov/pubmed/28337317", "http://www.ncbi.nlm.nih.gov/pubmed/17227860"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "A Role for Nuclear Actin in HDAC 1 and 2 Regulation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345839"}, {"offsetInBeginSection": 243, "offsetInEndSection": 406, "text": "Although the functions of HDAC proteins are becoming apparent both biochemically and clinically, how this class of proteins is regulated remains poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345839"}, {"offsetInBeginSection": 407, "offsetInEndSection": 485, "text": "We identified a novel interaction between nuclear actin and HDAC 1 and HDAC 2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345839"}, {"offsetInBeginSection": 663, "offsetInEndSection": 733, "text": "We find that monomeric actin is able to bind the class I HDAC complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345839"}, {"offsetInBeginSection": 734, "offsetInEndSection": 853, "text": "Furthermore, increasing the concentration of actin in HeLa nuclear extracts was able to suppress overall HDAC function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345839"}, {"offsetInBeginSection": 854, "offsetInEndSection": 951, "text": "Conversely, polymerizing nuclear actin increased HDAC activity and decreased histone acetylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345839"}, {"offsetInBeginSection": 1054, "offsetInEndSection": 1137, "text": "Together, our data suggest nuclear actin is able to regulate HDAC 1 and 2 activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345839"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "The epigenetic regulation of DNA structure and function is essential for changes in gene expression involved in development, growth, and maintenance of cellular function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927903"}, {"offsetInBeginSection": 291, "offsetInEndSection": 393, "text": "Histone deacetylase (HDAC) proteins have a major role in epigenetic regulation of chromatin structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927903"}, {"offsetInBeginSection": 394, "offsetInEndSection": 564, "text": "HDACs are enzymes that catalyze the removal of acetyl groups from lysine residues within histones, as well as a range of other proteins including transcriptional factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927903"}]}, {"id": "5aacd487fcf4565872000007", "body": "Which human gene encode for DNA polymerase \u03b8?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28668117", "http://www.ncbi.nlm.nih.gov/pubmed/27264557", "http://www.ncbi.nlm.nih.gov/pubmed/27657134", "http://www.ncbi.nlm.nih.gov/pubmed/28695890", "http://www.ncbi.nlm.nih.gov/pubmed/28570559", "http://www.ncbi.nlm.nih.gov/pubmed/28687761", "http://www.ncbi.nlm.nih.gov/pubmed/25775267", "http://www.ncbi.nlm.nih.gov/pubmed/24375106"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Expression and Structural Analyses of Human DNA Polymerase \u03b8 (POLQ).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28668117"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "DNA polymerase \u03b8 (POLQ), double-strand break repair, and cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "DNA polymerase theta (pol \u03b8) is encoded in the genomes of many eukaryotes, though not in fungi.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 96, "offsetInEndSection": 149, "text": "Pol \u03b8 is encoded by the POLQ gene in mammalian cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 150, "offsetInEndSection": 283, "text": "The C-terminal third of the protein is a family A DNA polymerase with additional insertion elements relative to prokaryotic homologs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 367, "offsetInEndSection": 457, "text": "Pol \u03b8 is important in the repair of genomic double-strand breaks (DSBs) from many sources.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 458, "offsetInEndSection": 697, "text": "These include breaks formed by ionizing radiation and topoisomerase inhibitors, breaks arising at stalled DNA replication forks, breaks introduced during diversification steps of the mammalian immune system, and DSB induced by CRISPR-Cas9.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 698, "offsetInEndSection": 783, "text": "Pol \u03b8 participates in a route of DSB repair termed \"alternative end-joining\" (altEJ).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 784, "offsetInEndSection": 874, "text": "AltEJ is independent of the DNA binding Ku protein complex and requires DNA end resection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 875, "offsetInEndSection": 969, "text": "Pol \u03b8 is able to mediate joining of two resected 3' ends harboring DNA sequence microhomology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}]}, {"id": "5ace3e3f0340b9f058000012", "body": "What is the biological role of Neddylation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25628956", "http://www.ncbi.nlm.nih.gov/pubmed/18247557", "http://www.ncbi.nlm.nih.gov/pubmed/25918018", "http://www.ncbi.nlm.nih.gov/pubmed/27956554", "http://www.ncbi.nlm.nih.gov/pubmed/18793140", "http://www.ncbi.nlm.nih.gov/pubmed/25531226", "http://www.ncbi.nlm.nih.gov/pubmed/25742093", "http://www.ncbi.nlm.nih.gov/pubmed/29074978", "http://www.ncbi.nlm.nih.gov/pubmed/23148618", "http://www.ncbi.nlm.nih.gov/pubmed/27591266"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Neddylation and deneddylation in cardiac biology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956"}, {"offsetInBeginSection": 124, "offsetInEndSection": 305, "text": "Similar to ubiquitination, neddylation is mediated by a cascade of three NEDD8 specific enzymes, an E1 activating enzyme, an E2 conjugating enzyme and one of the several E3 ligases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956"}, {"offsetInBeginSection": 306, "offsetInEndSection": 396, "text": "Neddylation is countered by the action of deneddylases via a process termed deneddylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956"}, {"offsetInBeginSection": 397, "offsetInEndSection": 678, "text": "By altering the substrate's conformation, stability, subcellular localization or binding affinity to DNA or proteins, neddylation regulates diverse cellular processes including the ubiquitin-proteasome system-mediated protein degradation, protein transcription, cell signaling etc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956"}, {"offsetInBeginSection": 679, "offsetInEndSection": 799, "text": "Dysregulation of neddylation has been linked to cancer, neurodegenerative disorders, and more recently, cardiac disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956"}, {"offsetInBeginSection": 800, "offsetInEndSection": 907, "text": "Here we comprehensively overview the biochemistry, the proteome and the biological function of neddylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956"}, {"offsetInBeginSection": 908, "offsetInEndSection": 1045, "text": "We also summarize the recent progress in revealing the physiological and pathological role of neddylation and deneddylation in the heart.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Nedd8 is a small ubiquitin-like protein that can be conjugated to substrate-proteins in a process known as neddylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18247557"}, {"offsetInBeginSection": 120, "offsetInEndSection": 299, "text": "Although neddylation plays a critical regulatory role in cell proliferation and development, the spectrum of Nedd8 substrates and its interaction network remain poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18247557"}, {"offsetInBeginSection": 300, "offsetInEndSection": 529, "text": "To explore the neddylation pathway at the proteome level, we have affinity purified Nedd8 modified and associated proteins from HEK293 cells stably expressing GST-Nedd8 and employed LC-MS/MS for subsequent protein identification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18247557"}]}, {"id": "5ab144fefcf4565872000012", "body": "The TRPM2 gene is associated with development of spontaneous thromboembolism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24646197", "http://www.ncbi.nlm.nih.gov/pubmed/28970008", "http://www.ncbi.nlm.nih.gov/pubmed/24931166", "http://www.ncbi.nlm.nih.gov/pubmed/21140288", "http://www.ncbi.nlm.nih.gov/pubmed/18503142", "http://www.ncbi.nlm.nih.gov/pubmed/27919223", "http://www.ncbi.nlm.nih.gov/pubmed/16252251", "http://www.ncbi.nlm.nih.gov/pubmed/15708008", "http://www.ncbi.nlm.nih.gov/pubmed/8800739", "http://www.ncbi.nlm.nih.gov/pubmed/11380448"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "The effects of hydrated C(60) fullerene on gene expression profile of TRPM2 and TRPM7 in hyperhomocysteinemic mice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646197"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "BACKGROUND: Hyperhomocysteinemia (HHcy) is associated with neurodegenerative diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646197"}, {"offsetInBeginSection": 784, "offsetInEndSection": 898, "text": "RESULTS: mRNA expression levels of TRPM2 were significantly increased in HHcy group compared to the control group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646197"}, {"offsetInBeginSection": 899, "offsetInEndSection": 1025, "text": "C(60)HyFn administration significantly decreased serum levels of homocysteine and TRPM2 mRNA levels in HHcy\u2009+\u2009C(60)HyFn group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646197"}, {"offsetInBeginSection": 1118, "offsetInEndSection": 1273, "text": "CONCLUSION: Administration of C(60)HyFn in HHcy mice significantly reduces serum homocysteine level, neuronal apoptosis and expression level of TRPM2 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646197"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1417, "text": "Increased expression level of TRPM2 induced by oxidative stress might be involved in the ethiopathogenesis of HHcy related neurologic diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646197"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931166"}, {"offsetInBeginSection": 316, "offsetInEndSection": 510, "text": "Here, we report that one such long non-coding RNA, TRPM2-AS, an antisense transcript of TRPM2, which encodes an oxidative stress-activated ion channel, is overexpressed in prostate cancer (PCa).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931166"}, {"offsetInBeginSection": 511, "offsetInEndSection": 714, "text": "The high expression of TRPM2-AS and its related gene signature were found to be linked to poor clinical outcome, with the related gene signature working also independently of the patient's Gleason score.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931166"}, {"offsetInBeginSection": 581, "offsetInEndSection": 785, "text": "Considering that TRPM2 is activated by oxidative stress, mediated cell death and inflammation, and is highly expressed in brain, the channel has been investigated in the context of central nervous system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21140288"}]}, {"id": "5abd2ce0fcf456587200002a", "body": "Which are the two main bacterial phyla in human gut?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19321416", "http://www.ncbi.nlm.nih.gov/pubmed/26061054", "http://www.ncbi.nlm.nih.gov/pubmed/19553672", "http://www.ncbi.nlm.nih.gov/pubmed/23982459", "http://www.ncbi.nlm.nih.gov/pubmed/24324923", "http://www.ncbi.nlm.nih.gov/pubmed/25516615", "http://www.ncbi.nlm.nih.gov/pubmed/24522631", "http://www.ncbi.nlm.nih.gov/pubmed/25873372", "http://www.ncbi.nlm.nih.gov/pubmed/25601048", "http://www.ncbi.nlm.nih.gov/pubmed/22205877"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "The adult human distal gut microbial community is typically dominated by 2 bacterial phyla (divisions), the Firmicutes and the Bacteroidetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416"}, {"offsetInBeginSection": 298, "offsetInEndSection": 466, "text": "Finished genome sequences were generated from Eubacterium rectale and E. eligens, which belong to Clostridium Cluster XIVa, one of the most common gut Firmicute clades.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416"}, {"offsetInBeginSection": 467, "offsetInEndSection": 655, "text": "Comparison of these and 25 other gut Firmicutes and Bacteroidetes indicated that the Firmicutes possess smaller genomes and a disproportionately smaller number of glycan-degrading enzymes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416"}, {"offsetInBeginSection": 656, "offsetInEndSection": 947, "text": "Germ-free mice were then colonized with E. rectale and/or a prominent human gut Bacteroidetes, Bacteroides thetaiotaomicron, followed by whole-genome transcriptional profiling, high-resolution proteomic analysis, and biochemical assays of microbial-microbial and microbial-host interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416"}, {"offsetInBeginSection": 1517, "offsetInEndSection": 1764, "text": "This simplified model of the human gut microbiota illustrates niche specialization and functional redundancy within members of its major bacterial phyla, and the importance of host glycans as a nutrient foundation that ensures ecosystem stability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416"}, {"offsetInBeginSection": 176, "offsetInEndSection": 236, "text": "The human gut is heavily populated with microbial organisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061054"}, {"offsetInBeginSection": 237, "offsetInEndSection": 393, "text": "Recent evidence suggests that obesity is influenced by specific bacterial phyla present in the human gut that have increased energy harvesting capabilities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061054"}, {"offsetInBeginSection": 507, "offsetInEndSection": 682, "text": "In this review, we also discuss the differences between the phylum ratio of the gut microbiota population of obese individuals and that of individuals who have healthy weight.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061054"}, {"offsetInBeginSection": 808, "offsetInEndSection": 981, "text": "The few studies to date have shown that weight-loss treatment may change microbial population of the gut, as there is a decrease in the ratio of Firmicutes to Bacteroidetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061054"}]}, {"id": "5ad6e431133db5eb7800000e", "body": "Which test is used for the definition of colour-blindness?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25452008", "http://www.ncbi.nlm.nih.gov/pubmed/26591383", "http://www.ncbi.nlm.nih.gov/pubmed/310055", "http://www.ncbi.nlm.nih.gov/pubmed/314267", "http://www.ncbi.nlm.nih.gov/pubmed/16431664", "http://www.ncbi.nlm.nih.gov/pubmed/22076482", "http://www.ncbi.nlm.nih.gov/pubmed/28274040", "http://www.ncbi.nlm.nih.gov/pubmed/306798", "http://www.ncbi.nlm.nih.gov/pubmed/9893853", "http://www.ncbi.nlm.nih.gov/pubmed/18942220"], "snippets": [{"offsetInBeginSection": 25, "offsetInEndSection": 84, "text": "Behavioural evidence for colour-blindness in harbour seals.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "All seals and cetaceans have lost at least one of two ancestral cone classes and should therefore be colour-blind.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 115, "offsetInEndSection": 295, "text": "Nevertheless, earlier studies showed that these marine mammals can discriminate colours and a colour vision mechanism has been proposed which contrasts signals from cones and rods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 469, "offsetInEndSection": 632, "text": "Using a psychophysical discrimination experiment, we showed that a harbour seal can solve a colour discrimination task by means of brightness discrimination alone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 890, "offsetInEndSection": 964, "text": "This finding speaks against rod-cone-based colour vision in harbour seals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1096, "text": "To test for colour-blindness, we used a cognitive approach involving a harbour seal trained to use a concept of same and different.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1196, "text": "We tested this seal with pairs of isoluminant stimuli that were either same or different in colour.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1293, "text": "If the seal had perceived colour, it would have responded to colour differences between stimuli.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 1294, "offsetInEndSection": 1382, "text": "However, the seal responded with \"same\", providing strong evidence for colour-blindness.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008"}, {"offsetInBeginSection": 519, "offsetInEndSection": 632, "text": "Additionally the colour intensities of the test window were quantified using a camera and photo editing software.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26591383"}]}, {"id": "5ab1483bfcf4565872000014", "body": "The common house cat, Felis silvestris catus and the domestic dog, Canis familiaris both belong to what taxonomic order?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26154131", "http://www.ncbi.nlm.nih.gov/pubmed/16772461", "http://www.ncbi.nlm.nih.gov/pubmed/17727851", "http://www.ncbi.nlm.nih.gov/pubmed/21846752", "http://www.ncbi.nlm.nih.gov/pubmed/15474307", "http://www.ncbi.nlm.nih.gov/pubmed/27135263", "http://www.ncbi.nlm.nih.gov/pubmed/7777329", "http://www.ncbi.nlm.nih.gov/pubmed/10640803", "http://www.ncbi.nlm.nih.gov/pubmed/25162450", "http://www.ncbi.nlm.nih.gov/pubmed/22233209"], "snippets": [{"offsetInBeginSection": 31, "offsetInEndSection": 116, "text": "A review of cat (Felis silvestris catus) cognition research past, present and future.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26154131"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "The domestic cat (Felis silvestris catus) has shared an intertwined existence with humans for thousands of years, living on our city streets and in our homes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26154131"}, {"offsetInBeginSection": 159, "offsetInEndSection": 338, "text": "Yet, little scientific research has focused on the cognition of the domestic cat, especially in comparison with human's other companion, the domestic dog (Canis lupus familiaris).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26154131"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1106, "text": "In addition to the scientific value of future work in this area, future research on cat cognition could have an important influence on the management and welfare of pet and free-roaming cats, leading to improved human-cat interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26154131"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The evolutionary basis for the feeding behavior of domestic dogs (Canis familiaris) and cats (Felis catus).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16772461"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The dentition, sense of taste and meal patterning of domestic dogs and cats can be interpreted in terms of their descent from members of the order Carnivora.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16772461"}, {"offsetInBeginSection": 296, "offsetInEndSection": 444, "text": "The preference of many dogs for large infrequent meals reflects the competitive feeding behavior of its pack-hunting ancestor, the wolf Canis lupus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16772461"}, {"offsetInBeginSection": 818, "offsetInEndSection": 1001, "text": "Their preference for several small meals each day reflects a daily pattern of multiple kills of small prey items in their ancestor, the solitary territorial predator Felis silvestris.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16772461"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Cortisol determination in hair and faeces from domestic cats and dogs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727851"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "The present study explored the feasibility of a hair cortisol assay in domestic cats (Felis silvestris catus) and dogs (Canis familiaris) as a valid and reliable alternative to existing non-invasive techniques for monitoring the hypothalamic-pituitary-adrenal (HPA) axis activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727851"}]}, {"id": "5abd31e0fcf456587200002c", "body": "What is ATAC-seq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28550296", "http://www.ncbi.nlm.nih.gov/pubmed/28075484", "http://www.ncbi.nlm.nih.gov/pubmed/27903897", "http://www.ncbi.nlm.nih.gov/pubmed/29155775", "http://www.ncbi.nlm.nih.gov/pubmed/27832532", "http://www.ncbi.nlm.nih.gov/pubmed/29030848", "http://www.ncbi.nlm.nih.gov/pubmed/28723572", "http://www.ncbi.nlm.nih.gov/pubmed/29052193", "http://www.ncbi.nlm.nih.gov/pubmed/27146274", "http://www.ncbi.nlm.nih.gov/pubmed/25559105"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Reducing mitochondrial reads in ATAC-seq using CRISPR/Cas9.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28550296"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "ATAC-seq is a high-throughput sequencing technique that identifies open chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28550296"}, {"offsetInBeginSection": 83, "offsetInEndSection": 182, "text": "Depending on the cell type, ATAC-seq samples may contain ~20-80% of mitochondrial sequencing reads.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28550296"}, {"offsetInBeginSection": 334, "offsetInEndSection": 578, "text": "We tested two approaches to decrease wasted sequencing in ATAC-seq libraries generated from lymphoblastoid cell lines: targeted cleavage of mitochondrial DNA fragments using CRISPR technology and removal of detergent from the cell lysis buffer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28550296"}, {"offsetInBeginSection": 987, "offsetInEndSection": 1158, "text": "The highest number of peaks and highest quality data was obtained by preparing samples with the original ATAC-seq protocol (using detergent) and treating them with CRISPR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28550296"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1397, "text": "This strategy reduced the amount of sequencing required to call a high number of peaks, which could lead to cost reduction when performing ATAC-seq on large numbers of samples and in cell types that contain a large amount of mitochondria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28550296"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Assay for Transposase-Accessible Chromatin Using Sequencing (ATAC-seq) Data Analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28075484"}, {"offsetInBeginSection": 248, "offsetInEndSection": 471, "text": "have developed a rapid method, requiring low numbers of living cells as input, for examining chromatin accessibility across the epigenome, known as the assay for transposase-accessible chromatin using sequencing (ATAC-seq).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28075484"}, {"offsetInBeginSection": 472, "offsetInEndSection": 645, "text": "The overall goal of this unit is to provide a thorough ATAC-seq data analysis plan, as well as describe how primary human blood samples can be processed for use in ATAC-seq.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28075484"}, {"offsetInBeginSection": 646, "offsetInEndSection": 772, "text": "In addition, a number of quality control parameters are discussed to ensure the integrity and confidence in the ATAC-seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28075484"}]}, {"id": "5abce6acfcf4565872000022", "body": "Please list 7 classes of drugs that interact with Warfarin.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19587643", "http://www.ncbi.nlm.nih.gov/pubmed/21397772"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587643"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Interactions of warfarin with other drugs or substances can pose a serious problem.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587643"}, {"offsetInBeginSection": 84, "offsetInEndSection": 388, "text": "We assessed three drug information compendia-Clinical Pharmacology, ePocrates, and Micromedex-and the warfarin sodium (Coumadin) product label (August 2007) approved by the US Food and Drug Administration for listings of interactions between warfarin and drugs, biologics, foods, and dietary supplements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587643"}, {"offsetInBeginSection": 389, "offsetInEndSection": 521, "text": "The drug information compendia and warfarin label differed greatly as to the total number of substances that interact with warfarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587643"}, {"offsetInBeginSection": 611, "offsetInEndSection": 797, "text": "The types of substances listed as interacting with warfarin were entire classes of drugs, individual drugs, and combinations; biologics; dietary supplements; foods; alcohol; and tobacco.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587643"}, {"offsetInBeginSection": 911, "offsetInEndSection": 1075, "text": "This study provides evidence that there is little concordance among commonly used drug compendia and product labels with respect to interactions involving warfarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587643"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397772"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "BACKGROUND: Because interactions with warfarin represent a serious risk to patients, drug information sources used by clinicians should contain accurate, timely, and practical drug interaction information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397772"}, {"offsetInBeginSection": 205, "offsetInEndSection": 395, "text": "OBJECTIVE: The aim of this study was to assess the information regarding warfarin interactions that is included in the official labeling of prescription products that interact with warfarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397772"}, {"offsetInBeginSection": 395, "offsetInEndSection": 751, "text": "METHODS: We examined the official labeling information approved by the US Food and Drug Administration for the 50 drugs, biologics, and drug classes that were commonly identified by 3 drug information compendia--Clinical Pharmacology, ePocrates(\u00ae), and Micromedex(\u00ae)--and the warfarin US prescribing information (PI) as having an interaction with warfarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397772"}]}, {"id": "5ac0aee419833b0d7b000004", "body": "Is a mutation of the  ZIKV's membrane protein prM responsible for the microcephaly in new-born infants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28916391", "http://www.ncbi.nlm.nih.gov/pubmed/28049830", "http://www.ncbi.nlm.nih.gov/pubmed/28971967", "http://www.ncbi.nlm.nih.gov/pubmed/28239447", "http://www.ncbi.nlm.nih.gov/pubmed/27876396", "http://www.ncbi.nlm.nih.gov/pubmed/28383800", "http://www.ncbi.nlm.nih.gov/pubmed/27355570", "http://www.ncbi.nlm.nih.gov/pubmed/28931684", "http://www.ncbi.nlm.nih.gov/pubmed/28198446", "http://www.ncbi.nlm.nih.gov/pubmed/27647195"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "The growing number of zika virus (ZIKV) infections plus a 20-fold increase in neonatal microcephaly in newborns in Brazil have raised alarms in many countries regarding the threat to pregnant women.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391"}, {"offsetInBeginSection": 199, "offsetInEndSection": 312, "text": "Instances of microcephaly and central nervous system malformations continue to increase in ZIKV outbreak regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391"}, {"offsetInBeginSection": 427, "offsetInEndSection": 590, "text": "High-resolution ZIKV structures recently identified by cryo-electron microscopy indicate that the overall ZIKV structure is similar to those of other flaviviruses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391"}, {"offsetInBeginSection": 591, "offsetInEndSection": 676, "text": "With its compact surface, ZIKV is more thermally stable than the dengue virus (DENV).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391"}, {"offsetInBeginSection": 773, "offsetInEndSection": 921, "text": "The ZIKV E protein, the major protein involved in receptor binding and fusion, is formed as a head-to-tail dimer on the surfaces of viral particles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391"}, {"offsetInBeginSection": 1608, "offsetInEndSection": 1849, "text": "Stabilized forms of ZIKV E:E dimer proteins have been successfully obtained either by introducing additional inter-subunit disulfide bond(s) in DII or via the direct assembly of E:E dimer proteins by immobilization with monomeric E proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391"}, {"offsetInBeginSection": 1974, "offsetInEndSection": 2122, "text": "Several forms of ZIKV VLPs have been reported featuring the co-expression of the prM-E, prM-E-NS1, C-prM-E, and NS2B/NS3 viral genes in human cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "The Zika virus (ZIKV) causes microcephaly and the Guillain-Barr\u00e9 syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049830"}, {"offsetInBeginSection": 75, "offsetInEndSection": 317, "text": "Little is known about how ZIKV causes these conditions or which ZIKV viral protein(s) is responsible for the associated ZIKV-induced cytopathic effects, including cell hypertrophy, growth restriction, cell-cycle dysregulation, and cell death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049830"}, {"offsetInBeginSection": 318, "offsetInEndSection": 401, "text": "We used fission yeast for the rapid, global functional analysis of the ZIKV genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049830"}]}, {"id": "5abcf0b0fcf4565872000024", "body": "What causes leishmaniasis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18457726", "http://www.ncbi.nlm.nih.gov/pubmed/23219435", "http://www.ncbi.nlm.nih.gov/pubmed/23286822", "http://www.ncbi.nlm.nih.gov/pubmed/15071036", "http://www.ncbi.nlm.nih.gov/pubmed/25228325", "http://www.ncbi.nlm.nih.gov/pubmed/26081889", "http://www.ncbi.nlm.nih.gov/pubmed/25988048", "http://www.ncbi.nlm.nih.gov/pubmed/2670376", "http://www.ncbi.nlm.nih.gov/pubmed/15259461", "http://www.ncbi.nlm.nih.gov/pubmed/25116660"], "snippets": [{"offsetInBeginSection": 184, "offsetInEndSection": 328, "text": "In Tunisia, leishmaniasis of the mucous membranes is rare, usually developing as a complication of cutaneous leishmaniasis via direct extension.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457726"}, {"offsetInBeginSection": 680, "offsetInEndSection": 817, "text": "The diagnosis of leishmaniasis was confirmed by histological and direct examinations revealing high numbers of amastigotes of Leishmania.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457726"}, {"offsetInBeginSection": 818, "offsetInEndSection": 971, "text": "Culture of the offending organism in NNN medium and isoenzymatic characterization resulted in identification of MON-80 Leishmania infantum leishmaniasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457726"}, {"offsetInBeginSection": 1188, "offsetInEndSection": 1291, "text": "Our case is also unusual in that zymodeme MON-80 is only rarely a cause of Mediterranean leishmaniasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457726"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219435"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Leishmaniasis is a neglected tropical disease caused by Leishmania protozoa and associated with three main clinical presentations: cutaneous, mucocutaneous and visceral leishmaniasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219435"}, {"offsetInBeginSection": 409, "offsetInEndSection": 520, "text": "However, in Sri Lanka, L. donovani causes mainly cutaneous leishmaniasis, while visceral leishmaniasis is rare.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219435"}, {"offsetInBeginSection": 0, "offsetInEndSection": 34, "text": "Old World cutaneous leishmaniasis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286822"}, {"offsetInBeginSection": 411, "offsetInEndSection": 474, "text": "L. donovani generally causes visceral disease in the Old World.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286822"}, {"offsetInBeginSection": 614, "offsetInEndSection": 693, "text": "Dermatologists should be aware of the clinical manifestations of leishmaniasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286822"}]}, {"id": "5ac138aa95d0062724000001", "body": "Which is the enzymatic activity of nardilysin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15544571", "http://www.ncbi.nlm.nih.gov/pubmed/21801775", "http://www.ncbi.nlm.nih.gov/pubmed/19234765"], "snippets": [{"offsetInBeginSection": 353, "offsetInEndSection": 499, "text": "Since for those processes its enzymatic activity is not required, it is now evident that nardilysin fulfills at least two distinct functions, i.e.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15544571"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Retinoic acid-induced upregulation of the metalloendopeptidase nardilysin is accelerated by co-expression of the brain-specific protein p42(IP4) (centaurin \u03b1 1; ADAP1) in neuroblastoma cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21801775"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "The mainly neuronally expressed protein p42(IP4) (centaurin \u03b11; ADAP1), which interacts with the metalloendopeptidase nardilysin (NRD) was found to be localized in neuritic plaques in Alzheimer disease (AD) brains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21801775"}, {"offsetInBeginSection": 564, "offsetInEndSection": 667, "text": "Some members of this M16 family act bi-functionally, as protease and as non-enzymatic scaffold protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21801775"}, {"offsetInBeginSection": 668, "offsetInEndSection": 745, "text": "Here, we show that p42(IP4) enhances the enzymatic activity of NRD 3-4 times.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21801775"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The peptidase nardilysin is involved in degradation of neuropeptides and limited intracellular proteolysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765"}, {"offsetInBeginSection": 108, "offsetInEndSection": 207, "text": "Recent reports point to an involvement of nardilysin in the pathophysiology of Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765"}, {"offsetInBeginSection": 208, "offsetInEndSection": 430, "text": "Nardilysin enhances the alpha-secretase activity of the disintegrin and metalloproteases (ADAMs) 10 and 17, thereby possibly contributing to reduced generation of amyloidogenic fragments from the amyloid precursor protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765"}, {"offsetInBeginSection": 431, "offsetInEndSection": 602, "text": "A prerequisite for the alpha-secretase-stimulating effect of nardilysin on the activity of ADAMs in vivo is cellular co-expression of nardilysin with ADAM10 and/or ADAM17.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765"}]}, {"id": "5aaef38dfcf456587200000f", "body": "Please list 10 conditions which play a role in causing atrial fibrillation.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19151857", "http://www.ncbi.nlm.nih.gov/pubmed/11978585", "http://www.ncbi.nlm.nih.gov/pubmed/24111315", "http://www.ncbi.nlm.nih.gov/pubmed/12781903", "http://www.ncbi.nlm.nih.gov/pubmed/7759722", "http://www.ncbi.nlm.nih.gov/pubmed/10646954", "http://www.ncbi.nlm.nih.gov/pubmed/16793213", "http://www.ncbi.nlm.nih.gov/pubmed/10535368", "http://www.ncbi.nlm.nih.gov/pubmed/10409531", "http://www.ncbi.nlm.nih.gov/pubmed/12746748"], "snippets": [{"offsetInBeginSection": 288, "offsetInEndSection": 453, "text": "Of the long list of various cardiac conditions associated with an increased risk of cardioembolic strokes, non-valvular atrial fibrillation is the most common cause.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19151857"}, {"offsetInBeginSection": 619, "offsetInEndSection": 801, "text": "Treatment with vitamin K-antagonists substantially reduces the long-term complications associated with cardioembolism in some high-risk patients, for example, in atrial fibrillation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19151857"}, {"offsetInBeginSection": 963, "offsetInEndSection": 1161, "text": "Apart from atrial fibrillation, there is relatively limited evidence for the role of antithrombotic therapy for other cardiac conditions associated with cardioembolism and how long one should treat.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19151857"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "The authors used death certificate data to evaluate national trends in the reporting of atrial fibrillation as an underlying or contributory cause of death for groups defined by age (45 years or older), sex, and race (Black vs. White) and to examine comorbidity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11978585"}, {"offsetInBeginSection": 263, "offsetInEndSection": 498, "text": "The multiple-causes mortality files from 1980 through 1998 were analyzed for decedents, with atrial fibrillation (International Classification of Diseases, Ninth Revision, code 427.3) listed as one of up to 20 conditions causing death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11978585"}, {"offsetInBeginSection": 499, "offsetInEndSection": 723, "text": "The number of decedents with atrial fibrillation increased from 18,947 in 1980 to 61,946 in 1998, and the proportion with atrial fibrillation reported as the underlying cause of death rose from 8.3% in 1980 to 11.6% in 1998.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11978585"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Simulating the role of anisotropy in human atrial cardioversion.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24111315"}, {"offsetInBeginSection": 134, "offsetInEndSection": 267, "text": "An established biophysical human cell model was adopted to reproduce Control and chronic atrial fibrillation (CAF) action potentials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24111315"}, {"offsetInBeginSection": 268, "offsetInEndSection": 381, "text": "The cell model was combined with a detailed human atrial geometry to construct a 3D realistic human atrial model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24111315"}, {"offsetInBeginSection": 382, "offsetInEndSection": 563, "text": "Scroll waves were simulated under Control and CAF conditions and the cardioversion parameters of stimulation strength and pacing duration were evaluated for scroll wave termination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24111315"}]}, {"id": "5ad3aa47133db5eb78000004", "body": "Which organ express and secretes the hormone FGF21?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22917661", "http://www.ncbi.nlm.nih.gov/pubmed/26116622", "http://www.ncbi.nlm.nih.gov/pubmed/25811804", "http://www.ncbi.nlm.nih.gov/pubmed/18467542", "http://www.ncbi.nlm.nih.gov/pubmed/26993043", "http://www.ncbi.nlm.nih.gov/pubmed/26654352", "http://www.ncbi.nlm.nih.gov/pubmed/24432989", "http://www.ncbi.nlm.nih.gov/pubmed/25215270", "http://www.ncbi.nlm.nih.gov/pubmed/28089565", "http://www.ncbi.nlm.nih.gov/pubmed/17623664"], "snippets": [{"offsetInBeginSection": 694, "offsetInEndSection": 799, "text": "Physical hypoxia (1% oxygen) and CoCl(2) treatment decreased both FGF21 mRNA and secreted protein levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22917661"}, {"offsetInBeginSection": 1871, "offsetInEndSection": 1967, "text": "The regulation of FGF21 by hypoxia may contribute to intestinal lipid metabolism and absorption.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22917661"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Most hormones secreted from specific organs of the body in response to diverse stimuli contribute to the homeostasis of the whole organism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116622"}, {"offsetInBeginSection": 140, "offsetInEndSection": 323, "text": "Fibroblast growth factor 21 (FGF21), a hormone induced by a variety of environmental or metabolic stimuli, plays a crucial role in the adaptive response to these stressful conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116622"}, {"offsetInBeginSection": 324, "offsetInEndSection": 529, "text": "In addition to its role as a stress hormone, FGF21 appears to function as a mediator of the therapeutic effects of currently available drugs and those under development for treatment of metabolic diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116622"}, {"offsetInBeginSection": 988, "offsetInEndSection": 1262, "text": "Finally, we discuss the current understanding of the actions of FGF21 as a crucial regulator mediating beneficial metabolic effects of therapeutic agents such as metformin, glucagon/glucagon-like peptide 1 analogues, thiazolidinedione, sirtuin 1 activators, and lipoic acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116622"}, {"offsetInBeginSection": 137, "offsetInEndSection": 231, "text": "Although the pancreas is an FGF21 target organ, its role in pancreatic islets remains obscure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811804"}, {"offsetInBeginSection": 232, "offsetInEndSection": 352, "text": "This study aimed to elucidate the physiological role of FGF21 in pancreatic islets using FGF21-knockout (FGF21-KO) mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811804"}, {"offsetInBeginSection": 827, "offsetInEndSection": 930, "text": "This phenotype probably results from enhanced growth hormone (GH) sensitivity in FGF21-KO mouse islets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811804"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1783, "text": "Our data indicate that FGF21 is important in the regulation of beta-cell proliferation and insulin synthesis, probably via modulation of GH signaling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811804"}]}, {"id": "5ad4f4f5133db5eb7800000a", "body": "What is the aim of the PhenCode database?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25385275"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "VariSNP, a benchmark database for variations from dbSNP.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275"}, {"offsetInBeginSection": 307, "offsetInEndSection": 473, "text": "These subsets were filtered against disease-related variants in the ClinVar, UniProtKB/Swiss-Prot, and PhenCode databases, to identify neutral or nonpathogenic cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275"}, {"offsetInBeginSection": 595, "offsetInEndSection": 729, "text": "The datasets will be updated with automated scripts on a regular basis and are freely available at http://structure.bmc.lu.se/VariSNP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275"}, {"offsetInBeginSection": 265, "offsetInEndSection": 306, "text": "VariSNP datasets are selected from dbSNP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "For development and evaluation of methods for predicting the effects of variations, benchmark datasets are needed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275"}, {"offsetInBeginSection": 115, "offsetInEndSection": 264, "text": "Some previously developed datasets are available for this purpose, but newer and larger benchmark sets for benign variants have largely been missing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275"}, {"offsetInBeginSection": 474, "offsetInEndSection": 594, "text": "All variant descriptions include mapping to reference sequences on chromosomal, genomic, coding DNA, and protein levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275"}]}, {"id": "5a9d99ac4e03427e73000002", "body": "What is measured with the Proseek panels?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28936257", "http://www.ncbi.nlm.nih.gov/pubmed/28586402", "http://www.ncbi.nlm.nih.gov/pubmed/25987887", "http://www.ncbi.nlm.nih.gov/pubmed/28694499", "http://www.ncbi.nlm.nih.gov/pubmed/19040730", "http://www.ncbi.nlm.nih.gov/pubmed/28437237", "http://www.ncbi.nlm.nih.gov/pubmed/28948068", "http://www.ncbi.nlm.nih.gov/pubmed/28734077"], "snippets": [{"offsetInBeginSection": 474, "offsetInEndSection": 654, "text": "Among 92 proteins in the Proseek Multiplex Oncology Iv2 panel, 87 were above the limit of detection (LOD) in liquid plasma and 56 among 92 above LOD in plasma applied to FTA cards.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1038, "text": "Our results demonstrate that samples applied to the indicating FTA elute micro card\u2122 are amendable to protein analyses, given that a sensitive protein detection assay is used.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257"}, {"offsetInBeginSection": 215, "offsetInEndSection": 361, "text": "A total of 92 biomarkers were measured before a standardized meal as well as 30 and 120 minutes afterwards with the Proseek Multiplex CVD III kit.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28586402"}, {"offsetInBeginSection": 882, "offsetInEndSection": 1166, "text": "EDTA plasma samples (1\u00a0\u03bcL) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek\u00ae Multiplex Oncology I proximity extension assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887"}, {"offsetInBeginSection": 1279, "offsetInEndSection": 1488, "text": "RESULTS: Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887"}, {"offsetInBeginSection": 503, "offsetInEndSection": 757, "text": "Using the Proseek Multiplex Inflammation assay, we measured in patients that had suffered mild TBI (n\u2009=\u200910) or severe TBI (n\u2009=\u200910) with extra-cranial injury or extracranial injury only (EC) (n\u2009=\u200910), 92 inflammation-associated proteins in serum obtained:", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28694499"}, {"offsetInBeginSection": 750, "offsetInEndSection": 962, "text": "Blood samples were obtained at baseline (0 hour), 6, 24, and 96 hours post PCI, and stored at -80\u00b0C until they were analyzed by PROSEEK Multiplex CVD and PROSEEK Multiplex INF (Olink Bioscience, Uppsala, Sweden).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28437237"}, {"offsetInBeginSection": 303, "offsetInEndSection": 448, "text": "A total of 92 biomarkers were measured before a standardized meal as well as 30 and 120\u00a0min afterward with the Proseek Multiplex Neurology\u00a0I kit.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948068"}, {"offsetInBeginSection": 534, "offsetInEndSection": 701, "text": "RESULTS: Plasma concentrations of MMP12 were measured at baseline in 3394 subjects with high-risk for cardiovascular disease (CVD) using the Olink ProSeek CVD I array.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28734077"}, {"offsetInBeginSection": 356, "offsetInEndSection": 517, "text": "Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887"}]}, {"id": "5ad247720340b9f058000017", "body": "What is a fibrocyte?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22043022", "http://www.ncbi.nlm.nih.gov/pubmed/22022512", "http://www.ncbi.nlm.nih.gov/pubmed/18427397", "http://www.ncbi.nlm.nih.gov/pubmed/28915889", "http://www.ncbi.nlm.nih.gov/pubmed/18025235", "http://www.ncbi.nlm.nih.gov/pubmed/24507087", "http://www.ncbi.nlm.nih.gov/pubmed/18052725", "http://www.ncbi.nlm.nih.gov/pubmed/26948996", "http://www.ncbi.nlm.nih.gov/pubmed/24822215", "http://www.ncbi.nlm.nih.gov/pubmed/22796709"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Subcellular distribution and relative expression of fibrocyte markers in the CD/1 mouse cochlea assessed by semiquantitative immunogold electron microscopy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22043022"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Spiral ligament fibrocytes function in cochlear homeostasis, maintaining the endocochlear potential by participating in potassium recycling, and fibrocyte degeneration contributes to hearing loss.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22043022"}, {"offsetInBeginSection": 288, "offsetInEndSection": 462, "text": "Fibrocyte cultures offer one source of transplantable cells, but determining what fibrocyte types they contain and what phenotype transplanted cells may adopt is problematic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22043022"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "High and low molecular weight hyaluronic acid differentially regulate human fibrocyte differentiation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512"}, {"offsetInBeginSection": 395, "offsetInEndSection": 555, "text": "FINDINGS: In this report, we show that HMWHA potentiates the differentiation of human monocytes into fibrocytes, while LMWHA inhibits fibrocyte differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512"}, {"offsetInBeginSection": 556, "offsetInEndSection": 690, "text": "Digestion of HMWHA with hyaluronidase produces small hyaluronic acid fragments, and these fragments inhibit fibrocyte differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512"}, {"offsetInBeginSection": 691, "offsetInEndSection": 871, "text": "Monocytes internalize HMWHA and LMWHA equally well, suggesting that the opposing effects on fibrocyte differentiation are not due to differential internalization of HMWHA or LMWHA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512"}, {"offsetInBeginSection": 1012, "offsetInEndSection": 1194, "text": "The addition of anti-CD44 antibodies potentiates fibrocyte differentiation, suggesting that CD44 mediates at least some of the effect of hyaluronic acid on fibrocyte differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512"}, {"offsetInBeginSection": 1195, "offsetInEndSection": 1355, "text": "The fibrocyte differentiation-inhibiting factor serum amyloid P (SAP) inhibits HMWHA-induced fibrocyte differentiation and potentiates LMWHA-induced inhibition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512"}, {"offsetInBeginSection": 1356, "offsetInEndSection": 1490, "text": "Conversely, LMWHA inhibits the ability of HMWHA, interleukin-4 (IL-4), or interleukin-13 (IL-13) to promote fibrocyte differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512"}]}, {"id": "5ad255210340b9f058000018", "body": "Is lumican a secreted protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17050378", "http://www.ncbi.nlm.nih.gov/pubmed/22266188", "http://www.ncbi.nlm.nih.gov/pubmed/15466200", "http://www.ncbi.nlm.nih.gov/pubmed/23480731", "http://www.ncbi.nlm.nih.gov/pubmed/20138170", "http://www.ncbi.nlm.nih.gov/pubmed/27126993", "http://www.ncbi.nlm.nih.gov/pubmed/12381269", "http://www.ncbi.nlm.nih.gov/pubmed/21421073", "http://www.ncbi.nlm.nih.gov/pubmed/12128073", "http://www.ncbi.nlm.nih.gov/pubmed/16259954"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Lumican, a small leucine-rich proteoglycan substituted with keratan sulfate chains is expressed and secreted by human melanoma cells and not normal melanocytes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17050378"}, {"offsetInBeginSection": 528, "offsetInEndSection": 816, "text": "In this study, the expression of lumican was studied in two human melanoma cell lines (WM9, M5) as well as in normal neonatal human melanocytes (HEMN) using real time PCR, western blotting with antibodies against the protein core and keratan sulfate, and treatments with specific enzymes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17050378"}, {"offsetInBeginSection": 817, "offsetInEndSection": 1017, "text": "Both human metastatic melanoma cell lines were found to express lumican mRNA and effectively secrete lumican in a proteoglycan form, characterized to be substituted mostly with keratan sulfate chains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17050378"}, {"offsetInBeginSection": 1071, "offsetInEndSection": 1179, "text": "This is the first time that the synthesis and secretion of lumican in human melanoma cell lines is reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17050378"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Secreted 70kDa lumican stimulates growth and inhibits invasion of human pancreatic cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266188"}, {"offsetInBeginSection": 161, "offsetInEndSection": 266, "text": "We used gene transfection techniques to examine the biological roles of lumican secreted from PDAC cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266188"}, {"offsetInBeginSection": 267, "offsetInEndSection": 364, "text": "Lumican-transfected PANC-1 cells secreted a 70-kDa lumican protein and had an active ERK pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266188"}, {"offsetInBeginSection": 594, "offsetInEndSection": 692, "text": "Thus, the 70-kDa lumican secreted by PDAC cells plays important roles in cell growth and invasion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266188"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "The small leucine-rich proteoglycan lumican was identified from a human placenta cDNA library by the expression cloning method as a gene product that interacts with membrane-type matrix metalloproteinase-1 (MT1-MMP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15466200"}, {"offsetInBeginSection": 217, "offsetInEndSection": 409, "text": "Coexpression of MT1-MMP with lumican in HEK293T cells reduced the concentration of lumican secreted into culture medium, and this reduction was abolished by addition of the MMP inhibitor BB94.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15466200"}]}]}